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Preface 
 
This thesis is a compilation of published and unpublished work investigating the 
mechanism of sulfonucleotide reductases (SRs) and the identification of SR inhibitors.  
Sulfur catalysis by metabolic pathways are essential for the de novo biosynthesis of 
cysteine in human pathogens, including Mycobacterium tuberculosis.  SRs catalyze the 
first committed step in the generation of reduced sulfur for cysteine and are a validated 
target for the development of antitubercular agents, particularly for the treatment of latent 
infection.   
 
In Chapter 1, we discuss the urgent need to discover new antibacterial targets for 
multidrug resistant and latent tuberculosis infection.  I explore different methods of 
identifying small-molecule inhibitors against the SR known as, adenosine-5’-
phosphosulfate (APS) reductase (APR), which is an essential enzyme for mycobacterial 
survival. 
 
In Chapter 2, we identify the first non-phosphate-based inhibitors of APR using virtual 
ligand screening and experimental validation of in silico hits.  This work has been 
published as Cosconati, S.*, Hong, J.A.*, Novellino, E., Carroll, K.S., Goodsell, D.S. and 
Olson, A.J., “Structure-based virtual ligand screening and biological evaluation of 
!! vi!
Mycobacterium tuberculosis adenosine 5’-phosphosulfate reductase inhibitors,” J. Med. 
Chem. (2008) Oct;51(21):6627-30.  * Co-first authors. 
 
In Chapter 3, we investigate the molecular determinants that underlie substrate binding 
and, specificity of APR.  This study presents the structural and functional features 
required for APR-ligand interaction of APR and provides the pharmacological roadmap 
for future rational inhibitor design.  These data are published as Hong, J.A., Bhave, D.P. 
and Carroll, K.S., “Identification of critical ligand binding determinants in Mycobacterium 
tuberculosis adenosine-5’-phosphosulfate reductase,” J. Med. Chem. (2009) 
Aug;52(17):5485-95. 
 
Chapter 4 details the role of a conserved active site residue, His252, in APR catalysis.  
Our biochemical and biophysical data demonstrate that His252 enhances substrate 
affinity via interaction with the substrate !-phosphate and endoxyclic ribose oxygen.  
This work has been published as Hong, J.A. and Carroll, K.S., “Deciphering the role of 
His252 in mycobacterial APS reductase catalysis,” J. Biol. Chem. (2011) 
Aug;286(32):28567-73. 
 
In Chapter 5, we probe the role of the iron-sulfur cluster cofactor in APR through EPR 
and kinetic studies.  We identify Lys144 as a “bridge” linking the iron-sulfur cluster and 
substrate and that this network ultimately tends to transition state stabilization. The 
citation for this article is Bhave, D.B., Hong, J.A., Lee, M., Jiang, W., Krebs, C., and 
Carroll, K.S., “Spectroscopic studies on the [4Fe-4S] cluster in adenosine 5’-phosphate 
!! vii!
reductase from Mycobacterium tuberculosis,” J. Biol. Chem. (2011) Jan;286(2):1216-26. 
 
Chapter 6 demonstrates that protein redesign is a powerful tool to examine substrate 
discrimination in family of SRs.  Although it has been proposed that SR substrate 
specificity is dictated by an active site phosphate-binding loop, our studies reveal that 
the iron sulfur cluster in APR is the major determinant of substrate specificity, thereby 
extending the known functions of protein-bound iron sulfur clusters.  This work has been 
accepted as Bhave D.B., Hong, J.A., Keller, R., Krebs, C., and Carroll, K.S., “Iron-sulfur 
cluster engineering provides insight into the evolution of substrate specificity among the 
family of sulfonucleotide reductases,” ACS Chem. Biol. (2011). 
 
Finally, Chapter 7 is a discussion of future directions toward the development and 
evaluation of APR inhibitors.  
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ABSTRACT 
 
Toward the Discovery of Small Molecules that Target Adenosine 5’-
Phosphosulfate Reductase  
by 
Jiyoung A. Hong 
Co-chairs: Kate S. Carroll and John Montgomery 
Adenosine-5’-phosphosulfate reductase (APR) is an iron-sulfur protein that catalyzes the 
first committed step in the de novo biosynthesis of cysteine in mycobacteria.  APR is a 
validated target for the development of new antitubercular agents, particularly for the 
treatment of latent infection.  The goal of this research is to develop small-molecule 
inhibitors of APR that serve as tools for biological discovery or as leads for drug 
discovery.  Toward this end, we have combined virtual ligand screening (VLS), rational 
structure-based design, and enzyme mechanism analysis. Through VLS and 
experimental testing, we have identified the first nonphosphate-based inhibitors of APR 
and discovered an additional ligand-binding site, which could be exploited for the design 
of bifunctional small-molecules.  To facilitate the development of potent and specific 
inhibitors of APR, we have also probed the molecular determinants that underlie binding 
and specificity via a series of substrate and product analogs.  Our findings reveal a 
critical role for the !-phosphate group and provide evidence for ligand-specific 
conformational states within the C-terminal domain.  In addition, we demonstrate that a 
conserved histidine within the flexible segment plays an essential role in substrate 
!! xxvii!
binding and in closure of the active site lid.  Subsequently, a structure-based approach 
was utilized in the design and synthesis of an irreversible cysteine-targeted inhibitor of 
APR, which locks the enzyme in its closed, inactive state.  Finally, we have investigated 
the function of the iron-sulfur cluster in APR and provide kinetic evidence that the 
cofactor plays an essential role in substrate specificity of sulfonucleotide reductases.  
Collectively, these data further our understanding of the APR reaction mechanism and 
pave the way for development of new inhibitors to target this therapeutically important 
class of enzymes. 
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Chapter 1 
Strategies for discovering inhibitors against adenosine 5’-phosphosulfate 
reductase 
 
1.1 Abstract 
Even today tuberculosis remains a deadly infectious disease.  The current 
chemotherapy is resulting in poor patient compliance and the emergence of drug 
resistance strains.  In addition to toxic side effects, the TB drugs target biological 
processes required for bacterial growth and are less effective against latent tuberculosis 
infection.  With new advances in mycobacterial genomic and metabolic studies, new 
drug targets have been identified.  Adenosine 5’-phosphosulfate reductase (APR), an 
enzyme involved in mycobacterial sulfate assimilation is one of the validated drug 
targets against latent tuberculosis.  Herein, we outline a combination of computational 
and rational design strategies to identify small molecule inhibitors of APR that may 
represent new leads for drug development. !
 
1.2 The current TB epidemic and chemotherapy 
The history of Tuberculosis (TB) reveals that the disease has been a great threat to 
human health since ancient times.  Definite signs of TB were identified as early as 2400 
BC, in the spinal column of Egyptian mummies.  Physicians in ancient Greece called this 
disease "phthisis" (consumption) to reflect its wasting nature and considered it as the 
most widespread and fatal disease of their time.  This trend continued during the 17th 
and 18th centuries, when 25% of all deaths in Europe were related to TB (1).  It was in 
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1720 that a physician, Benjamin Marten, first suggested in his “A Theory of 
Consumption” that TB might be caused by small living creatures that are transmitted 
through the air to other patients.  Then, in 1882, Robert Koch discovered Mycobacterium 
tuberculosis as the bacterium that causes TB (2, 3).  However, it was almost a century 
later, in 1944 when Selman Waksman introduced Streptomycin purified from 
Streptomyces griseus as the first effective antibiotic against TB.  Following this 
breakthrough in drug discovery, a cocktail of four drugs, including isoniazid, rifampin, 
pyrazinamide and ethambutol were discovered during the 1950s and '60s and are still in 
use today (4, 5).   
 
Today, Tuberculosis remains one of the deadliest infectious diseases and major 
challenges in global health.  More than one-third of the world population is infected with 
TB, and one in every ten of these individuals develop TB at some point in their lifetime.  
In fact, in 2009, 1.7 million people died of TB including 380,000 people with HIV, a 
number equal to 4,700 deaths a day (6).  Most casualties are in developing countries 
including Southeast Asia, Africa and Western pacific regions where TB is still endemic 
and sufficient treatment is not available (7-9).  In 1993, the World Health Organization 
(WHO) declared TB as a global emergency and developed a strategy to control TB 
globally (10).  Following proper treatment, most cases of TB were curable.  However, the 
typical treatment regime for TB takes 6-9 months with 4-5 different antibiotics. The 
requirements of extensive chemotherapy have resulted in poor compliance leading to 
the emergence of drug resistant strains of TB.  Currently, 50 million people are 
estimated to be infected with multi-drug resistant (MDR) stains of M. tuberculosis, only 
50-70 % of which are curable.  In addition, extensively-drug resistant (XDR) strains are 
emerging with very high mortality rates (11).  In addition to the toxic side effects of the 
aggressive antibiotic therapy, most of the current drugs target only biological processes 
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required for bacterial growth such as cell wall biosynthesis, protein and DNA/RNA 
synthesis (5)  However less active subpopulations of TB also exist in a dormant or 
persistent phase and are not effectively killed by the current treatment.  Taken together, 
the problem of MDR-TB and the lack of effective treatment against persistent bacteria, 
stress the urgent need for identification of novel antibacterial targets.  In 2006, WHO 
launched a new ‘Stop TB’ strategy which called for immediate attention to identify new 
chemical scaffolds for possible drug candidates against TB, supported by an increase in 
research funds (12).  This significant step toward TB eradication promise to accelerate 
the understanding of the fundamental aspects of mycobacterial metabolism, 
pathogenesis and the discovery of potential drugs.   
 
1.3 Life cycle of TB infection 
M. tuberculosis infection is a complex process that initiates with aerosol inhalation to the 
host lung (13, 14).  Therein, the mycobacteria are engulfed by host immune cells known 
as macrophages.  By a complex mechanism that is not fully understood, the bacteria 
prevent maturation of the phagosome and its fusion with lysosomes.  In response to the 
infection, macrophages produce pro-inflammatory signals – cytokines and chemokines – 
that recruit additional host immune cells (T-cells and neutrophils) to the infected tissue 
(14, 15). These immune cells enclose the infected macrophage and segregate it from 
the surrounding tissue in a structure called the granuloma, which is the defining 
pathological feature of this disease.  By unknown mechanisms, the infection can be 
reactivated after many years or decades to produce active, infectious TB.  This event is 
often associated with a reduction in immune function due to co-infection with HIV, drug 
use, or aging.  Reactivated granuloma cracks and spills thousands of viable, infectious 
bacilli into the airway, resulting in lung tissue damage.  Coughing is induced by this 
damage and provides an exit strategy for the bacteria to spread to another host (9).  
! 4!
 
1.4 Survival strategy of M. tuberculosis   
M. tuberculosis has to survive within the hostile environment of the macrophage, where 
superoxide and nitric oxide are generated in response to infection.  Once the granuloma 
is formed, mycobacteria enter a persistent or “latent” state characterized by lack of cell 
division and induction of metabolism.  These latent mycobacteria are difficult to eradicate 
since they are not reliant on machinery targeted by conventional antibiotics.  A better 
understanding of bacterial survival within the granuloma and/or the seeking of efficacy 
against latent M. tuberculosis is required for effective treatment (16).   
 
Recently, bacterial genes involved in sulfur metabolism have been shown to be up-
regulated in response to the oxidatively hostile environment (17, 18).  Sulfur is an 
essential element for life (9, 19), is used mainly in cysteine biosynthesis.  Cysteine is 
one of amino acids, and also serves as a building block for the biosynthesis of reduced 
sulfur containing metabolites such as methionine and mycothiol (9).  These reduced 
sulfur-containing biomolecules are known to be involved in antioxidant defense.  For 
instance, mycothiol (MSH) is the major low-molecular mass thiol in most action-mycetes, 
including mycobacteria.  MSH is the equivalent of glutathione in mycobacteria and is 
associated with the protection of M. tuberculosis from toxic oxidants and antibiotics.  
Another reduced sulfur-containing metabolite, coenzyme A (CoA), is utilized for lipid 
metabolism, which plays an important role in the unique cell wall structure and virulence 
of bacteria by inducing cytokine mediated events (20).  Moreover, the sulfuryl moiety can 
be transferred to proteins, polysaccharides and lipids for regulating cell-to-cell 
communication (21).  Hence, the pathway used for the production of reduced sulfur, 
known as the sulfate assimilation pathway, is paramount to mycobacterial virulence and 
survival.   
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1.5 Sulfate assimilation pathway in mycobacteria 
Sulfate assimilation begins with the active transport of inorganic sulfate (SO42–) across 
the mycobacterial cell membrane (Figure 1.1).  Imported sulfate is activated by 
adenylation to form adenosine 5’-phosphosulfate (APS) using ATP sulfurylase.  APS lies 
at a metabolic hub where in one pathway it can be phosphorylated at the 3’-hydroxy 
position on the ribose ring by APS kinase and ATP to form 3’-phosphoadenosine 5’-
phosphosulfate (PAPS).  PAPS can later transport the sulfate to hydroxyl or amide 
moieties of metabolites involved in cell-cell communication (21). In the other reductive 
pathway, the terminal sulfate group of APS is reduced to sulfite (SO32–) by APS 
reductase (APR).  In this reaction, APS is reduced to SO32– and adenosine 5’-phosphate 
(AMP).  Thioredoxin (Trx), a 12.7 kDa protein with a redox active disulfide bond, serves 
as a cofactor and supplies the reducing potential necessary for this two electron 
reduction.  The sulfite is further reduced to sulfide, which is used for the biosynthesis of 
reduced sulfur-containing metabolites such as cysteine, methionine, CoA, iron-sulfur 
clusters and MSH (Figure 1.1).  Interestingly, not all microorganisms that assimilate 
sulfate use APS as the source of sulfite.  Instead, some organisms such as E. coli and S. 
cerevisiae reduce the related metabolite PAPS, using PAPS reductase (PAPR).  Both 
enzymes, APR and PAPR belong to the family of sulfonucleotide reductases (SR) and 
share the structural and sequence homology, and a conserved reaction mechanism.  
SRs are highly significant with respect to primary metabolism in prokaryotes, have 
enormous antimicrobial potential and carry out an unusual chemical reaction (22).  
Furthermore, SRs can be studied in order to elucidate mechanistic details and 
fundamental evolutionary relationships.  The strategies to develop the small molecule 
inhibitors shed light into the mechanism, targeting and therapeutic potential of APR.  
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1.6 Strategies to identify small molecule inhibitors of APR 
In this study we present an overview of the process of drug discovery and highlight the 
combination of strategies that we have employed towards identifying potential small 
molecule inhibitors of APR.  In general, drug discovery is a challenging process that can 
take decades and consume over a billion dollars in resources (23-25).  Figure 1.2 
outlines the workflow of the process of drug discovery.  The process of drug discovery 
involves the identification of candidates, characterization, screening and assays for 
therapeutic efficacy.  After the identification and validation of a biological target protein, 
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Figure1.1.  The sulfate assimilation pathway in mycobacteria (9)  
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the process of finding a new inhibitors against the target, usually involves high 
throughput screening (HTS) using large libraries of chemical compounds.  Recently, 
computational-aided screening is used to dock virtual libraries to a target.  Another 
method for drug discovery is drug design, whereby the biochemical and biophysical 
properties of the target are studied and prediction is made to fit into active site.  Once a 
lead compound is identified the compound is optimized for its selectivity and 
pharmacokinetic properties.  Even though the process was shown as a linear workflow in 
Figure 1.2, it is actually an iterative process.  Herein, we focus on developing strategies 
to discover small molecule inhibitors, which can eventually become lead candidates for 
drug design (26). 
 
1.6.1 Target identification 
The complete genome sequence of M. tuberculosis (27) and functional studies provide 
an opportunity to identify novel drug targets.  Molecular profiling using genomic 
knowledge has been recognized as a well-established strategy for identifying drug 
targets.  This technique correlates changes in gene (genomics) and protein (proteomics) 
expression in response to varying environmental conditions.  An obvious example is 
mRNA expression profiling using DNA microarrays for large-scale analysis of cellular 
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Figure1.2.  The process of drug discovery phase with various methods.  
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transcripts by comparing expression levels of mRNAs (28).  Using microarray technology 
in a transposon site hybridization (TraSH) assay, Sassetti and coworkers identified the 
compete set of genes required for the growth of mycobacteria under different conditions 
(17, 29).  From this assay, APR was identified in a screen for essential virus genes in M. 
bovis (29), consistent with its important metabolic role.  Moreover, the gene encoding 
APR was actively expressed during the dormant phase of M. tuberculosis in the 
environment of the macrophage (9).  Although these techniques identify large numbers 
of targets including APR, the correlative nature of the data they generate means that it is 
not possible to determine whether changes in gene protein expression are a cause or 
effect of the disease and it is necessary to validate the functional role of potential targets 
in the disease phenotype (28). 
 
1.6.2 Target validation 
Once a protein target has been identified, it has to undergo a validation process wherein 
its role in the disease is clearly defined. Target validation is required when the target is 
expressed in the disease-relevant cells and target modulation in model organisms 
improves the disease phenotype (30).  Genetically modified transgenic or knockout 
animals are extremely useful in the target validation.  Recently, Senaratne and 
coworkers demonstrated the attenuation of an APR mutant in a murine model of M. 
tuberculosis infection (31).  Moreover, the authors established that APR plays a central 
role in protecting M. tuberculosis against the effects of reactive nitrogen species and is 
critical for bacterial survival during the adaptive phase of the immune response of TB 
infection (31).  Notably, APR is not found in humans and therefore represents an 
attractive therapeutic target.  
 
1.6.3 Lead inhibitor identification 
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Traditional methods for drug discovery have mainly relied on trial-and-error via high 
throughput screening (HTS) of large chemical compound libraries.  Since the technology 
was introduced in 1984, the field of HTS has evolved the process of lead drug discovery 
(32).  Even though there has been an increase in the library of available screening 
compounds and the time for screening has been shortened by automation of technology, 
a disadvantage of HTS remains and the number of newly discovered drugs via HTS has 
been relatively low (33).  To apply HTS for the discovery of inhibitors to APR, we need to 
develop a robust, efficient and economical biochemical assay.  In the past, several 
assays, including a coupled enzyme assay and sulfite detection methods, have been 
proposed, but selectivity and the high cost of reagents have limited the use of these 
assays for HTS.  Our lab has undertaken the development of a fluorophore to detect the 
release of sulfite by APR.  This represents a promising approach toward the 
development of assays for HTS and is currently under way.  As discussed above, For 
the HTS method, serendipity plays an important role in finding new drugs.  However, 
current trends in drug discovery have shifted from discovery to design, which means that 
understanding the biochemistry of the proteins that cause the disease is necessary prior 
to designing compounds that are capable of modulating the role of these proteins (34).  
Furthermore, the advances in new technologies have fueled the development of new 
methods for drug design such as computer-aided screening and rational design (35-38). 
 
1.6.3.1 Virtual ligand screening   
Computer-aided drug design has become an essential technique used in the 
pharmaceutical industry, and capitalizes on the availability of structural information of the 
target protein.  For instance, a well-developed strategy known as Virtual ligand 
screening (VLS) involves in silico screening of the chemical compound databases to 
identify small molecules inhibitors of enzyme targets (39, 40).  In order to employ VLS 
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for the discovery of inhibitors for APR, we have exploited Autodock, one of the most 
widely used docking programs that has been used to identify inhibitors (41).  Autodock 
uses a fast conformational search method based on genetic algorithms, along with an 
empirical free energy force field calibrated against a large set of diverse ligand-receptor 
complexes.  This combination allows Autodock to find an optimal docked conformation 
with modest computational effort, while predicting free energies of binding leads to VLS 
(42).  Molecular docking is performed with the crystal structure of the target and the 
!
 
Figure 1.3.  Strategies to develop the small molecular inhibitors against APR, A. Virtual ligand screening  
(VLS) and B Rational design.  
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virtual ligand library as shown in Figure 1.3A.  Using the x-ray crystal structure of 
Pseudomonas aeruginosa APR (PaAPR), we have initiated small scale screening of the 
NCI (National Cancer Institute) diversity set library.  The results are filtered based on the 
docking score, which consists of the lowest free binding energy and cluster size as well 
as compounds identified from the screen and investigated experimentally for their 
potency. These lead compounds will serve as a starting point for structure activity 
relationship (SAR) studies and provide scaffolds for the construction of potent inhibitors 
(41, 43).  There are several advantages of the application of VLS for our study.  First, 
VLS does not require small molecule compound collections, synthesized ligand libraries 
or a purified target receptor.  Second, this process is fast, economical and does not rely 
on the availability of chemical compounds.  Finally, VLS avoids the need to consider 
influences that could possibly interfere with experimentally applied assay conditions 
such as limited solubility, aggregate formation and side interactions (33). 
 
1.6.3.2 Rational drug design 
Rational drug design is based on the lock and key analogy first postulated in 1894 by 
Emil Fischer (44).  This analogy helps explain the specific interaction between an 
enzyme and its substrate if we consider the enzyme as the lock and its substrate as the 
key.  It has also been observed that enzymes are rather flexible structures, in which the 
active site amino acid residues position themselves to make optimum contacts with the 
substrate.  Extending the idea that the enzyme and the substrate possess specific 
complementary geometric shapes that fit exactly into one another, an induced fit model 
has been proposed for rational drug design wherein small molecules are designed such 
that they complementary in shape and charge to the active site of the enzyme.  This 
powerful technique that has now come to dominate the drug discovery process.  In fact, 
the discovery of drugs for HIV infection and AIDS was performed entirely via a rational 
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drug design approach targeting HIV protease binding sites (45, 46).   
 
For our study, the crystal structure of PaAPR bound to APS serves as a starting point to 
identify functional groups on the substrate that are likely to contribute favorably to ligand 
binding (Figure 1.3B).  The protein monomer has a Rossmann-like fold with a central six-
stranded !-sheet interleaved with seven "-helices that create a deep active site pocket.  
The enzyme coordinates a [4Fe-4S] cluster via four cysteine residues.  The substrate 
APS extends across the C-terminal ends of the ! strands such that its phosphosulfate 
moiety is positioned toward the [4Fe-4S] cluster (47).  Using chemically synthesized 
substrate/product analogs of APR, we can perform functional experiments to investigate 
the contacts between APR and its substrate.  Analyses of the energetic contribution of 
individual portions of APS to the enzyme-binding interaction will offer valuable insights 
into substrate recognition of APR.  Furthermore, the mapping of interactions 
(electrostatic, hydrogen bonding, hydrophobic and charged) in the active site will provide 
a pharmacology roadmap for future inhibitor design.  Active site interactions are defined 
by the residues where the substrate binds.  In the case of APR, it involves positively 
charged Lys and Arg residues, which make contacts with the phosphosulfate moiety and 
the phosphate-binding loop, which interacts with the ribose sugar of APS.  In addition, 
there are two dynamic elements, the C-terminal peptide that bears the catalytically 
essential cysteine residue and the Arg-loop.  These dynamic features of the enzyme 
suggest that APR can undergo conformational rearrangement at the catalytic step and 
adopt either an ‘open’ or a ‘closed’ conformation depending on the position of the C-
terminal peptide over or out of the active site, respectively (47).  Exploring the dynamics 
of the C-terminal peptide would provide clues for designing effective inhibitors that trap 
certain conformations and deactivate the enzyme.  Additionally, the exact role of the 
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[4Fe-4S] cluster in catalysis and the binding determinants for the interaction of SRs with 
Trx need to be elucidated to understand the mechanistic details of SRs.  These 
investigations would facilitate the design of inhibitors that target the iron-sulfur cluster or 
disrupt protein-protein interactions.   
 
One of the probable reasons for why most experimental compounds entering clinical 
trials fail is a lack of mechanistic knowledge of the biological target (25).  Rational design 
approach can help bridge this gap as it not only helps to understand the molecular 
interactions between ligands and enzymes, but also facilitates elucidation of the enzyme 
mechanisms using biochemical and biophysical analysis.  Our understanding of 
biological ligand-receptor systems leads the way to applications in the drug discovery 
process and the successful design of efficient, specific, and non-toxic small-molecule 
therapeutics.   Other chapters in this thesis describe our efforts towards the identification 
of APR inhibitors, leading to new fundamental insights in bacterial sulfur metabolism that 
could have a major impact on human health. 
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Chapter 2 
Structure-based virtual ligand screening and biological evaluation of 
Mycobacterium tuberculosis Adenosine 5’-phosphosulfate reductase inhibitors 
 
This work has been published as “Structure-based virtual ligand screening and biological 
evaluation of Mycobacterium tuberculosis adenosine 5’-phosphosulfate reductase 
inhibitors.” J. Med. Chem. 2008, 51, 6627-6630.  I performed all biological testing of hits 
identified from the virtual ligand screen. 
 
2.1 Abstract 
Tuberculosis is among the world’s deadliest infectious diseases.  Adenosine 5’-
phosphosulfate reductase (APR) catalyzes the first committed step in bacterial sulfate 
reduction and is a validated drug target against latent tuberculosis infection.  We 
performed a virtual screening to identify APR inhibitors.  These inhibitors represent the 
first non-phosphate-based molecules to inhibit APR.  Common chemical features lay the 
foundation for the development of agents that could shorten the duration of 
chemotherapy by targeting the latent stage of TB infection.   
 
2.2. Introduction 
Despite advances in chemotherapy and the Bacillus Calmette-Guérin (BCG) vaccine, 
tuberculosis (TB) remains a leading infectious killer worldwide (1, 2).  Although drugs 
exist to treat TB, they are not effective against bacilli that persist in a dormant or latent 
state within host lesions (3, 4).  As a result, current treatments for TB require a cocktail 
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of three to five drugs for at least 6 months, a regime that many patients are unable or 
unwilling to follow (5).  The lengthy and complex therapy also contributes to the 
development of drug-resistant TB, which is even more difficult and expensive to treat.  
Of the 9 million known cases of TB worldwide, as many as 2% could be extensively 
drug-resistant (6).  This statistic raises the specter of virtually untreatable strains of TB 
and represents a severe public health problem.  For these reasons, there is an urgent 
need for drugs that target the latent phase of TB infection.  
 
To this end, microbial sulfate metabolism represents a promising new area for TB 
therapy (7).  Reduction of inorganic sulfate is the means by which bacteria produce 
sulfide, the oxidation state of sulfur required for the synthesis of essential biomolecules 
including amino acids, proteins, and metabolites (7-10).  Adenosine 5’-phosphosulfate 
reductase (APR, encoded by cysH) catalyzes the first committed step in bacterial sulfate 
reduction.  In this reaction adenosine 5!-phosphosulfate (APS) is reduced to sulfite and 
adenosine 5!-phosphate (AMP) (11).  Consistent with its important metabolic role APR 
was identified in a screen for essential genes in M. bovis BCG and cysH is actively 
expressed during the dormant phase of M. tuberculosis and in the environment of the 
host macrophage (7).  Most recently, Senaratne et al. demonstrated that APR is required 
for survival in the latent phase of TB infection (12).  APR is not found in humans and 
thus represents a unique target for antibacterial therapy.  Recognizing its value as novel 
antibiotic target, in 2006 Chartron et al. reported the three-dimensional (3D) crystal 
structure of Pseudomonas aeruginosa APR in complex with APS substrate (13).  P. 
aeruginosa and M. tuberculosis APR are related by high sequence homology (27.2% of 
sequence identity and 41.4% of sequence similarity), particularly in residues that line the 
active site (Appendix 3.7.2).  In this structure, APS is situated in a deep active site cavity 
with the phosphosulfate extending toward the protein surface.! 
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Conserved and semiconserved residues 
participate in four main-chain hydrogen bonds 
with adenine and the ribose O2!hydroxyl 
(Figure 2.1).  Interaction between the 
phosphosulfate and APR occurs via strictly 
conserved residues Lys144, Arg242, and 
Arg245 (Figure 2.1).  The phosphosulfate is 
also positioned opposite an [4Fe-4S] cofactor 
and Cys140.  However, the substrate is not in 
direct contact with the [4Fe-4S] cluster; the 
sulfate oxygens are 7 Å from the closest iron 
atom and 6 Å from the closest cysteine sulfur 
atom.  
 
To date, only nucleotide-based inhibitors have been reported for APR, and these are 
expected to have limited bioavailability (14).  Solution of the P. aeruginosa APR structure 
in complex with substrate affords a new opportunity for the discovery of inhibitors, 
particularly in the application of high-throughput docking of molecular databases to 
identify lead compounds.  To this end, we have taken an approach that combines 
computational docking methods with biochemical evaluation.  
 
2.3 Results and Discussion 
2.3.1 Virtual ligand screening of NCI diversity set 
!
 
Figure 2.1.  Experimental binding 
conformations of APS in APR structure. 
Substrate is displayed with carbon atoms in 
green, and key binding site residues are 
labelled.  Hydrogen bonds are represented 
with dashed yellow lines. 
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The new version of AutoDock (AD4) (15) was used to conduct virtual ligand screening 
(VLS) of the National Cancer Institute (NCI) Diversity Set (16) against the P. aeruginosa 
APR crystal structure (PDB code 2GOY).  Initial docking calculations were performed 
using APS substrate to evaluate APR as a structural model for VLS.  The docked 
conformation determined by AD4 with the lowest predicted binding energy (-9.46 
kcal/mol, "GAD4) was in excellent agreement with the bound conformation observed for 
APS in the crystal structure (rmsd 0.7 Å); the calculated positions of the adenine ring, 
ribose sugar, and phosphosulfate group were 
almost identical to those found in the crystal 
structure.  On the basis of these encouraging 
results, VLS calculations were performed with 
the APR crystal structure using the database 
of compounds in the NCI Diversity Set.  The 
VLS results were sorted on the basis of their 
predicted binding free energies ("GAD4), 
which ranged from -3.16 to -13.76 kcal/mol, 
and according to the cluster size for each 
docking conformation.  Solutions with a 
predicted binding free energy greater than -
8.0 kcal/mol and a cluster size lower than 20 
out of 100 individuals were discarded. 
 
 
 
Figure 2.2.  Results of the VS (using AD4) of 
the NCI Diversity Set against APR. a) Bars 
represent numbers of Diversity Set 
compounds with predicted free energies of 
binding in the indicated 1 kcal/mol bins.  Red 
bars highlight the energies of those 
compounds having a "GAD4 lower than -8 
kcal/mol.  b) Bars represent the population of 
the frequency of occurrence of the largest 
cluster for each docked ligand.  Red bars 
highlight a frequency of occurrence higher 
than 20 out of 100. 
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Cluster size is included in these 
criteria as an empirical measure of the 
configurational entropy, as shown in 
previous work (14).  On the basis of 
these criteria, 14.8% of the solutions 
had energies lower than -8.0 kcal/mol, 
43.3% had a cluster population higher 
than 20 individuals, and 10.0% (192 
compounds) met both these criteria  
(Figure 2.2).  The predicted binding 
conformations for these 192 solutions 
were visually inspected.  Compounds 
that were not predicted to interact with 
important residues such as Lys144, 
Arg242, or Arg245 were removed from 
consideration.  After this final step, 42 
compounds corresponding to 2% of 
the original NCI Diversity Set were 
selected for further analysis.  When 
ordered from NCI (The NCI/DTP Open 
Chemical Repository), three of these 
compounds were not available, so 39 compounds were obtained for biochemical testing.  
Assessment of the 39 top-ranked compounds from the VLS as potential inhibitors of 
APR was performed using a standard radioactive assay, measuring APR reduction of 
35S-labeled APS substrate.  The compounds that exhibited significant inhibitory activity 
(more than 50% inhibition) are listed in Table 1, along with the AD4 binding energies and 
Table 2.1.  Structures, AutoDock Binding Energies and 
Activities of APR First Generation Inhibitor 
Compounds. !
Chemical  
Structure 
NSC 
Number 
#GAD4 
(kcal/mol) 
Kd 
(µM) 
O
S
O
COO-
! 16211 -8.72 180.35 
O
NO2
NO2 ! 133896 -8.75 37.11 
N
N
N
COO- ! 327704 -8.21 46.85 
N
O N
S
N
N N
N
HH2N
NO2
! 348401 -9.63 15.19 
O
COO-
COO-
H
OH
!
9746 -9.34 127.19 
!
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measured activities.  Three compounds from this set, tested at 100 µM, inhibited APR 
activity by more than 50%: 133896, 327704, and 348401 (Table 2.1).  In particular, 
348401 resulted in more than 90% inhibition (Table 2.1).  Compounds listed in Table 1 
were predicted to have the similar affinities for APR (see Table 1, "GAD4); however, the 
experimental binding constants span a range of 6.81-48.11 µM.  This is not unexpected, 
since the computed binding energies in calibration experiments typically have errors in 
the range of 2 kcal/mol, which corresponds roughly to a 30-fold difference in predicted 
binding constants.  The above-mentioned compounds, representing the most potent 
inhibitors from our screen, were investigated further and were found to produce 
concentration-dependent inhibition of APR activity without promiscuous inhibition.  Data 
were fit to a competitive inhibition model (R2 # 0.98), and the inhibition constant (Ki) was 
determined for each compound in Table 2.1.  Under the conditions employed for these 
assays the Ki was equal to the dissociation constant (Kd) of each compound.  
Dissociation constants for the most potent inhibitors in Table 1 ranged from 15 to 50 µM. 
 
2.3.2 Virtual ligand screening of NCI similarity database 
Second-generation lead compounds were identified by docking and assaying 
compounds from similarity searches, based on chemical structures and substructures of 
the Diversity Set leads.  This search was performed using the Enhanced NCI Database 
Browser, a Web-based graphical user interface with a large number of possible query 
types and output formats.  The 890 out of 250 000 compounds were identified in the 
Open NCI database with at least 80% Tanimoto similarity and docked.  The 40 highest-
scoring solutions, ranked according to the criteria outlined above, were experimentally 
evaluated using our biochemical assay.  Five compounds were identified with 
dissociation constants less than 50 µM, with four similar to primary lead 133896 (60826, 
55545, 57476, and 23180) and one similar to primary lead 348401 (228155).   
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The similarity search based on the 
parent compound 133896 identified 
three new leads (60826, 55545, and 
57476) with a 9-fluorenone core 
structure and activity against APR and 
the 9-fluorenone core structure (Table 
2.2).  The dihydrophenanthrendione 
23180 was the most potent inhibitor 
identified in this study, with a 
dissociation constant of less than 10 
µM.  Visual inspection of the predicted 
binding pose for 23180 (Figure 2.3a) 
reveals that the aromatic polycyclic 
scaffold inserts into a profound gorge 
(referred to as L1) and makes 
favorable hydrophobic contacts with 
the side chains of residues Leu90 and Ile98.  Additional interactions include the nitro 
functional group in proximity to positively charged active site residues Lys144 and 
Arg245 (referred to as P1) as well as hydrogen bonding from the carbonyl oxygens in 
the aromatic moiety to the backbone amide of Leu85 and side chain of Ser62.   
 
Similar binding poses and interactions are predicted for compounds 133896, 60826, 
55545, and 57476.  However, these molecules have one less carbonyl oxygen in the 
aromatic moiety relative to the dihydrophenanthrendione chemical scaffold.   
 
Table 2.2.  Structures, AutoDock Binding Energies and 
Activities of APR Second Generation Inhibitor 
Compounds. !
Chemical Structure NSC Number 
#GAD4 
(kcal/mol) 
Kd 
(µM) 
O
NH
NO2
O
 
60826 -8.46 31.79 
O
NO2
O2N  
55545 -8.23 48.11 
O
NO2
F
F
 
57476 -8.60 44.59 
O
O
NO2  
23180 -8.94 6.81 
N
O
N
S
N+
NO2
O-  
228155 -8.7 19.51 
!
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As a result, the 9-fluorenone-derived compounds 
are not predicted to form a hydrogen bond with 
Ser62 and could account for the difference in 
potency between the two structural cores.  We 
also note that neither 9-fluorenone nor 2-nitro-9-
fluorenone, which are closely related to 133896, 
exhibited significant activity against APR.  Rather, 
our data indicate that a H-bond acceptor group is 
required at position 3 or 4 of the 9-fluoronone 
scaffold to acquire inhibitor potency (Table 2.2 
and Figure 2.3).   
 
Previous studies show that compound 23180 can 
inactivate the tyrosine phosphatase CD45 via a 
catalytic and oxygen-dependent reaction 
(Kinactivation 4300 M-1s-1) (17).  Although the precise 
mechanism remains unknown, inactivation of 
CD45 by 23180 is correlated with oxidation of a 
catalytic cysteine residue to sulfinic and sulfonic 
acid.  To test whether 23180 inhibited APR in a 
similar fashion, control experiments were performed.  Unlike CD45, preincubation of 
APR with 23180 did not result in enzyme inactivation and Cys256 was not covalently 
modified. 
 
Compound 327704 is structurally unrelated to other inhibitor cores identified by these 
studies.  Nonetheless, this compound is also predicted to interact with the L1 pocket via 
!
 
Figure 2.3.  Docked conformations of 
NSC23180 (a) and NSC348401 (b) in 
APSR structure.  Ligands are displayed 
as in Figure 2.1.  Hydrogen bonds are 
represented with dashed yellow lines. 
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its polycyclic aromatic ring and the P1 region through the polar carboxylate group.   
 
Compounds 348401 and 228155 contain a benzoxadiazole moiety.  This functional 
group adopts the same binding pose in both compounds and is oriented in a way that 
maximizes electrostatic interactions with Arg242 and Lys144 (Figure 2.3b).  Each 
benzoxadiazole is distinguished by a pendent thioaryl group, which is embedded in a 
hydrophilic cleft (referred as L2) and forms two hydrogen bonds to the side chains of 
Asp66 and Glu65.  The low micromolar activity of 348401 and 228155, combined with 
the ability to chemically derivatize the purine scaffold, suggests that this compound class 
may be a promising lead.   
 
Interestingly, though compounds 
23180 and 348401 contain a 
polycyclic aromatic ring, they are 
not predicted to adopt the same 
binding position and interact with 
similar residues (Figure 2.4).  
Rather, 23180 is positioned deep 
inside the L1 cavity, flanked by the 
[4Fe-4S] cluster while 34801 
occupies the shallower and more 
polar L2 region of the active site, 
which is consistent with the more 
polar nature of the ring in this 
compound.  Nevertheless, both classes of inhibitors are predicted to interact with the 
conserved positively charged residues that border both clefts in the P1 site.  These 
!
 
Figure 2.4.  Binding pose of both NSC23180 and 
NSC348401 in the APSR binding site.  Ligands and 
residues belonging to the P1 site and are depicted in 
capped sticks colored by atom types.  Residues 
belonging to the L1 and L2 sites are depicted as MSMS 
surface colored with #G colors, the protein secondary 
structure (white ribbon) is also depicted. 
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observations suggest that a ligand, which can occupy both L1/L2 clefts and bears polar 
hydrogen bond accepting groups to interact with the P1 site, may exhibit higher activity 
against APR.  We are currently testing this model, and the results of these studies will be 
reported in due course.   
 
2.4 Conclusion 
In conclusion, we have applied virtual ligand screening of compounds from the NCI 
database to identify low micromolar inhibitors of M. tuberculosis APR, a validated target 
against latent TB infection.  The molecules described here are the first non-phosphate-
based inhibitors of this enzyme and may form the basis for development of an APR 
inhibitor pharmacophore.  Further studies on the inhibitors identified here should also 
shed light into the mechanism, targeting, and therapeutic potential of this enzyme. 
 
2.5 Experimental Procedure 
2.5.1 Virtual Screening Calculations  
The AutoDock 4.0 (AD4) (15, 18) software package, as implemented through the 
graphical user interface called AutoDockTools (ADT) (19), 
was used to dock small molecules to APR.  The enzyme 
file was prepared using published coordinates (PDB 
2GOY) (13).  The terminal residues were modified to 
charged quaternary amine and carboxylate forms.  The 
[4Fe-4S] cluster was retained with the protein structure.  
Charges of this group were manually assigned.  In our 
case, the cluster is believed to have two ferric (+3) and 
two ferrous (+2) irons (20).  Since the eight sulfur atoms (four belonging to the cluster 
and four belonging to the four cysteines) have a net charge of -1, the total net charge of 
Table 2.3. Calculated Charges 
for [Fe4S4(SCH3)4]2- !
Atom ESP Charges 
Feox  +0.642 ($2)  
Fered  +0.635 ($2)  
S*ox  -0.584 ($2)  
S*red  -0.580 ($2)  
Sox  -0.574 ($2)  
Sred  -0.571 ($2)  !
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the system should be of -2.  Noodleman and co-workers calculated the ESP charges for 
models of the cluster in this oxidation state (21).  These charges were added to APR 
iron-sulfur cluster atoms and to the four sulfur of the coordinating cysteines (Table 2.3).   
 
All other atom values were generated automatically by ADT.  The docking area was 
assigned visually around the enzyme active site.  A grid of 80 Å x 80 Å x 80 Å with 0.375 
Å spacing was calculated around the docking area for 13 ligand atom types using 
AutoGrid4.  These atom types were sufficient to describe all atoms in the NCI database.  
For VS, compound structures of the NCI Diversity Set and the ones derived from the 
similarity search were prepared using the ZINC database server 
(http://zinc.docking.org/uploads.html) (22) to take into account the different protomeric 
and tautomeric states of each compound.  All the ligands were then converted in the 
AutoDock format file (.pdbqt).  For each ligand, 100 separate docking calculations were 
performed.  Each docking calculation consisted of 10 million energy evaluations using 
the Lamarckian genetic algorithm local search (GALS) method.  The GALS method 
evaluates a population of possible docking solutions and propagates the most 
successful individuals from each generation into the subsequent generation of possible 
solutions.  A low-frequency local search according to the method of Solis and Wets is 
applied to docking trials to ensure that the final solution represents a local minimum.  All 
dockings described in this paper were performed with a population size of 150, and 300 
rounds of Solis and Wets local search were applied with a probability of 0.06.  A 
mutation rate of 0.02 and a crossover rate of 0.8 were used to generate new docking 
trials for subsequent generations, and the best individual from each generation was 
propagated to the next generation.  The docking results from each of the eight 
calculations were clustered on the basis of rootmeansquare deviation (rmsd) between 
the Cartesian coordinates of the atoms and were ranked on the basis of free energy of 
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binding.  The top-ranked compounds were visually inspected for good chemical 
geometry.  Pictures of the modeled ligand/enzyme complexes were rendered with PMV 
(19).!
 
2.5.2 Preparation of NCI Compounds 
Compounds determined by AD4 to have low binding energies to APR were requested in 
groups of 40 and received from the Drug Synthesis and Chemistry Branch, 
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, 
National Cancer Insititute (http://dtp.nci.nih.gov/branches/dscb/repo_request.html).  
Chemical compounds were dissolved in DMSO to 10 mM final concentration and stored 
at room temperature. 
 
2.5.3 Enzyme Purification 
Purification of APR was carried out as previously described (13).   
 
2.5.4 APS Reductase Activity Assay 
APR activity was assayed using a modification of an assay for monitoring 35SO42- release 
from ATP-sulfurylase as follows (20).  Reactions were performed in a final volume of 100 
µl.  At various time points, a 10 µl aliquot was removed from the reaction and added to 
0.5 ml of a 2% (w/v) charcoal solution containing 20 mM Na2SO3.  The suspension was 
vortexed, clarified by centrifugation and a 400 µl aliquot of the supernatant solution, 
containing the radiolabeled sulfite product, was counted in 10 ml of scintillation fluid.  
35S-labeled APS was synthesized and purified as previously described (23) with the 
inclusion of an additional anion exchange purification step (5 ml Fast Flow Q column 
(GE Healthcare) eluting with a linear gradient of ammonium bicarbonate, pH 8.0, from 
0.005 to 0.7 M. 
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2.5.5 General Kinetic Methods.  
Unless otherwise specified, the reaction buffer was 100 mM Bis-Tris pH 7.5, 5 mM DTT, 
and the temperature was 30 °C.  The auxillary protein reductant, thioredoxin was added 
at 10 µM. With the exception of slow reactions, the enzymatic reactions were monitored 
to completion (# 3 half lives) and rate constants were obtained by nonlinear least-
squares fit to a single exponential (Kaleidagraph).  To ensure single-turnover reactions, 
the concentration of APR was kept in excess of the concentration of labeled APS (~1 
nM).  Two or three concentrations of APR were chosen that were at least 10-fold below 
the KM value.  Under these conditions, the observed rate constant was linearly 
dependent on enzyme concentration.  Thus, reactions were first order in APS and APR 
in all cases.  Under subsaturing conditions, with [APS] << KM, the Michaelis-Menton 
equation (eq 1) simplifies to equation 2 (24).  The reaction progress curve was plotted as 
a function of time and the fractional extent of reaction, and fit by a single-exponential 
function (eq 3) to yield kobs, which is the product of enzyme concentration and the 
apparent second-order rate constant (eq 4).  Kinetic data were measured in at least two 
independent experiments and the standard error was typically less than 15%. 
Vobs = [E][S]kcat/(Km + [S])  (1) 
Vobs = (kcat/Km)[E][S]   (2) 
fraction product = 1 – e-kobst   (3) 
kobs = (kcat/Km)[E]   (4) 
 
2.5.6 Inhibitor Screening.  
For initial screening, compounds were tested in kinetic assays at 100 µM final 
concentration.  Compounds that inhibited more than 50% at this concentration were 
analyzed further as described below.   
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2.5.7 Analog Dissociation Constants.  
The standard assays and conditions described above were used to monitor the kcat/Km 
for reduction of APS in the presence and absence of inhibitor.  Values of Ki were 
determined from the dependence of the observed rate constant (kobs) on inhibitor 
concentration.  With subsaturating APS, the inhibition constant is equal to the 
dissociation constant (Ki = Kd).  Except in cases where solubility was a limiting factor, a 
range of inhibitor concentrations was employed from at least 5-fold below to 10-fold 
above the inhibition constant.  Nonlinear least-squares fits of the equation for 
competitive inhibition (eq 5) gave excellent fits in all cases, and the standard error was 
typically less than 15%.   
(kcat/Km)obs = (kcat/Km)/(1 + [I]/Ki) (5) 
 
2.5.8 Catalytic inactivation of APR by 2-nitro-9,10-phenanthrenedione. APR (9 µM) 
was incubated with compound 23180 (0.9 µM) or DMSO and enzyme activity was 
measured at 1, 15 and 30 min.  No statistical difference was observed in the activity of 
the enzyme in these experiments indicating that compound 23180 did not catalytically 
inactivate APR. 
 
2.5.9 Thiol Quantification. 
Labeling of APR by the thiol-reactive probe NBDCl was carried out using a modification 
of a following the published procedure (17).  Briefly, APR (10 µM) was incubated, at 
room temperature, in a final volume of 1 ml of buffer containing 50 mM BisTris (pH=7.5), 
1 mM EDTA, and 1 mM DTT with (a) DMSO or (b) 10 µM compound 23180.  NBDCl (50 
µM) was added to each of the resulting solutions and incubated for 30 minutes at room 
temperature.  Excess NBDCl was removed from the labeled APR by ultracentrifugation 
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prior to the UV-vis scan.  No loss in APR thiol labeling was observed in the presence of 
inhibitor. 
 
2.5.10 Promiscuous Inhibition.  
At the suggestion of one reviewer, we tested members of each structural class of 
inhibitor for promiscuous inhibition.  Assays were carried out as described above in the 
presence of 0.01% Triton, and showed no significant difference in Kd with the assay 
without detergent.  We also performed a gel shift assay of trypsin activity acting on APR 
in the presence of inhibitors. By this gel assay, none of the inhibitors at concentrations of 
50 !M changed the proteolysis pattern of trypsin and qualitatively indicates that the 
compounds are not inhibiting trypsin. 
 
2.6 Appendices  
Figure 2.6.1 Structure based sequence alignment of 17 APR from prokaryotes. 
The ClustalW Multiple Sequence Alignment program was used. Strictly conserved 
residues are outlined in red, red letters indicate conserved residues and conserved 
regions are boxed in blue.  Alignment pictures were rendered with the server ESPript 2.2 
(http://espript.ibcp.fr) 
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Figure 2.6.2 Structure based sequence alignment of PaAPR and MtAPR. 
The ClustalW Multiple Sequence Alignment program was used.  Strictly conserved 
residues are outlined in red, red letters indicate conserved residues and conserved 
regions are boxed in blue.  Residues flanking the active site are outlined in green.  
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Chapter 3 
Identification of critical ligand binding determinants in Mycobacterium 
tuberculosis adenosine-5’-phosphosulfate reductase 
 
This work has been published as “Identification of critical ligand binding determinants in 
Mycobacterium tuberculosis adenosine-5’-phosphosulfate reductase” J. Med. Chem. 
2009, 52, 5485-5495.  I purified the enzyme required for these experiments and 
conducted all subsequent kinetic and thermodynamic analyses.  I synthesized all 
analogs, with the exception of thio-APS, !-fluoro ADP, and compounds in Figure 3.6.  
 
3.1 Abstract 
Mycobacterium tuberculosis adenosine-5’-phosphosulfate (APS) reductase is an iron-
sulfur protein and a validated target to develop new antitubercular agents, particularly for 
the treatment of latent infection.  To facilitate the development of potent and specific 
inhibitors of APS reductase (APR), we have probed the molecular determinants that 
underlie binding and specificity through a series of substrate and product analogues.  
Our study highlights the importance of specific substituent groups for substrate binding 
and provides functional evidence for ligand-specific conformational states.  An active site 
model has been developed for M. tuberculosis APR that is in accord with the results 
presented here as well as prior structural data reported for Pseudomonas aeruginosa 
APR and related enzymes.  This model illustrates the functional features required for the 
interaction of APR with a ligand and provides a pharmacological roadmap for the rational 
design of small molecules as potential inhibitors of APR present in human pathogens, 
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including M. tuberculosis. 
 
3.2 Introduction 
Reduced sulfur appears in organic compounds essential to all organisms as constituents 
of proteins, coenzymes, and cellular metabolites (1-3).  In the amino acid cysteine, the 
thiol functional group plays important biological roles in redox chemistry, metal binding, 
protein structure, and catalysis (4).  In many human pathogens such as Mycobacterium 
tuberculosis and Pseudomonas aeruginosa, activation of inorganic sulfur for the 
biosynthesis of cysteine proceeds via adenosine 5$-phosphosulfate (APS) (5, 6).  This 
high-energy intermediate is produced by the action of ATP sulfurylase, which condenses 
sulfate and adenosine 5’-triphosphate (ATP) to form APS.  The iron-sulfur protein, APS 
reductase (APR) catalyzes the first committed step in sulfate reduction and is a validated 
target to develop new anti-tubercular agents, particularly for the treatment of latent 
infection (7-9). 
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Figure 3.1.  Sulfate assimilation pathway in M. tuberculosis.  The majority of sulfate reducing bacteria 
use APS as their source of sulfite.  In this reaction, APS is reduced to sulfite and adenosine-5!-
monophosphate (AMP) by APR.  Sulfite, in turn, is reduced by later enzymes in this metabolic pathway, 
forming first sulfide before incorporation into cysteine and, ultimately, to methionine and other essential 
reduced sulfur-containing biomolecules.!
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APR catalyzes the reduction 
of APS to sulfite (HSO3–) and 
adenosine 5’-monophosphate 
(AMP) using reduction 
potential supplied by the 
protein cofactor, thioredoxin 
as shown in Figure 3.1.  
Functional and structural 
studies have been used to investigate the mechanism of APR from sulfate-assimilating 
bacteria (10-12).  The proposed mechanism in Figure 3.2 involves nucleophilic attack by 
cysteine 256 (Residue numbers throughout this chapter correspond to the APR 
sequence from P. aeruginosa (Appendix 3.6.1) on the sulfur atom in APS to form an 
enzyme S-sulfocysteine intermediate, E-Cys-S%–SO3–, which is then reduced through 
intermolecular thiol-disulfide exchange with thioredoxin.  The iron-sulfur cluster in APR is 
essential for activity; however, it is not involved in redox chemistry and its exact role 
remains unknown (6, 10).  
 
Crystal structure determination at 2.7 Å of P. aeruginosa APR (PaAPR) in complex with 
APS provided the first insight into the molecular basis for substrate recognition (Figure 
3.3) (12).  M. tuberculosis APR (MtAPR) and PaAPR are related by high sequence 
homology (27.2% of sequence identity and 41.4% of sequence similarity), particularly in 
the residues that line the active site.  The protein monomer folds as a single domain with 
a central six-stranded ! sheet, interleaved with seven "-helices (Figure 3.3).  Opposite 
the nucleotide at one end of the active site is the [4Fe-4S] cluster.  Three additional 
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Figure 3.2.  Mechanism of sulfonucleotide reduction.  
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elements define the active site: the 
P-loop (residues 60-66), the LDTG 
motif (residues 85-88) and the Arg-
loop (residues 162-173).  APS fits 
into the active site cavity with the 
phosphosulfate moiety extending 
toward the protein surface and ten 
residues interact directly, via 
hydrogen bonding or hydrophobic 
interactions with the substrate.  The 
C-terminal segment of residues 250-
267, which carries the catalytically 
essential Cys256, is disordered in 
this structure, but would be 
positioned above the active site cleft.   
 
Not all organisms that assimilate sulfate reduce APS as the source of sulfite.  Through 
divergent evolution, some organisms, such as Escherichia coli and Saccharomyces 
cerevisiae reduce the related metabolite 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) (11), which is produced by APS kinase from ATP and APS (13).  PAPS 
reductases (PAPR) lack the iron-sulfur cofactor, but utilize the same two-step 
mechanism shown in Figure 3.2 (10, 11).  S. cerevisiae PAPR (ScPAPR), crystallized in 
the presence of the product, 3’-phosphoadenosine 5’-phosphate (PAP) (14) has a fold 
similar to APR (1.6-Å rms deviation over 117 residues).  In the structure of yeast PAPR, 
the Arg-loop and C-terminal segment are folded over the active site and this 
  
 
Figure 3.3.  The structure of P. aeruginosa APS 
reductase in complex with substrate, APS (PDB 2GOY).  
The C-terminal segment of residues starting at Glu249 
carries the catalytically essential Cys256 and is 
disordered. 
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conformation reveals additional enzyme-ligand contacts, which may also form between 
APR and its substrate, APS.  
 
Even though M. tuberculosis has plagued humans for millennia, the antibiotic regime is 
complex and effective drugs that specifically target latent TB infection are yet to be 
developed (15).  Novel targets (16, 17) and treatment strategies (18, 19) are emerging, 
but new avenues for therapeutic intervention must continue to be explored in order to 
combat multidrug-resistant strains of TB, which pose a significant threat to global human 
health (20).  To this end, APR represents an attractive target for therapeutic intervention 
because it is essential for mycobacterial survival in the latent phase of TB infection (9) 
and humans do not possess an analogous metabolic pathway.  Recently, we have 
discovered small-molecule inhibitors of APR through virtual ligand screening (21).  
However, the development of more specific and potent inhibitors will be greatly aided 
through knowledge of the functional importance of interactions between the substrate 
and enzyme at the active site, which have not yet been experimentally addressed. 
 
Herein, we probe binding determinants of the MtAPR active site using synthetic ligand 
analogs.  These studies define chemical groups that are essential for molecular 
recognition and reveal a network of electrostatic interactions, which play an important 
role in substrate discrimination.  An active site model has been developed for MtAPR 
that is in accord with the results presented here as well as prior structural data reported 
for PaAPR and related enzymes.  This model illustrates the functional features required 
for the interaction of APR with a ligand and provides a pharmacological road map for the 
rational design of small-molecules as potential inhibitors of APR present in human 
pathogens, including M. tuberculosis. 
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3.3 Results and Discussion 
The substrate and fragments studied and results obtained in these experiments are 
summarized in Tables 3.1-3 and Figures 3.4-9.   
 
3.3.1 Substrate Affinity   
As a starting point to explore the molecular recognition properties of APR, we 
determined the Kd value of substrate APS for MtAPR from the dependence of the 
observed rate constant for S-sulfocysteine formation (Appendix 3.6.2), as described in 
Experimental procedures.  The substrate APS binds to APR with a Kd value of 0.2 !M 
(Table 3.1), which is ~3-fold lower than the value of the reported substrate Km (22). 
 
3.3.2 Affinity of Substrate Fragments 
To gain further insight into substrate recognition of MtAPR, we analyzed the energetic 
contribution of individual portions of APS to the enzyme-binding interaction.  The results 
obtained in these experiments are summarized in Table 1.  The product AMP differs 
chemically from the natural substrate, APS, by the absence of the sulfate moiety.  The 
loss of sulfate from APS reduced binding to APR about 30-fold (2 kcal/mol), 
demonstrating that the AMP moiety makes a substantial contribution (7.3 kcal/mol) to the 
overall binding affinity (9.3 kcal/mol) of APS.  Deletion of the adenine or phosphate 
group from AMP decreased binding to APR by ~170-fold (3.1 kcal/mol) and ~550-fold 
(3.8 kcal/mol), respectively.  Fragments of adenosine – D-ribose and adenine – exhibited 
weak binding activity toward APR (0.2 and %1.5 kcal/mol).  The respective free energy of 
binding to sulfate and phosphate dianions was %0.7 and 1.6 kcal/mol.  Figure 3.4 
summarizes the binding properties of the substrate, APS and product, AMP for MtAPR 
as compared with those of the fragments obtained by cutting these ligands at several 
positions, including the glycosidic bond, and at &- or !-positions within the diester moiety.  
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In all cases, the Kd value of APS or AMP was lower than those of its pieces.  However, 
the free energies ('Gconn) associated with these connectivity effects for APR are modest 
(%2.2 kcal/mol), as compared to values that have been determined for adenosine (30) 
and cytidine deaminases (31) (~10 kcal/mol).  
 
Table 3.1. Ligand dissociation constants for substrate-fragments with APR. 
Ligand Structure Kd [µM][c] 
!!G 
[kcal/mol][d] pKa 
APS[a] 
N
NN
N
NH2
O
OHOH
OPO
O–
O
S–O
O
O
 
0.20 N/A ~2 (O)[e] 
AMP 
N
NN
N
NH2
O
OHOH
OP–O
O–
O
 
5.4 2.0 6.8 (O) (23) 
5'-
Phosphoribose 
O
OHOH
OP–O
O–
O
OH
 
93 5.1 ~6.8 (O)[f] 
Adenosine 
N
NN
N
NH2
O
OHOH
HO
 
3000 5.8 3.6 (N1), 12.4 (O) (24) 
Phosphate OHP–O
O–
O
 
66000 7.7 1.97 (O), 6.82 (O), 12.5 (O) (25) 
Ribose 
O
OHOH
HO
OH
 
680000 9.1 12.22 (O) (26) 
Adenine[b] N
NN
H
N
NH2
 
# 90000 # 7.3 4.15 (N1), 9.80 (N9) (26) 
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Sulfate[b] O–S–O
O
O  
# 
310000 # 8.6 -3 (O), 1.89 (O) (27) 
[a] The Kd of APS was measured under single turnover conditions, in the absence of thioredoxin, as 
described in the methods section.  [b] Due to the limits of solubility or solution ideality the reported values are 
lower limits.  [c] For substrate-fragments in this table values of Ki were determined under single turnover 
conditions from the dependence of the observed rate constant at a given inhibitor concentration under 
conditions of subsaturating APS, such that Ki is equal to the Kd.  Each value reflects the average of at least 
two independent experiments, and the standard deviation was less than 15% of the value of the mean.  
Kinetic data were nonlinear-least squares fit to a model of competitive inhibition.   [d] Energetic difference in 
affinity of APS relative to inhibitor, ''G = -RTln(KdAPS/KdFragment).  [e] pKa estimated from value measured for 
2’-deoxy-5’-phosphoribose (28).  [f] pKa estimated from value measured for 3’-phospho-5’-
adenosinephosphosulfate (29).   
 
3.3.3 Affinity of Substrate Analogs 
3.3.3.1 !-Nucleotide Substitution  
The results above suggest that the !-sulfate group plays a modest role (%2.0 kcal/mol) in 
molecular recognition of APS.  To probe this observation in further detail, we 
investigated binding affinities for a panel of nucleotide analogs containing systematic 
modifications at the !-position (Table 3.2 and Figure 3.5).  A phosphate oxyanion has 
nearly the same size and shape as a sulfate oxyanion, four atoms arranged tetrahedrally 
around a sulfur instead of a phosphorous (32, 33).  However, the overall charge of these 
analogs differs since the !-sulfate is monoanionic, whereas the !-phosphate is dianionic.  
Replacement of the !-sulfate moiety with !-phosphate, as in adenosine 5’-diphosphate 
(ADP), diminished binding to APR about 20-fold (1.8 kcal/mol).  To determine whether 
this decrease in binding affinity is due to additional negative charge at the !-position of 
ADP, relative to APS, we examined sulfur (ADP!S), fluorine (ADP!F), or amine 
(AMPPN) substitution of the !-phosphate nonbridging oxygen atom in ADP (Table 3.2 
and Figure 3.5).  Sulfur substitution is considered to be a good mimic of the phosphate 
moiety since it is isosteric, pseudoisoelectronic, and has a similar charge distribution and 
similar net charge at physiological pH (34, 35).  Fluorine substitution replaces 
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an ionizable hydroxyl group, thereby mimicking the protonated nucleotide species in net 
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Figure 3.4.  Effects of cutting the substrate, APS and the product, AMP into fragments on ligand Kd 
values.  The energetic effect that results from connectivity was calculated based on the affinity of the 
parent ligand ‘XY’, compared with the affinities of its pieces, ‘X’ and ‘Y’: #Gconn = -RTln(KXY/KXKY), as 
previously reported (23). 
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charge at all pH values (36) and, at neutral pH, amine substitution neutralizes the -1 
charge at the !-position.  Compared to ADP, substitution by sulfur increased binding 
affinity by 2.0 kcal/mol, fluorine increased binding by less than two-fold (0.3 kcal/mol), 
and introduction of the amine group decreased the free energy of binding for APR by 2.8 
kcal/mol.   
 
Table 3.2. Ligand dissociation constants for substrate analogs with APR. 
Ligand Structure Kd [µM][a] 
!!G 
[kcal/mol][b] pKa 
ADP!S 
N
NN
N
NH2
O
OHOH
OPO
O–
O
P–O
O
S–
 
0.15 -0.17 5.2 (O) (34) 
ADP"S[c] 
N
NN
N
NH2
O
OHOH
OPO
O
S–
P–O
O–
O
 
0.80 0.83 6.8 (O) (37) 
ADP!F 
N
NN
N
NH2
O
OHOH
OPO
O–
O
PF
O–
O
 
2.5 1.5 N/A 
ADP 
N
NN
N
NH2
O
OHOH
OPO
O–
O
P–O
O–
O
 
4.3 1.8 6.4 (O) (37) 
AMPCF2P 
N
NN
N
NH2
O
OHOH
OPCF2
O–
O
P
O
–O
O–
 
13 2.5 ~5.7 (O)[d] 
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AMPCP 
N
NN
N
NH2
O
OHOH
OPCH2
O–
O
P
O
–O
O–
 
27 2.9 8.1 (O) (38) 
APS"S[c] 
N
NN
N
NH2
O
OHOH
OPO
O
S–
S–O
O
O
 
43 3.2 ~1.6 (O)[e] 
AMPNP 
N
NN
N
NH2
O
OHOH
OPNH
O–
O
P
O
–O
O–
 
260 4.3 7.7 (O), 8.25 (N) (39) 
AMPPN 
N
NN
N
NH2
O
OHOH
OPO
O–
O
PH2N
O–
O
 
410 4.6 3.0 (O), 8.15 (N)[f] 
APS!M 
N
NN
N
NH2
O
OHOH
OPCH2
O–
O
S
O
–O
O
 
700 4.9 ~3.7 (O)[g] 
[a] For substrate analogs in this table values of Ki were determined under single turnover conditions from the 
dependence of the observed rate constant at a given inhibitor concentration under conditions of 
subsaturating APS, such that Ki is equal to the Kd.  Each value reflects the average of at least two 
independent experiments, and the standard deviation was less than 15% of the value of the mean.  Kinetic 
data were nonlinear-least squares fit to a model of competitive inhibition.  [b] Energetic difference in affinity of 
APS relative to inhibitor, ''G = -RTln(KdAPS/KdAnalog).  [c] Kd value for the diastereoisomeric mixture of Rp and 
Sp isomers.  [d] pKa estimated from value for mono- and difluoro-substituted benzylphosphonic acid (40).  [e] 
pKa estimated from effect of thio-substitution on ADP"S (37).  [f] pKa estimated from value measured for 
phosphoramidic acid (41).  [g] pKa estimated from effect of !-methylene-substitution on AMPCP (38). 
 
Taken together, the above data suggest that a net charge of -2 correlates with potent 
enzyme-ligand interactions.  The negative charge can be localized entirely to the &-
position, as in AMP, or it can be distributed across the diester, as in ADP!F.  The 
similarity of Kd values for AMP and ADP could reflect different modes of nucleotide 
binding.  For example, the &-phosphate of AMP could occupy the same position as the 
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!-phosphate in ADP, thereby establishing key electrostatic interactions with Lys144, 
Arg242, and Arg245 (Figure 3.3).  However, an upward shift in the position of AMP 
would likely weaken important enzyme-binding contacts with the adenine ring and ribose 
sugar of AMP (Figure 3.3).  An alternative possibility is that the C-terminus and Arg-loop 
of APR could adopt different conformations, depending on whether ADP or AMP is 
bound at the active site.  In other words, binding energy gained through additional 
charge-charge interactions between the !-phosphate moiety of ADP, Lys144, Arg242 
and Arg245 could be cancelled by a decrease in favorable interactions with residues in 
the C-terminus and the Arg-loop.  Evidence in support for the latter proposal is provided 
in Section 3.3.5 below.   
 
Interestingly, oxyanion substitution of the fluorine group slightly decreased binding 
affinity, whereas thiolate substitution increased binding potency by almost 30-fold.  The 
larger size and polarizability of the sulfur atom could enhance binding affinity by: (i) 
shortening the distance to residues that directly contact the ligand, and/or (ii) enabling 
additional electrostatic or stacking interactions with APR (42).  Finally, we note that 
neutralizing the -1 charge of the !-phosphate, as in AMPPN, is clearly unfavorable.  This 
significant energetic penalty likely results from repulsive electrostatic interactions 
between the amine group, which is protonated at physiological pH (Figure 3.5), and 
adjacent positively charged residues (Figure 3.3).  In line with this hypothesis, the 
!
 
Figure 3.5.  Electrostatic potential surfaces of substrate, APS and related nucleotide analogs.  Color gradient: red 
corresponds to most negative and blue corresponds to most positive.   
! 48!
binding affinity of AMPPN for APS reductase increased at elevated pH (Appendix 3.6.5).  
 
3.3.3.2 "-!  Bridging Oxygen Substitution 
Interactions between the 5’-phosphate and two highly conserved residues – Arg171 and 
His259 – are observed in the structure of ScPAPR bound to PAP (14).  However, owing 
to the mobility of the Arg-loop and C-terminal residues, no direct contacts to the &-
phosphate are observed in the structure of APR (12) (Figure 3.3).  To gain insight into 
the functional importance of these contacts for MtAPR we examined the contribution of 
the &-( bridging oxygen to binding affinity (Table 3.2).  Replacing the P&-O-S( bridging 
oxygen in APS with a methylene group (P&-CH2-S() significantly decreased binding 
affinity by ~3,500-fold (4.9 kcal/mol).  Comparison of ADP with AMPNP (P&-NH–P(), 
AMPCF2P (P&-CF2-P(), and AMPCP (P&-CH2-P() shows that imino, difluoromethylene, 
or methylene substitutions reduced binding potency by approximately 60-fold (2.5 
kcal/mol), 3-fold (0.7 kcal/mol), and 6-fold (1.1 kcal/mol), respectively. 
 
The above findings demonstrate that the &-( bridging oxygen does contribute to ligand 
recognition.  Nonetheless, these data pose several questions: Why is the methylene 
substitution more detrimental for APS binding, relative to the energetic penalty paid for 
analogs modification of ADP?  And, why does AMPNP bind more weakly to APR 
compared to AMPCF2P?  Replacing the bridging oxygen with a methylene group 
decreases the S/P–X–P bond angle, increases S/P–X bond length, increases the 
negative charge density on nonbridging oxygens, but makes the phosphate and sulfate 
groups less acidic (43, 44).  It is possible that methylene subsitution of ADP is less 
detrimental to binding because (i) the phosphonate moiety has more torsional freedom, 
allowing the nucleotide to adopt an alternative favorable binding mode, and/or (ii) 
conformational differences in the C-terminal and Arg-loop segments minimize 
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unfavorable contacts to the &-( bridging position of AMPCP.  NMR studies show that 
AMPPNP and PNP exist in solution primarily as the imido tautomers (39).  Thus, the 
observed decrease in binding affinity could be due to restricted rotation about the P&-
NH–P( bonds.   
 
3.3.3.3 "-Nucleotide Substitution.   
Next, we examined the effect of sulfur substitution at the "-nonbridging oxygen atom 
using the analogs, APS"S and ADP"S (Table 2).  (In principle, APS"S could be utilized 
as a substrate by APR.  However, under saturating conditions, no evidence for formation 
of the S-sulfocysteine intermediate has been obtained (data not shown).  At present, it is 
not understand why APR does not effectively reduce APS"S.  One possible explanation 
is that the "-sulfur substitution disrupts contact with residues that could be important for 
stabilizing charge development in the transition state, such as Arg171 and His259.)  
Comparison of APS and APS"S shows that sulfur substitution for oxygen decreased 
binding by more than 200-fold (3.2 kcal/mol).  However, compared to ADP, the binding 
potency of ADP"S increased by approximately 5-fold (1 kcal/mol).  The larger energetic 
penalty for "-sulfur substitution of APS could result from ligand-related differences in 
enzyme conformation, analogous to the scenario presented in the subsection above. !
 
3.3.4. Affinity of Product AMP Analogs 
3.3.4.1 "-Nucleotide Substitution   
To probe the molecular binding determinants of APR at the "-position in greater detail, 
we compared the Kd value for the product, AMP to values measured for related analogs 
(Table 3).  The respective effects of substitution at the &-oxygen by sulfur (AMPS) or 
amine (AMPN) are -0.3 and +1.8 kcal/mol, compared to AMP.  The modest increase in 
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binding energy that results from sulfur modification is similar to the effect observed with 
ADP"S.  The reduction in binding affinity of AMPN also parallels the decrease in 
observed for AMPPN.   
 
In PAPR, residues in the P-loop interact with the 3’-phosphate of PAP (14, 46).  
However, in APR the acidic residue, Asp66, interacts with amide groups of the P-loop 
and thus, appears to mimic the interaction of the negatively charged 3’-phosphate group.  
To investigate the role of the 3’-hydroxyl group in ligand discrimination (see also Section 
3.3.4.2 below) we determined the binding affinity for 3’-AMP, which reverses the position 
of the 5’-phosphate and 3’-hydroxyl groups (Table 3).  Switching the position of the 
phosphate moiety decreased binding by ~600-fold (3.8 kcal/mol) indicating that, while 
the analog binds poorly, the 3’-phosphate does not impact binding to APR, as compared 
to adenosine.  By contrast, addition of a 3’-phosphate group to AMP, as in PAP, 
decreased binding affinity by 3.0 kcal/mol.  The energetic penalty for 3’-phosphate in 
PAP, but not 3’-AMP, likely reflects additional binding interactions to the 5’-phosphate, 
which could decrease conformational freedom and increase unfavorable protein-ligand 
contacts. 
 
Table 3. Ligand dissociation constants for product AMP analogs with APR. 
Ligand Structure Kd [µM][a] 
!!G 
[kcal/mol][b] pKa 
5'-AMPS 
N
NN
N
NH2
O
OHOH
OP–O
O
S–
 
3.3 -0.30 5.3 (O) (34) 
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5'-AMPN 
N
NN
N
NH2
O
OHOH
OP
O–
O
H2N
 
100 1.8 ~3.0 (N), ~8.15 (O)[c]  
3',5'-ADP 
N
NN
N
NH2
O
OHO
OP
O–
O
–O
P O–O
O–  
770 3.0 2.49 (O), 8.61(O) (45) 
3'-AMP 
N
NN
N
NH2
O
OHO
HO
P O–O
O–  
3200 3.8 5.92 (O) (23) 
[a] For analogs in this table values of Ki were determined under single turnover conditions from the 
dependence of the observed rate constant at a given inhibitor concentration under conditions of 
subsaturating APS, such that Ki is equal to the Kd.  Each value reflects the average of at least two 
independent experiments, and the standard deviation was less than 15% of the value of the mean.  Kinetic 
data were nonlinear-least squares fit to a model of competitive inhibition.  [b] Energetic difference in affinity of 
AMP relative to inhibitor, ''G = -RTln(KdAMP/KdAnalog).  [c] pKa estimate from value measured for 
phosphoramidic acid (41). 
 
3.3.4.2 Purine and Ribose Substitution   
Next, we analyzed the relative energetic contributions of individual purine and ribose 
substituents to the enzyme-binding interaction.  Owing to the relative difficulties 
traditionally associated with the preparation of ADP analogs and the weak binding of 
adenosine, we determined affinities for a series of compounds derived from the AMP 
scaffold.  As shown in Figure 3.6, energetic penalties for individual substitutions ranged 
from 0.6 to 4.7 kcal/mol.  First, we probed interactions between the N6 amine and N1 of 
adenine and Leu85 (Figure 3.3), the first residue in the conserved LDTG motif.  Loss of 
the N6 amine from AMP reduced the free energy of binding to APR by 1.8 kcal/mol.  
Replacing hydrogen atoms with methyl groups at the N6 position of adenine decreased 
! 52!
binding affinity by 35-fold (2.1 
kcal/mol) per substitution.  
Inverting the hydrogen bond 
donor and acceptor, as in 
inosine 5’-monophosphate, 
was also disfavoured (4.7 
kcal/mol), presumably due to 
electrostatic repulsion between 
the O6-keto and the Leu85 
carbonyl, and the N1 by the 
Leu85 amine.  Likewise, 
introduction of an N1 amine 
markedly reduced the affinity 
of this analog for APR (4.7 
kcal/mol).  In subsequent 
experiments, we determined 
the binding potency of AMP analogs with substitutions at the 2, 7 and 8-positions of the 
purine ring.  Methylation at N2 had a detrimental effect on binding (3.4 kcal/mol), likely 
due to steric clashes with the surrounding adenine-binding pocket (Figure 3.3).  The 
structure of APR bound to APS shows that C8-H group is directed toward the 5’-
phosphosulfate moiety (Figure 3.3).  Not surprisingly then, amine substitution at this 
position decreased the free energy of binding by 3.7 kcal/mol.  No contacts are formed 
between N7 and APR (Figure 3.3).  Consistent with this observation, replacing N7 with a 
carbon atom had a relatively minor effect on binding affinity (0.6 kcal/mol).  Finally, we 
investigated the influence of modification at the 2’ and 3’-hydroxyl groups of the ribose 
sugar.  2’-deoxy and methoxy group substitutions reduced the free energy of binding by 
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OCH3
NH2
HN
H2N
OP
O
O–
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Figure 3.6.  Free energy of binding for purine and ribose-
modified analogs of product, AMP.  Numbers represent the 
energetic effect of a given substitution in kcal/mol, relative to 
AMP (##G = -RTln(KdAnalog/KdAMP).  Positive ##G’s indicate a 
penalty for substitution.   
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a respective 4.0 and 3.6 kcal/mol, whereas 3’-deoxy substitution had only a modest 
effect on binding affinity (0.9 kcal/mol).  This indicates that hydrogen bonds between the 
2’-hydroxy group and Ser60 and Gly161 residues (Figure 3.3) play a vital role in 
substrate recognition.   
 
3.3.5 pH Dependence of Ligand Binding   
The pH dependence for ligand binding provides information about the relative affinities of 
the different nucleotide ionization states, and thus provides information about the active 
site environment.  Initially, we investigated the pH dependence for APS binding.  
However, the substantial increase in reaction rate at higher pH precludes measurement 
by conventional kinetic methods (data not shown).  As an alternative, we determined the 
affinities of APR for the substrate analog, ADP, and product, AMP, as a function of pH to 
investigate whether ionizations at " and !-positions are important for binding affinity 
(Figure 3.7).  The pH dependence for ADP binding is best fit by a pKa of 6.4 ± 0.2, which 
could reflect ionizations of the free enzyme and ligand (Figure 3.7A).  The most likely 
candidate for this ionization is the ligand, as the second pKa values of phosphate esters 
fall in this region (37).  If this were true, the pH profile would be expected to shift to lower 
pH for an ADP analog with lower pKa values.  To test this, we determined the pH 
dependence for ADP!S, which differs in its respective pKa value by approximately one 
pH unit (34).  The pH dependence for ADP!S binding is best fit by a pKa of 5.8 ± 0.2 
(Appendix 3.6.4A).  The dependence of the pKa upon the identity of the ligand suggests 
that deprotonation of the ligand is responsible for the increase in binding at higher pH.   
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The pH dependence for AMP 
binding is best to best fit by a 
pKa of 8.1 ± 0.1 (Figure 6.7B), 
which could reflect ionizations 
of the free enzyme and ligand, 
as described above.  The 
simplest model to explain the 
weaker binding of AMP below 
pH 8 is that the dianion binds 
more tightly than the 
monoanion.  However, the 
apparent pKa for AMP differs 
from the expected pKa of 6.8 
by more than one unit.  The 
discrepancy between the 
experimental data and the 
simplest model is most likely 
due to concurrent ionization of 
the enzyme that affects ligand 
binding, leading to shift in the 
apparent pKa of AMP.  One 
model that could account for 
this upward deviation is that an 
enzymatic group with a pKa of 
~6 contributes slightly (~5-fold) 
to AMP binding when protonated.  The most likely residue to exert such an effect on 
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Figure 3.7.  pH dependence for ADP (A) and AMP (B) binding.  
The association equilibrium constant, (Ka = 1/Kd) is plotted as a 
function of pH.  Values of Kd were determined by inhibition of 
APS reductase (pH 6.0-9.5).  Buffers were as follows: MES (pH 
6.0-6.5), BisTris (pH 6.5-7.5), TrisHCl (pH 7.5-9.5), CAPS (pH 
9-9.5).  See Experimental procedures for additional details.  (A) 
The pH dependence for ADP binding.  Nonlinear-least-squares 
fit of the data to a model for a single ionization gave pKa values 
of 6.4 ± 0.2.  (B) The pH dependence for AMP binding.  The 
dashed line represents the best fit of a model for a single 
ionization and yields a pKa of 7.9 ± 0.1.  
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ligand binding is His259, which interacts with the 5’-phosphate of PAP in the structure of 
S. cerevisiae PAPR (14).  Since a stimulatory effect is not observed for ADP binding, the 
C-terminal segment containing His259, and possibly the Arg-loop, may adopt different 
conformations depending on whether ADP or AMP is bound at the active site.  To further 
confirm that the apparent pKa measured for AMP depends upon the identity of the ligand, 
we measured the pH dependence for AMPS binding (Appendix 3.6.4B).  The resulting 
data are best fit by a pKa of 7.7 ± 0.1.  The downward shift in apparent pKa suggests that 
deprotonation of the ligand is responsible for the increase in binding at higher pH.  
 
The observed pH dependence for ADP and AMP binding indicates that the dianion binds 
more tightly to APR than the monoanion.  These data seemingly contradict our earlier 
comparison between ADP and ADP!F, whose net charges differ by one unit, but bind to 
APR with similar affinity (Table 3.2 and Figure 3.5).  Indeed, fluorine modification is often 
used to determine whether binding of mono- or dianionic phosphate is favored (40).  
However, hydroxyl and fluorine groups are distinguished by unique chemical properties.  
For example, the high electron density of fluorine gives rise to the ability to act as an 
acceptor in hydrogen bonds (47).  By contrast, the hydroxyl group is a strong dipole, with 
spatially separated partial positive and negative charges that can donate as well as 
accept hydrogen bonds (Figure 3.5).  Hence, the weaker binding observed for the 
monoanion may not reflect a loss of charge-charge interactions, but rather an energetic 
penalty that results from unfavorable charge-dipole interactions with the hydroxyl group. 
 
3.3.6 Effect of Mg2+on Ligand Affinity   
In the absence of metal ions, APS binds ~20-tighter to APR, compared to ADP and AMP.  
However, the cellular concentrations of these nucleotides are higher than APS (48) and 
thus, raise an important question: How does APS compete against binding of ADP or 
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AMP to the active site of APR in the cell?  For the majority of biochemical reactions 
using ATP and, related nucleotides, the active species is the Mg2+ complex rather than 
the free nucleotide (49).  To gain insight into ligand discrimination by APR in vivo, we 
measured the Kd values for APS, ADP and AMP in the presence of Mg2+.  These studies 
show that the Kd value of APS was independent of Mg2+ concentration (data not shown).  
This observation is consistent with weak formation constants of APS with Mg2+ (50) and 
the general observation that other sulfonucleotide binding enzymes, such sulfokinases 
and sulfotransferases also do not require Mg2+ as a cofactor (10).  However, Mg•ADP 
and Mg•AMP complexes bind approximately 5-6 times weaker to APR, as compared to 
the free nucleotide (Appendix 3.6.6).  The observed reduction in binding energy is most 
likely due to repelling interactions with multiple positively charged amino acids in the 
enzyme active site, such as Lys144, Arg242 and Arg245 (Figure 3.3).  Together, these 
findings indicate that APR discriminates against noncognate adenosine nucleotides 
through favourable interactions with the sulfate moiety of APS and by disfavouring the 
binding of Mg2+-nucleotide complexes. 
 
3.4 Conclusion: Implications for Rational Inhibitor Design   
Given that APR is essential for mycobacterial survival during persistent infection (51), 
small-molecule inhibitors of APR might be a source for new drugs to treat latent 
tuberculosis infection.  The increasing number of antibiotic-resistant strains suggests 
that the availability of such compounds could play an important role in treating the 
disease and minimizing the negative impact on human health.  By defining chemical 
groups that are essential for molecular recognition, the work described here sets the 
stage for the development of such drugs.  Figure 3.8 summarizes the network of 
interactions predicted to occur between APR active site residues and substrate, APS.  
The structural model was constructed by homology to ScPAPR (14) and systematically 
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tested in the present study, from the perspective of the ligand.  The total binding energy 
!!
Figure 3.8.  APS reductase interactions with substrate, APS inferred from P. aeruginosa APS reductase 
(PDB deposition 2GOY) and S. cerevisiae PAPS reductase (PDB deposition 2OQ2) structures and functional 
data obtained in the present study.  (A) Summary of proposed active site contacts to APS.  (B) Summary of 
proposed active site contacts to APS, plotted in two dimensions.  A total of nine protein residues are shown 
in proximity around the ligand, with hydrogen bonding interactions shown where detected.  Hydrogen bonds 
are draw as dotted lines with arrows denoting the direction of the bond.  Interactions from substrate or the 
residue backbones of the enzyme are distinguished from the interactions with residue side chains by a solid 
dot at the end of the interaction line.  Active site residues between P. aeruginosa and M. tuberculosis APS 
reductase are largely conserved, with the exception of residues implicated in hydrophobic interactions (Ser62 
to Met67, Ser84 to Phe87, Phe61 to Asn66).  The corresponding numbers for residues conserved between 
M. tuberculosis and P. aeruginosa APS reductase are: Ser65 (Ser60), Leu88 (Leu85), Lys145 (Lys144), 
Gly162 (Gly161), Arg171 (Arg171), Arg237 (Arg242), Arg240 (Arg245) Cys249 (Cys256), and His252 
(His259).  See also Appendix 3.6.1. 
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of APS resulting from these collective interactions is 9.3 kcal/mol and our data indicate 
several features that are essential for optimized substrate and inhibitor binding.  The 
hydrophobic adenine-binding pocket, pyrimidine ring, 2’-hydroxyl and the "-position are 
the main determinants for strong target affinity (Figure 3.9).  The significant losses of 
binding affinity that are found to result from apparently minor structural modifications of 
ligands at these key positions have encouraging implications for inhibitor design and 
suggests that, in some cases, the potency of a weak inhibitor might be greatly enhanced 
by one or two simple modifications.  Our studies also suggest that small-molecules that 
target dynamic elements within the active site – particularly Arg171, Cys256 and His259 
– may lead to inhibitors with improved binding affinity.  Alternatively, molecules that trap 
an inactive, “open” conformational state of APR may also represent new opportunities 
for inhibitor design (16). 
 
3.5 Experimental Procedures 
3.5.1 Materials 
Inosine, adenosine, 2-aminoadenosine, 3’-deoxyadenosine, 2’-deoxyadenosine and 1-
methyladenosine were purchased from Sigma.  5’-Phosphoribose, 3’-phosphoadenosine, 
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Figure 3.9.  Pharmacophore model of substrate, APS.  Chemical structure of APS highlighting key hydrogen bond 
accepting (HBA) and donating (HBD) interactions, ionic interactions, and van der Waals interaction, based on 
functional data obtained in the present study. 
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3’5’-diphosphoadenosine, adenine and ribose were also purchased from Sigma.  7-
Deazaadenosine-5-O-monophosphate and purine riboside-5’-O-monophosphate were 
from Biology Life Science Institute.  Nucleosides and other analogs were of the highest 
purity available, typically # 98%.  Additional reagents and solvents were purchased from 
Sigma or other commercial sources and were used without further purification. 
 
3.5.2 General Synthetic Methods 
Reactions that were moisture sensitive or using anhydrous solvents were performed 
under a nitrogen or argon atmosphere.  Analytical thin layer chromatography (TLC) was 
performed on pre-coated silica plates obtained from Analtech.  Visualization was 
accomplished with UV light or by staining with ethanolic H2SO4 or ceric ammonium 
molybdate.  Nucleosides were purified by flash chromatography using Merck silica gel 
(60-200 mesh).  
 
3.5.3 Preparation of Nucleoside and Nucleotide Analogs   
N6, N6-Dimethyl-5’-phosphoadenosine was prepared from inosine by the procedure 
described by Veliz and Beal (52) and purified by flash chromatography developed in 
60:40 ethyl acetate:hexanes.  N6-Methyl-5’-phosphoadenosine was prepared via 
reaction of 6-bromoinosine with methylamine as previously described (53).  8-Amino-5’-
phosphoadenosine was prepared by selective bromination of adenosine at the C8 
position, exchange of bromine for azide, followed by reductive hydrogenation to afford 
the amine, as previously described (54).  2’-Methoxy-5’-phosphoadenosine was 
prepared from adenosine, by reaction with methyl iodide under alkaline conditions as 
previously described (55).  Adenosine 5’-O-!,",-imidodiphosphate (AMPNP) was 
synthesized by reaction of 5’-tosyladenosine (56) with imidodiphosphate salt (56, 57).  
Adenosine 5’-O-!,"-difluoromethylenediphosphate (ADP!F) was prepared by coupling 
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5’-tosyladenosine to difluoro substituted methylenediphosphonic acid, as previously 
reported (56, 58).  Adenosine 5’-O-thiophosphosulfate (APS"S) was synthesized by 
reacting pyridine-N-sulfonic acid with adenosine 5’-O-thiopshophate (AMPS), as 
previously described (59).   
 
3.5.4 Nucleoside Phosphorylation 
Nucleotide analogs were synthesized by chemical phosphorylation of the corresponding 
adenosine analog, followed by purification via reversed phase HPLC. Nucleosides were 
phosphorylated by reaction of nucleoside with POCl3 as described (60).  The nucleoside 
(0.15 mmole) was suspended in triethylphosphate at 0 °C (0.65 ml).  Water (1 equiv) 
was added to the reaction.  Subsequently, POCl3 (3-5 equivalents) were added over a 
period of 30 min with constant stirring.  The suspension was kept stirring for an 
additional 1.5 h, when the white suspension became a clear solution.  Water (1 ml) was 
added to hydrolyze the phosphoryl chloride and terminate the reaction.  The pH was 
neutralized to ~7 by dropwise addition of NH4OH. The reaction was passed over a C18 
SPE column (Fisher) to remove the majority of the triethylphosphate.  Nucleotides were 
purified by reversed phase HPLC employing isocratic separation in 20 mM ammonium 
acetate, pH 7 on a semi-preparative C18 column.  The physical and spectral data for 
these analogs (confirmed by 1H, 13C and 31P NMR and mass spectrometry) were 
consistent with those previously reported for these compounds.  The concentrations 
nucleotide analogs was determined by absorbance at 260 nm, assuming &260 = 15,300 
M-1 cm-1 (23). 
 
3.5.5 Enzyme purification.   
Purification of APR was carried out as previously described (61). 
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3.5.6 General Kinetic Methods.   
35S-labeled APS was synthesized and purified as previously described (61) with the 
inclusion of an additional anion exchange purification step on a 5-ml FFQ column (GE 
Healthcare) eluting with a linear gradient of ammonium bicarbonate, pH 8.0.  The 
reduction of APS to sulfite and AMP was measured in a 35S-based assay as previously 
described (62).  Reactions were quenched by the addition of charcoal solution (2% w/v) 
containing Na2SO3 (20 mM).  The suspension was vortexed, clarified by centrifugation 
and an aliquot of the supernatant containing the radiolabeled sulfite product was counted 
in scintillation fluid.  APR activity was measured in single turnover reactions, with trace 
amounts of 35S-APS (~1 nM) and excess protein.  These reactions can typically be 
followed to #90% completion (Appendix 3.6.5), and the reaction time courses fit well to 
eq 1, in which Frac P is the fraction product, k is the observed rate constant, and t is 
time: 
! 
Frac P =1" exp"kobs t  (1) 
 
Unless otherwise specified, the standard reactions conditions were 30 °C with 100 mM 
bis-tris propane at pH 7.5, DTT (5 mM), and thioredoxin (10 !M).  Kinetic data were 
measured in at least two independent experiments and the standard error was typically 
less than 15%. 
 
The affinity of APR (E) for APS was determined from the dependence of the observed 
rate constant for S-sulfocysteine formation on protein concentration according to eq 2: 
! 
Kobs =Kmax "
[E]
K1/ 2 + [E]
# 
$ 
% 
& 
' 
(   (2) 
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In this equation, kobs is the observed rate constant at a particular protein concentration, 
kmax is the maximal rate constant with saturating protein, and K1/2 is the protein 
concentration that provides half the maximal rate.  To ensure that the chemical step was 
rate-determining, reactions were performed in NaMes (10 mM) at pH 5.5 and control 
experiments demonstrate that the enzyme is stable under these assay conditions (data 
not shown).  Because the chemical step is rate-determining for S-sulfocysteine formation 
(kst < , kmax is equal to the rate constant for the reaction of the E•APS complex, and K1/2 is 
equal to the dissociation constant (Kd) of APS for APR.  The concentration of active 
protein was determined by direct titration with a high concentration of APS (i.e. [APS] >> 
Kd).  In theory, the binding affinity of APS could increase at physiological pH.  However, 
several lines of evidence argue against this possibility.  First, the pKa of the !-sulfate 
moiety is less than 2 and thus, at pH 5.5, the sulfonucleotide is completely ionized.  
Second, the pH dependence of ADP binding (see below) reflects the pKa of this 
nucleotide in solution.  Finally, the Kd measured at pH 5.5 is in line with the apparent Km 
value measured at pH 8.0 (22). 
 
The affinity of various ligands for APR was determined by inhibition methods.  The 
observed rate constant of the reaction: E + 35S-APS ' products (kobs) was determined at 
varying inhibitor (I) concentrations (Appendix 3.6.4B), and the [I]-dependence was fit to a 
simple model for competitive inhibition (eq 3).  In eq 3, ko is the rate of the reaction in the 
absence of analog, and Ki is the inhibition constant of the analog.  With subsaturating 
APR, Ki is equal to the equilibrium dissociation constant (Kd) of the ligand. 
! 
kobs = ko "
Ki
[I] +  Ki
# 
$ 
% 
& 
' 
(   (3) 
 
3.5.7 pH Dependence of Inhibitor Binding.   
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Values of Ki were determined by inhibition of APS reduction (pH 6-9) with [35S-APS] << 
K1/2, such that Ki is expected to be the Kd.  The following buffers were used for the 
indicated pH ranges: NaMES (6.0-7.0), Bis-Tris (6.5-7.5), Tris (7.5-9.0) and CAPS (9.0-
9.5).  Reactions were typically carried out with 100 mM buffer and the standard assays 
and conditions described above were used to monitor kcat/Km for reduction of 35S-APS in 
the presence and absence of inhibitor.  The rate constants at each pH value for multiple 
reactions were averaged, and the standard deviations were %15% of the average.  pKa 
values were determined using eq 4, derived from a model where the binding of the 
ligand depends on a single ionizable group.  
! 
Kd ,app =KdHA "
Ka
Ka +  [H+]
+KdA# "
[H+]
Ka +  [H+]
  (4) 
 
3.5.8 Energetic Contribution of Ligand Substituents to Binding.   
The energetic contributions of individual ligand substitutents to APR binding were 
expressed as ''G = -RTln(Kd1/ Kd2) in which R is the gas constant, T is the temperature 
(303 K), and Kd is the equilibrium dissociation constant.  A negative value of ''G 
indicates that a given substitutent contributes to ligand binding by APR. 
 
3.5.9 Electrostatic Surface Potentials.   
The electrostatic surface potential was calculated using PM3 semi-empirical molecular 
orbital calculations implemented in SPARTAN software (Wavefunction, Inc) for the fully 
optimized structure.  
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3.6 Appendices  
Figure 3.6.1 Structure based sequence alignment of APR from Pseudomonas 
aeruginosa, Mycobacterium tuberculosis and Saccharomyces cerevisiae.   
The ClustalW Multiple Sequence Alignment program was used.  Strictly conserved 
residues are outlined in red, red letters indicate conserved residues and conserved 
regions are boxed in blue.  Alignment picture was rendered with the server ESPript 2.2 
(http://espript.ibcp.fr). 
                                                                      Pseudomonas_aeruginosa    
Pseudomonas_aeruginosa        1                 SA   QD   MSQ      LASSL  KS Q   K A E       ISFS AE V...MLPFATIPATERN  AQH  PSP   PFDLPA     AD  P DIL A F HFGDELW    G  D 
Mycobacterium_tuberculosis    1                 AA   AE   ATA      TDETF  IG A   V G R       VVAS MA AMSGETTRLTEPQLREL  RGA  LDG   TDMLRW     GD  G GGG S H GWTTCNY    N  D 
Saccharomyces_cerevisiae      1                 KT   NN   VTQ      NEQLI  ET Q   A S V       TTAF LT L...............M  YHL  DII   EQLDHW     KL  P EII W I TFPHLFQ    G  G 
                                                                      Pseudomonas_aeruginosa    
Pseudomonas_aeruginosa       68 V  D   K             DT      T          Y            P     E           LV MA  LN VFSL  E Y IDQVRE  IAI VLS D LL KEK SW RN...VK GRLHP RF H G.... D PR PLV GLF
Mycobacterium_tuberculosis   71 V  D   K             DT      T          Y            P     E           LV LA  VR VIFL  E I RDAIES  VRV NVT E VA ELL LA PG...VP GYHFV GT V D.... L HT .QD GKD
Saccharomyces_cerevisiae     56 V  D   K             DT      T          Y            P     E           TI ML  LS LLFI  Q L KNEIEK  QTI VYK D ES ASK FS EKYYMPE LHHFP TL K YQPKN H GC ADF YGD
                                                   TTT                Pseudomonas_aeruginosa    
Pseudomonas_aeruginosa      131              K  P                RR      R        D           K NPL   F R E IR IE L RKLAGV A AT Q   QS T SQV VLEI GAF LY F   SSY DGHG CCG K R W G . D PG A STPEKP M
Mycobacterium_tuberculosis  133              K  P                RR      R        D           K NPL   F R E LR VV L KTLRGY A VT L   DA T ANA LVSF ETF LV V   AAA NPH. CCR G S W G . V P. P K..... W
Saccharomyces_cerevisiae    126              K  P                RR      R        D           K NPL   L E K LA VE A RAYKEL I AV T   SQ A SQL IIEI ELN IL I   INW KDDD YDY H H S F G K GS S G..... W
                                     TT        TT                     Pseudomonas_aeruginosa    
Pseudomonas_aeruginosa      200 T   V  YI       N L   GY SIG    T         R GRW     T  ECG H           EE   LEL Y  ER      R L Q  E   EEA    L AGNLS WG RM P S H I CEPC PV PN HE WW HK ISKA..
Mycobacterium_tuberculosis  195 T   V  YI       N L   GY SIG    T         R GRW     T  ECG H           QD   NDV V  RE      A A A  S   LAK    L ASLED QE AD L P V P CAPC KP EG DP QG .. ......
Saccharomyces_cerevisiae    191 T   V  YI       N L   GY SIG    T         R GRW     T  ECG H           EQ   NNV Y  DL      Q K E  A   KAK    I EASRF KQ DA P E L R DYHS PV EG DE KG .. FAQFLK
                                                                      Pseudomonas_aeruginosa    
Pseudomonas_aeruginosa    ...                                                                   
Mycobacterium_tuberculosis ...                                                                   
Saccharomyces_cerevisiae    259 QDA                                                                   
!1 !2 "1 
!3 "2 !4 "3 !5 
!6 !7 !8 "4 #1 "5 "6 
!9 #2 #3 #4 
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Figure 3.6.2 The apparent affinity, K1/2, of APR in single turnover experiment.   
The affinity of APR (E) for APS was determined from the dependence of the observed 
rate constant for S-sulfocysteine formation on protein concentration according to: 
 
! 
Kobs =Kmax "
[E]
K1/ 2 + [E]
# 
$ 
% 
& 
' 
(  
 
In this equation, kobs is the observed rate constant at a particular protein concentration, 
kmax is the maximal rate constant with saturating protein, and K1/2 is the protein 
concentration that provides half the maximal rate.  Because the chemical step is rate-
determining for S-sulfocysteine formation, kmax is equal to the rate constant for the 
reaction of the E•APS complex, and K1/2 is equal to the dissociation constant (Kd) of APS 
for APR.  The concentration of active protein was determined by direct titration with a 
high concentration of APS (i.e. [APS] >> Kd). 
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Figure 3.6.3 pH dependence for ADP!S (A) and AMPS (B) binding.   
The association equilibrium constant, (Ka = 1/Kd) is plotted as a function of pH.  Values 
of Kd were determined by inhibition of APS reduction (pH 6.0-9.5).  See methods for 
details.  (A) The pH dependence for ADPbS binding.  Nonlinear-least-squares fit of the 
data to a model for a single ionization gave pKa values of 5.8 ± 0.15.  The pKa of AD 
Implications for rational inhibition design PbS in solution is 5.2 (34).  (B) The pH 
dependence for AMPS binding.  The dashed line represents the best fit of a model for a 
single ionization and yields a pKa of 7.7 ± 0.15.  The pKa of AMPS in solution is 5.3 (34).   
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Figure 3.6.4 The radioactive assay for APR.   
(A) The reaction progress curve for APR.  Under the subsaturating concentration of 
substrate, the reaction is described by the apparent second-order rate constant, kcat/Km, 
which under the conditions of this assay is ~2 $ 106 M-1s-1.  (B) AMP inhibits APR activity.  
Nonlinear least squares fit to a model of competitive inhibition gives a Kd value of 5.4 !M.  
Figure S4
0
0.2
0.4
0.6
0.8
1.0
0 9 18 27 36 45
F
ra
c
ti
o
n
 P
Time (min)
0
0.05
0.1
0.15
0.2
0.25
0 20 40 60 80 100
k
o
b
s
 (
m
in
-1
)
5!-AMP (µM)
A
B
 
! 69!
Table 3.6.5!Ligand dissociation constants for nitrogen-containing ligands at pH 7.5 
and pH 9.0 with APR.[a]!
Ligand Structure 
Kd pH 
7.5 
[µM] 
Kd pH 
9.0 
[µM] 
!!G 
[kcal/mol][b] pKa 
5'-
AMPN 
N
NN
N
NH2
O
OHOH
OPH2N
O
Oœ
 
100 82 -0.16 3.0 (O), 8.15 (N)[c] 
AMPNP 
N
NN
N
NH2
O
OHOH
OP
H
N
Oœ
O
PœO
O
Oœ
 
257 110 -0.53 7.7 (O), 8.25 (N) (39) 
AMPPN 
N
NN
N
NH2
O
OHOH
OPO
Oœ
O
PH2N
O
Oœ
 
410 56.8 -1.2 3.0 (O), 8.15 (N)[c] 
[a] For ligands in this table values of Ki were determined at pH 7.5 or 9.0 under single 
turnover conditions from the dependence of the observed rate constant at a given 
inhibitor concentration under conditions of subsaturating APS, such that Ki is equal to 
the Kd.  Each value reflects the average of at least two independent experiments, and 
the standard deviation was less than 15% of the value of the mean.  Kinetic data were 
nonlinear-least squares fit to a model of competitive inhibition.  [b] Energetic difference in 
affinity of ligand at pH 9.0 relative to pH 7.5, ''G = -RTln(Kd9.0/Kd7.5).  [c] pKa estimate 
approximated from value for phosphoramidic acid (41). 
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Table 3.6.6 Ligand dissociation constants for AMP and ADP with APR in the 
presence and absence of MgCl2.[a]!
Ligand MgCl2 [mM] Kd ["M] !!G [kcal/mol][b] 
AMP 0 5.4 N/A 
 0.5 21 0.82 
 2.0 31 1.0 
ADP 0 4.3 N/A 
 0.5 7.3 0.32 
 2.0 20 0.93 
[a] For ligands in this table values of Ki were determined at pH 7.5 and the concentration 
of MgCl2 indicated under single turnover conditions from the dependence of the 
observed rate constant at a given inhibitor concentration under conditions of 
subsaturating APS, such that Ki is equal to the Kd.  Each value reflects the average of at 
least two independent experiments, and the standard deviation was less than 15% of the 
value of the mean.  Kinetic data were nonlinear-least squares fit to a model of 
competitive inhibition.  [b] Energetic difference in affinity for ligand with magnesium 
relative to without metal ion, ''G = -RTln(Kd+MgCl2/Kd–MgCl2). 
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Chapter 4 
Deciphering the role of histidine 252 in mycobacterial adenosine 5’-
phosphosulfate reductase catalysis 
 
This work has been published as “Deciphering the role of histidine 252 in Mycobacterial 
APS reductase catalysis.” J. Biol. Chem. 2011, 286, 28567-28573.  I prepared all 
materials used in these experiments and conducted all subsequent kinetic and 
thermodynamic analyses.  
 
4.1 Abstract 
Mycobacterium tuberculosis adenosine 5’-phosphosulfate reductase (APR) catalyzes the 
first committed step in sulfate reduction for the biosynthesis of cysteine and is essential 
for survival in the latent phase of TB infection.  The reaction catalyzed by APR involves 
the nucleophilic attack by a conserved cysteine residue, Cys249 on adenosine 5$-
phosphosulfate (APS), resulting in a covalent S-sulfocysteine intermediate that is 
reduced in subsequent steps by thioredoxin to yield the sulfite product.  Cys249 resides 
on a mobile active site lid at the C-terminus, within a ECG(L/I)H motif.  Owing to its strict 
conservation among sulfonucleotide reductases and its proximity to the active site 
cysteine, it has been suggested that His252 plays a key role in APR catalysis, 
specifically as a general base to deprotonate Cys249.  Using site-directed mutagenesis 
we have changed His252 to an alanine residue and analyzed the effect of this mutation 
on the kinetic parameters, pH-rate profile and ionization of Cys249 of APR.  These 
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findings were further supported by isothermal titration calorimetry (ITC) to provide a 
thermodynamic profile of ligand-protein interactions.  Interestingly, our data demonstrate 
that His252 does not perturb the pKa of Cys249 or play a direct role in rate-limiting 
chemical steps of the reaction.  Rather, we show that His252 enhances substrate affinity 
via interaction with the &-phosphate and the endocyclic ribose oxygen.  From an applied 
standpoint, this study suggests that small-molecules targeting dynamic elements within 
the active site, particularly His252, may lead to inhibitors with improved binding affinity. 
 
4.2 Introduction 
Tuberculosis (TB) remains a serious threat to public health, and new drugs are needed 
to simply and shorten treatment, and fight multi-drug resistant TB.  Toward this end, the 
inhibition of cysteine biosynthesis and, by extension, associated downstream 
metabolites represents fertile ground for the development of novel antibiotics (1, 2).  In 
mycobacteria, the enzyme adenosine 5$-phosphosulfate reductase (APR) catalyzes the 
committed step in the biosynthesis of cysteine (Scheme 4.1) and is a validated target to 
develop new anti-TB agents, particularly for the treatment of latent infection (3, 4).  APR 
lacks a human homolog, but is highly conserved across a wide range of bacterial 
species (5), raising the possibility that APR may also represent an attractive target for 
the discovery or rational 
design of broad-spectrum 
antibiotics.  Moreover, APR 
is also present in plants 
and is recognized as a 
potential target for 
herbicide development (6-
8).  
!
 
Scheme 4.1.  Reaction catalyzed by APR.  !
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The importance of APR for microbial and plant survival has motivated investigations into 
its catalytic mechanism (9-12).  These studies provide support for the two-step 
mechanism shown in Scheme 4.2, which involves nucleophilic attack by conserved 
Cys2491 on adenosine 5$-phosphosulfate (APS) leading to the formation of a covalent 
enzyme S-sulfocysteine intermediate, E-Cys-S%–SO3– bound to adenosine 5$-
monophosphate (AMP).  The sulfite product is then released via thiol-disulfide exchange 
with free thioredoxin in bacterial APR or via the action of the C-terminal thioredoxin-like 
protein domain in plant APR.  In addition, APR contains a [4Fe-4S] cluster (iron-sulfur 
cluster) 2  that is 
essential for catalytic 
activity (6, 13-15).  
However, it is not 
involved in redox 
chemistry and its role 
remains an active 
area of investigation 
(16, 17).  
 
In 2006, the crystal structure of Pseudomonas aeruginosa APR (PaAPR) was solved in 
complex with APS, providing direct insight into substrate recognition (18). PaAPR and 
Mycobacterium tuberculosis APR (MtAPR) are homologous proteins sharing 27% 
identity and 41% similarity (Appendix 4.6.1), particularly in residues that line the active !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Residue numbers in this manuscript correspond to the APR sequence from M. tuberculosis (Figure 4.6, 
Appendix 4.6.1). 
2 The only known exception is the enzyme from Physcomitrella Patens, which lacks the [4Fe-4S] cluster, but 
retains APR activity (16). 
!
 
Scheme 4.2.  Proposed mechanism of sulfonucleotide reduction. 
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site (84% identity and 92% similarity).  PaAPR and MtAPR have comparable reaction 
kinetics and ligand binding affinity (10, 19).  Likewise, the structure of PaAPR has been 
successfully employed in virtual ligand screening to identify low-micromolar chemical 
inhibitors of MtAPR (20). 
 
The structure of PaAPR shows that APS binds in a deep active site cavity with the 
phosphosulfate extending toward the protein surface (Figure 4.1A).  Conserved and 
semiconserved residues participate in four main-chain hydrogen bonds with adenine and 
the ribose O2! hydroxyl.  Interaction between the phosphosulfate and APR occurs via 
strictly conserved residues Lys145, Arg237, and Arg240.  The phosphosulfate is also 
positioned opposite the [4Fe-4S] cluster3.  The C-terminal 18 residues, carrying the 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3 APS is not in direct contact with the [4Fe-4S] cluster; the sulfate oxygens are 7 Å from the closest iron 
atom and 6 Å from the closest cysteine sulfur atom. 
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Figure 4.1.  (A) Structure of PaAPR in complex with substrate, APS (PDB 2GOY).  The C-terminal segment carries 
the catalytically essential cysteine is disordered.  (B) Structure superposition of PaAPR bound to APS (gold, PDB 
2GOY) and ScPAPR bound to PAP (orange, PDB 2OQ2).  Overall structures show the proteins adopt a Rossman-
like nucleotide binding fold with a central six stranded b-sheet and the substrates (APS and PAP) bind to active site 
in similar manner.  Shown is the [4Fe-4S] cluster present only in PaAPR but absent in ScPAPR.  The ScPAPR 
structure (orange) shows the complete intact C-terminal tail containing the strictly conserved active site ECG(I/L)H 
motif bound over the active site pocket. (C) A homology model of MtAPR was constructed using the Swiss Model 
server. The models were based upon ScPAPR (PDB 2OQ2) and the multiple sequence alignment from the 
sequence analysis step. The C-terminal segment of MtAPR shows direct interactions between the substrate (APS) 
and His252. The His252 is also 4.2 Å (magenta) from the Sg of Cys249 for plausible role in catalysis.!!
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catalytically essential Cys249, were disordered in the structure of PaAPR.  The lack of 
electron density information, coupled with limited proteolysis studies, led to the proposal 
that Cys249 resides on a flexible “lid peptide” that closes over the active site pocket 
upon ligand binding (18).   
 
This hypothesis was later confirmed when Fisher and colleagues reported the crystal 
structure of the related enzyme, 3$-phosphoadenosine-5$-phosphosulfate (PAPS) 
reductase from Saccharomyces cerevisiae (ScPAPR) in complex with adenosine 3$,5$-
diphosphate (PAP) (21).  Although APS and PAPS differ by a 3$-phosphate and PAPR 
lacks the [4Fe-4S] cluster4, structural and functional studies show that the two-step 
mechanism for sulfite production in Scheme 2 is conserved among this family of 
enzymes, known collectively as sulfonucleotide reductases (SRs) (10, 18, 22, 23).  SRs 
share ~25% overall amino acid identity, including two highly conserved domains, the 
sulfonucleotide-binding pocket and C-terminal segment containing the K(R/T)ECG(L/I)H 
catalytic motif (Appendix 4.6.1; see also Ref. 18 for an alignment of 38 APR and 34 
PAPR amino acid sequences).  Likewise, SRs have virtually identical three-dimensional 
structures (superposition of 140 C& backbone atoms from PaAPR and ScPAPR yields 
an r.m.s. deviation of 0.98 Å; Figure 4.1B).  Significantly, the crystal structure of ScPAPR 
shows the flexible C-terminal segment folded over the active site pocket.  In this 
conformation, a strictly conserved histidine residue His252 within the K(R/T)ECG(L/I)H 
motif is in proximity to the active site ligand and Cys249 (Figure 4.1B).  These three-
dimensional relationships are recapitulated in the homology model of MtAPR, generated 
on the basis of sequence alignment and ScPAPR template structures (r.m.s. deviation of 
0.06 Å for C& backbone atoms; Figure 4.1C). !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 The only known exception is the enzyme from Bacillus subtilis, which possess an [4Fe-4S] cluster, but can 
utilize both substrates (13). 
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On the basis of conservation and juxtaposition to the catalytic cysteine, it was recently 
proposed that His252 acts as a general base in SRs to deprotonate the Cys249 
nucleophile (21).  However, this hypothesis has not yet been directly tested and thus, the 
precise function of this active site residue remains unknown.  Herein, we have used site-
directed mutagenesis to change His252 in MtAPR to an alanine residue and analyzed 
the effect of this mutation on the kinetic parameters, pH-rate profile and ionization of 
Cys249 of APR.  These studies were further supported by isothermal titration calorimetry 
(ITC) to provide a thermodynamic profile of ligand-protein interactions.  Collectively, 
these data indicate that His252 does not perturb the pKa of Cys249 or play a direct role 
during chemical steps that lead to S-sulfocysteine formation.  Instead, we show that 
interactions with His252 increase substrate affinity, which might be used in further 
inhibitor design to trap the enzyme in a closed, inactive conformation. 
 
4.3 Results and Discussion 
4.3.1 Kinetic characterization of WT and His252Ala MtAPR 
To advance our understanding of the molecular recognition and catalytic mechanism of 
MtAPR, we used site-directed mutagenesis to change His252 to an alanine residue, and 
characterized single turnover kinetic parameters for wild-type and His252Ala.  Mutation 
of His252 to Ala reduced kcat/Km by 230-fold (Table 4.1), indicating that this residue 
contributes to catalytic efficiency by enhancing substrate affinity and/or stabilizing the 
catalytic transition state.  To gain further insight into the role of the conserved active-site 
histidine residue we compared the saturating single-turnover rate constant (kmax), the Km 
and the substrate dissociation constant (Kd) for wild-type and His252Ala MtAPR (Table 
1; see also Appendix 4.6.2-5 for representative data).  The results show that alanine 
substitution of His252 decreased the value of kmax by only two-fold, whereas Km and Kd 
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were both weakened by more than two orders of magnitude.  Additional control 
experiments showed that there was no difference in iron incorporation or [4Fe-4S] 
cluster stability between the wild-type and variant MtAPR (Appendix 4.6.6), consistent 
with the approximate distance (~10 Å) between His252 and the metallocenter. 
 
Table 4.1: Single-Turnover Rate and Equilibrium Constants for Wild-Type and 
His252Ala MtAPRa  
Enzyme 
kcat/Km 
(M-1 min-1)b 
(kcat/Km)rel 
kmax 
(min-1)c 
(kmax)rel 
Km 
()M)d 
(Km)rel 
Kd 
()M)e 
(Kd)rel 
Wild-type 3.0 x 106 230 2.8 2.0 0.2f >250 0.2 450 
H252A 1.5 x 104 (1) 1.4 (1) >50g (1) 90 (1) 
 
aMeasurements are the average of #3 independent determinations and the S.D. was %15% of the value in all 
cases.  Unless otherwise stated, reaction conditions are 100 mM Bis-Tris propane, pH 6.5, 5 mM 
dithiothreitol, and 10 )M thioredoxin at 30 °C (see Materials and Methods).  Values in parenthesis are 
references values (i.e., other values normalized to this rate).  bkcat/Km values were measured as described in 
Materials and Methods.  cSingle-turnover rate constants with saturating wild-type or His252Ala MtAPR.  dKm 
values for S-sulfocysteine formation were measured in the absence of thioredoxin by varying the 
concentration of wild-type or His252Ala MtAPR (see Materials and Methods).  eDissociation constants were 
measured using ultrafiltration at 30 °C (100 mM Bis-Tris propane, pH 6.5) as described in Materials and 
Methods.  fFrom Ref. (27).  gIn Bis-Tris propane at pH 7.5.  Due to technical limitations of the TLC-based 
assay only a lower limit could be obtained.  
 
4.3.2 pH dependence on catalysis of WT and His252Ala MtAPR 
To examine the role of His252 in greater detail and provide additional insight into the 
overall catalytic mechanism of APR, we measured the pH dependence of kcat/Km for the 
wild-type enzyme and the His252Ala mutant.  Figure 4.2 illustrates that the acidic limb 
for reaction of APS with wild-type or His252Ala has a first-order dependence on the 
proton concentration, consistent with a single inactivating protonation at acidic pH.  For 
kcat/Km, these kinetic pKa values could represent ionization of either free enzyme or 
substrate.  The data described below support the model with ionization of the Cys249 
nucleophile.   
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The acidic limb of the pH dependence 
for the APR-catalyzed reduction of 
APS is best fit by a pKa of 6.1 ± 0.1 
and 6.3 ± 0.1 for wild-type and 
His252Ala MtAPR, respectively 
(Figure 4.2).  The most likely 
candidate for this ionization is the 
enzyme – specifically of catalytic 
cysteine – since the substrate pKa falls 
significantly below this region.  To test 
this proposal, we determined the pKa 
of Cys249 by measuring the change in 
absorbance of ultraviolet (UV) light at 
240 nm resulting from formation of the thiolate anion, as previously described (23, 28, 
29).  For these studies, we utilized Cys59Ala MtAPR, which has identical kinetic 
properties to the native enzyme (10, 15), but eliminates a non-conserved cysteine that 
could confound the analysis.  
 
The pH dependence of the molar extinction coefficient of Cys59Ala MtAPR at 240 (&240) 
displays a transition with a pKa of 6.2 ± 0.1 (Figure 4.3A).  The change in &240 is most 
likely due to ionization of Cys249, as indicated by the absence of a pH-dependent 
transition for Cys59Ala Cys249Ala MtAPR (Figure 4.3A).  The pH dependence of the 
molar extinction coefficient of Cys59Ala His252Ala MtAPR at 240 (&240) shows a 
transition with a pKa of 6.0 ± 0.1 (Figure 4.3B).  For comparison, we evaluated the pKa of 
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Figure 4.2.  pH dependence for kcat/Km with APS 
substrate.  The dashed lines represent the best fit with 
a single rate-controlling ionization (eq 5).  (A) The pH 
dependence for reduction of APS yields a pKa value of 
6.1 ± 0.1 for wild-type (*) and 6.3 ± 0.1 for His252Ala 
(+) MtAPR.  The average of three independent 
determinations is shown, and the error bars indicate 
the standard deviations. 
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Cys249 within a synthetic peptide derived from the last 10 C-terminal residues of MtAPR 
(Appendix 4.6.5B).  The pKa of the thiol in the peptide segment was determined as 8.3, 
consistent with the pKa value of free cysteine solution (30).  Interestingly, our 
experiments indicate that thiolate formation at Cys249 correlates with decrease in signal 
at &240, as opposed to the increase that is normally observed.  Therefore, the ionization 
constant of Cys249 was verified by an independent method using the thiol-specific 
reagent, monobromobimane (mBBr) (24).  In this assay, the pKa value of Cys249 for 
Cys59Ala MtAPR was determined to be 6.0 ± 0.1 (Appendix 4.6.5A), which is within 
error of the UV-based method.  The similarity of the kinetic pKa and the pKa value for 
Cys249 deprotonation strongly suggest that the observed inflection in kcat/Km 
corresponds to the ionization of the active site cysteine to form the thiolate anion.   
 
To further investigate the molecular recognition properties for wild-type and His252Ala 
MtAPR, we compared the pH dependence for binding of the nucleotide product, AMP.  
As shown in Figure 4.4, the logarithm of the association constant (Ka = 1/Kd) shows a 
first-order dependence on the proton concentration.  The acidic limb for wild-type MtAPR 
binding to AMP has a pKa of 8.1 ± 0.1, as previously reported (19).  The pKa values 
observed in product affinity could reflect ionizations in either, or both, the ligand and the 
enzyme, analogous to the pH dependence for kcat/Km discussed above.  A likely 
explanation for the weaker binding of AMP below pH 8 is that the dianion binds more 
tightly than the monoanion.  However, the apparent pKa differs from the pKa of AMP in 
solution (~6.8) by more than one unit.  The discrepancy between the experimental data 
and this model is most likely due to concurrent ionization of the enzyme that affects 
ligand binding, leading to shift in the apparent pKa of AMP.  One model that could 
account for this upward deviation is that an enzymatic group with a pKa of ~6 contributes 
slightly (~5-fold) to AMP binding when protonated.  Given its proximity to the &-
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phosphate, the most likely residue to 
exert such an effect on ligand binding 
is His252.  Consistent with this 
proposal, the acidic limb for His252Ala 
MtAPR binding to AMP displays a pKa 
of 6.4 ± 0.1 (Figure 4.4).  An additional 
observation from these data is that 
binding of the nucleotide product to 
His252Ala is weaker at physiological 
pH and above, as compared to wild-
type MtAPR.  For example, at pH 7.5 
wild-type and His252Ala MtAPR bind 
to AMP with respective Kd values of 
5.4 ± 0.2 !M and 50.5 ± 3 !M. 
 
4.3.3 Binding interaction between 
His252 and substrate 
The crystal structure of scPAPR (21) 
and the model of MtAPR shown in 
Figure 4.1 indicate that the side chain 
of His252 is positioned within 
hydrogen bonding distance of the &-
phosphate and the endocyclic ribose 
oxygen of the active site ligand.  
Previous studies have demonstrated 
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Figure 4.3.  Determination of the pKa for MtAPR 
Cys249.  The pKa of Cys249 was determined by 
monitoring the change in the extinction coefficient at 
240 nm (#&240) as a function of pH, which monitors 
formation of the thiolate anion.  (A) Cys59Ala MtAPR 
(*) exhibits a #&240 transition corresponding to a pKa of 
6.2 ± 0.1, where mean data and associated standard 
deviations for triplicate measurements are shown.  The 
dashed line shows the nonlinear regression fit of eq 9 
to the measured data.  Cys59Ala Cys249Ala MtAPR 
(+) shows no transition, indicating that the ionization of 
Cys249 is solely responsible for the observed 
transition in APR.  (B) Cys59Ala His252Ala MtAPR 
exhibits a #&240 transition corresponding to a pKa of 6.0 
± 0.1, where mean data and associated standard 
deviations for triplicate measurements are shown.  The 
dashed line shows the nonlinear regression fit of eq 9 
to the measured data. 
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the relative importance of the &-
phosphate group for AMP binding to 
MtAPR (~3 kcal/mol) (19); however, 
the contribution of oxygen O4 in the 
ribose sugar has not been 
investigated.  To examine the 
importance of the hydrogen bond 
contact between His252 and the 
endocyclic ribose oxygen, we 
synthesized 5’-phosphoaristeromycin, 
which replaces O4 in AMP with a 
methylene unit.  Binding studies 
indicate that at pH 7.5 this analog 
binds to MtAPR with a Kd value of 25 
± 2.5 !M (Figure 4.5) or 5-fold more 
weakly than AMP.  These data 
indicate that the interaction of His252 
with the ribose O4 makes a modest 
contribution to ligand recognition (~1 
kcal/mol).  
 
To substantiate the role of His252 in 
substrate binding we performed 
additional biophysical experiments.  In 
initial experiments, we attempted to 
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Figure 4.4.  The pH dependence for AMP binding.  
The association equilibrium constant (Ka = 1/Kd) is 
plotted as a function of pH.  Values of Ki were 
determined by inhibition of APS reduction with [S] < 
KM, such that Ki is expected to be Kd.  The average of 
three independent determinations is shown, and the 
error bars indicate the standard deviations.  Nonlinear-
least-squares fit of the data to a model for a single 
ionization (eq 6) gave pKa values of 8.1 ± 0.1 for wild-
type MtAPR (*) and 6.4 ± 0.1 for His252Ala MtAPR 
(+).  
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Figure 4.5.  Binding of 5’-phosphoaristeromycin to 
MtAPR.  The average of three independent 
determinations is shown, and the error bars indicate 
the standard deviations.  Nonlinear-least-squares fit of 
the data to a model for simple competitive inhibition 
(eq 4) gave a dissociation constant (Kd) of 25 !M. 
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monitor the spectral perturbation of non-catalytic 2'(3')-O-(N-Methylanthraniloyl) (MANT) 
and N6-etheno substrate analogs.  However, the affinity of these ligands for wild-type 
MtAPR was extremely weak (Kd >1 mM) and associated signal changes were unreliably 
small (not shown).  As an alternative approach, we employed isothermal titration 
calorimetry (ITC) to measure affinities for wild-type and His252Ala MtAPR for substrate, 
APS and product, AMP (Appendix 4.6.7).  ITC offers a direct and complete 
characterization of the thermodynamic interaction whereby the ligand is titrated into the 
protein (31, 32).  This analysis indicates that APS binds to wild-type MtAPR with a Kd of 
0.6 ± 0.3 !M as compared to 42 ± 6.2 !M for His252Ala.  Furthermore, AMP binds to 
wild-type MtAPR with a Kd of 7.5 ± 1.4 !M compared to 67 ± 8.4 !M for His252Ala.  
These data are in excellent agreement with the other kinetic and thermodynamic values 
obtained from our radiolabeled biochemical assay (i.e., Table 4.1 and Figure 4.4).   
 
4.4 Conclusion 
Collectively, the data presented herein provide strong support for the existence of a 
direct interaction between His252 in the C-terminus with ligands including APS and 
nucleotide product, AMP.  The flexible C-terminal segment must fold over the active site 
upon substrate binding to bring Cys249 in proximity to the (-sulfate group.  In this 
context, our studies do not support a role for His252 as a general base that deprotonates 
the catalytic cysteine since: i) wild-type and His252Ala exhibit similar pKa values for both 
kcat/Km and Cys249 deprotonation, and ii) alanine substitution of His252 has an 
extremely modest affect on kmax.  Rather, our data show that His252 plays an important 
role in ligand binding and likely facilitates docking of the C-terminal residues.  These 
studies also reveal that the pKa value of the cysteine nucleophile is perturbed downward 
by more than two units (i.e., 6.2) relative to the value we obtained for this residue within 
a peptide (i.e., 8.3).  The low pKa value of Cys249 in MtAPR is consistent with the 
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essential catalytic function of this residue.  Positively charged amino acids in the active 
site, including Lys145, Arg242, and Arg245, are likely candidates for stabilization of the 
thiolate.   
 
A critical motivating factor for these studies is that APR is essential for mycobacterial 
survival during persistent infection (4).  This key discovery has led to the proposal that 
small-molecule inhibitors of APR might be a source for new drugs to treat latent 
tuberculosis infection (1, 33).  The increasing number of antibiotic-resistant strains 
suggests that the availability of such compounds could play an important role in treating 
the disease and minimizing the impact on human health.  Defining active site residues 
that are essential for molecular recognition in MtAPR sets the stage for the development 
of such drugs.  Toward this end, targeting dynamic elements within the active site, 
particularly Cys249 and His252, may increase the potency of APR inhibitors. 
 
4.5 Experimental Procedures 
4.5.1 Materials 
All chemicals, unless stated otherwise, were purchased from the Sigma Chemical 
Company and were of the highest purity available.  The C-terminal peptide 
(AKTECGLHASW) was synthesized by solid-phase peptide synthesis using Fmoc-based 
chemistry and HPLC purified to >98%.  The molecular weight of the peptide was 
confirmed by mass spectrometry (1202.4 Da).  Aristeromycin was synthesized from 
dimethyl-3-cyclopentene-1,1-dicarboxylate as previously described (24).  5'-
Phosphoaristeromycin was prepared by chemical phosphorylation of aristeromycin using 
established methods (25).  The physical and spectral data for 5’-phosphoaristeromycin 
were consistent with values reported in the literature for this nucleotide (25). 
 
! 88!
4.5.2. Mutagenesis and Protein Expression 
The construction of the expression vector encoding wild-type MtAPR cloned into the 
vector pET24b (Novagen) has been previously described (26).  The His252Ala mutant 
plasmid was prepared using Quik-change site-directed mutagenesis (Stratagene).  Wild-
type and mutant MtAPR were overexpressed and purified to homogeneity according to 
published procedures using Ni-affinity and gel filtration column chromatography (17). 
 
4.5.3 General APS Reductase Assay 
APR assays were performed as described previously (17, 19).  All assays were 
conducted at 30 °C.  Unless otherwise indicated, the reaction conditions included 100 
mM Bis-Tris propane (pH 6.5), supplemented with 5 mM dithiothreitol (DTT), and 10 )M 
Escherichia coli thioredoxin.  Production of 35SO32- from 35S-APS was monitored using 
charcoal-based separation and scintillation counting as previously reported (19).  For 
each time point, the fraction product was calculated according to eq 1. 
F = P/(P+S) (1) 
 
where F is the fraction converted to product, P is product, and S is intact substrate].  
Reactions progress curves were analyzed using Kalediagraph (Synergy Software), as 
described below. 
 
4.5.4 Single-Turnover Kinetics 
Single-turnover APR assays were performed in the standard reaction buffer, as 
described above.  To ensure single-turnover reactions, the concentration enzyme was 
kept in excess over the concentration of 35S-APS (typically 2.5 nM).  Reactions were 
followed to completion (# 5 half-lives) except for very slow reactions.  The reaction 
progress curve was plotted as the fraction of product versus time and was fit by a single 
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exponential using Kaleidagraph (eq 2) where F is the fraction product, A is the fraction of 
substrate converted to product at completion, kobs the observed rate constant, and t time. 
F = A[1 – exp(–kobst)] (2) 
kobs = kmax[E]/(K1/2 + [E]) (3) 
 
Under single-turnover conditions, the concentration dependence of the enzyme is 
hyperbolic (eq 3).  The maximal observed rate constant (kmax) corresponds to the rate of 
reaction at a saturating enzyme concentration, and the K1/2 value indicates the 
concentration at which half of the substrate is bound.  For K1/2 determinations, the APR 
concentration was varied over a wide range and reactions were carried out in the 
absence of thioredoxin, as described previously (19).  Although we refer to the K1/2 value 
for maximal activity as Km, the value could differ from the Km value for multiple turnover 
because the latter can be affected by product release.  At least two or more enzyme 
concentrations were averaged to obtain the kcat/Km value (kcat/Km = kobs/[E] for conditions 
in which [E] << K1/2).  Under these conditions, the observed rate constant is linearly 
dependent upon enzyme concentration, and independent of substrate across a 
concentration range of at least 4-fold, which demonstrated that substrate was not 
saturating.  The reported kcat/Km values are for single-turnover conditions, but are 
equivalent to steady-state kcat/Km (17). 
 
The single-turnover rate constant (kmax) was determined at saturating concentration of 
APR, and this was confirmed by the observation of the same rate constant at two 
different concentrations of APR.  Under these conditions, the observed rate constant is 
equal to the maximal single-turnover rate constant (kobs = kmax) and monitors steps after 
binding up to and including the chemical step (eq 3).  The inhibition constant (Ki) was 
measured for various ligands by inhibiting the APR reaction under kcat/Km conditions with 
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varying concentration of inhibitor (I).  The data were fit to a simple model for competitive 
inhibition (eq 4) and, with subsaturating APR, the Ki is equal to the equilibrium 
dissociation constant (Kd) of the inhibitor. 
(kcat/Km)obs = (kcat/Km)/(1+ [I]/Ki) (4) 
 
4.5.5 pH Dependence for kcat/Km 
The following buffers were used for the indicated pH range: NaMES (6.0-7.0), Bis-Tris 
Propane (6.5-7.5), Tris-HCl (7.5-9.0), and NaCAPS (9.0-9.5).  Reactions were carried 
out with 100 mM buffer.  The rate constants obtained at each pH value for multiple 
reactions were averaged, and the standard deviations were % 25% of the average.  The 
data was fit to a model for a single rate-controlling ionization as described by eq 5.   
(kcat/Km) = (kcat/Km)max/(1+ [H+]/Ka) (5) 
 
4.5.6 pH Dependence of Inhibitor Binding 
The following buffers were used for the indicated pH range: NaMES (6.0-7.0), Bis-Tris 
Propane (6.5-7.5), Tris-HCl (7.5-9.0), and NaCAPS (9.0-9.5).  Reactions were carried 
out with 100 mM buffer.  The conditions described above were used to monitor kcat/Km 
for reduction of 35S-APS in the presence and absence of inhibitor.  The rate constants at 
each pH value for multiple reactions were averaged, and the standard deviations were % 
25% of the average.  Ka values were determined using eq 6, derived from a model where 
the binding of the ligand depends on a single ionizable group.   
Kdapp = Kd/(1+ [H+]/Ka) (6) 
 
4.5.7 Determination of Substrate Affinity 
The Kd for 35S-APS from wild-type and His252Ala MtAPR-ligand complexes was 
measured using an ultrafiltration binding assay reported by Hernick and Fierke (27).  In 
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brief, the concentration of substrate was kept low (i.e., below the Kd) and constant, and 
the concentration of the enzyme was varied from 0 to 50 !M (wild-type) or 0 to 400 !M 
(His252Ala).  The enzyme was added to reaction buffer containing 100 mM Bis-Tris 
Propane, pH 6.5 with 5 nM APS at 30 °C and then transferred into ultrafiltration devices 
(Microcon 30 kDa cutoff, Millipore), and the free and bound ligand separated by 
centrifuging the samples at 3,000 rpm for 2.5 min.  Equal volumes of the filtrate and 
retentate were removed and quantified using scintillation counting.  The ratio of EL/Ltotal 
was determined as a function of [E]total, and the Kd value was obtained by fitting eq 7 to 
these data.  
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4.5.8 Spectrophotometric pKa Determination of Cys249 
Buffer exchange of APR was performed using a PD-10 column (GE Healthcare) that had 
been pre-equilibrated with degassed water.  Ionization of Cys249 was monitored by 
absorption of the thiolate anion at 240 nm (23) using a Cary 50 UV-visible spectrometer 
(Varian) and a 1 cm path length quartz cuvette.  APR was diluted to a final concentration 
of 20 !M in 10 mM MES buffers of various pH (5.0-8.0), and the absorption of the 
sample was monitored at 240 and 280 nm after correction for the absorption of the MES 
buffer alone.  The extinction coefficient at 240 nm (&240) was calculated using the ratio of 
absorbance at 280 and 240 nm (eq 8). 
&240  = &280 x (A240/A280) (8) 
 
A240/A280 is the ratio of the absorbance of the protein at 240 and 280 nm, &280 is the 
known extinction coefficient of APR at 280 nm (36815 M-1cm-1), and &240 is the extinction 
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coefficient at 240 nm (23).  The data were plotted as a function of pH, and the pKa was 
determined by fitting a version of the Henderson–Hasselbalch equation to the data (eq 
9). 
&240
O (pH) = &240SH + (&240S– – &240SH)/(1 + 10pKa-pH) (9) 
 
4.5.9 Isothermal Titration Calorimetry (ITC) 
Wild-type and His252Ala MtAPR were exchanged into 100 mM BisTris propane buffer, 
pH 7.5.  ITC experiments were performed using an iTC200 calorimeter from MicroCal 
(Northhampton, MA).  Experiments were carried out by titrating wild-type MtAPR (50 !M) 
with APS or AMP (250 !M) and His252Ala MtAPR (50 !M) with APS or AMP (1 mM) at 
30 °C.  A total of 20 injections were performed with a spacing of 180 s and a reference 
power of 5 !cal/s.  Control experiments to determine the heat of dilution for each 
injection were performed by injecting the same volume of APS or AMP into the sample 
cell containing only buffer.  The heat of dilution generated by the compounds was 
subtracted, and the binding isotherms were plotted and fit (eq 10) to a single-site binding 
model using Origin ITC software.  
! 
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where q is the directly measured amount of heat released during each injection, v is the 
volume of the reaction, Li is the ligand concentration at the ith injection.  The Kd was 
calculated as the inverse of the Ka. 
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4.6 Appendices  
Figure 4.6.1 Sequence alignment of APR from Pseudomonas aeruginosa, 
Mycobacterium tuberculosis and PAPR from Saccharomyces cerevisiae 
Sequence alignment of APR from Pseudomonas aeruginosa, Mycobacterium 
tuberculosis and PAPR from Saccharomyces cerevisiae generated by ClustalW (1) and 
rendered by ESPript 2.2 (http://espript.ibcp.fr).  Strictly conserved residues are boxed in 
red, similar residues are represented by red letters indicate conserved residues, and 
conserved regions are boxed in blue.  Residues flanking the active site are boxed in 
green.  
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Figure 4.6.2 Wild-type MtAPR (A) and His252Ala MtAPR (B) binding to substrate 
(APS) as measured by ultrafiltration assay.   
The lines indicate the best fit of eq 7 to the data and yield 0.2 mM for wild-type APR (pH 
6.5) and 90 mM for His252Ala APR (pH 6.5). 
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Figure 4.6.3 The C-terminal residue histidine 252 does not play a role in chemical 
catalysis.  
(A) The kmax for wild-type MtAPR measured under single turnover conditions was 2.8 
min-1.  (B) The kmax for the His252Ala variant measured under single turnover condition 
was 1.4 min-1.  
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Figure 4.6.4 The Km for S-sulfocysteine formation for wild-type (A) and His252Ala 
MtAPR (B) measured under single turnover conditions.   
Representative data are shown for reactions that were conducted in duplicate, and the 
error bars indicated the standard deviation (in many cases, the standard deviation is 
smaller than the symbol).  
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Figure 4.6.5  Determination of the pKa value for the Cys249 nucleophile in MtAPR.   
(A) The pKa of Cys249 as determined by monobromobimane (mBBr) labeling.  The 
fluorescent reaction product of mBBr and Cys249 was measured by incubating 
Cys59Ala MtAPR (200 )M) with mBBr (0.2 mM).  Nonlinear-least-squares fit of the data 
to eq 9 gave a pKa value of 6.0 ± 0.1.  (B) The pKa of cysteine in the C-terminal peptide 
was determined to be 8.3 ± 0.1. 
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Figure 4.6.6 Relative stability of the [4Fe-4S] cluster in wild-type (! ) and 
His252Ala MtAPR (" ). 
Proteins (10 )M) were stored under aerobic conditions at 4 ˚C for 2 days.  Enzyme 
activity and molar extinction coefficient (see inset for representative data at 0 (red 
circles) and 48 hours (black circles) were monitored during this period.  
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Figure 4.6.7 ITC binding curve for APS binding to wild-type (A) or His252Ala 
MtAPR (B), and AMP binding to wild-type (C) or His252Ala MtAPR (D).   
Representative plots from ITC experiments are illustrated with raw data in the upper 
panel and fitting curves in the lower panel.  The dissociation constant, Kd values 
calculated by curve fitting (eq 10) are: 0.6 )M (A), 42 )M (B), 7.5 )M (C), and 67 )M (D).   
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Chapter 5 
Spectroscopic studies on the [4Fe-4S] cluster in adenosine 5’-phosphosulfate 
reductase from Mycobacterium tuberculosis  
 
This work has been published as “Spectroscopic studies on the [4Fe-4S] cluster in 
adenosine 5’-phosphosulfate reductase from Mycobacterium tuberculosis.” J. Biol. Chem. 
2011, 286, 1216-1226.  My contributions to this work include generation of Lys144Ala 
APR by site-directed mutagenesis and measuring APR kinetic parameters. 
 
5.1 Abstract 
Mycobacterium tuberculosis adenosine 5$-phosphosulfate (APS) reductase (MtAPR) is 
an iron-sulfur protein and a validated target to develop new antitubercular agents, 
particularly for the treatment of latent infection.  The enzyme harbors a [4Fe-4S]2+ cluster 
that is coordinated by four cysteinyl ligands, two of which are adjacent in the amino acid 
sequence.  The iron-sulfur cluster is essential for catalysis; however, the precise role of 
the [4Fe-4S] cluster in APR remains unknown.  Progress in this area has been 
hampered by the failure to generate a paramagnetic state of the [4Fe-4S] cluster that 
can be studied by electron paramagnetic resonance spectroscopy.  Herein, we 
overcome this limitation and report the EPR spectra of MtAPR in the [4Fe-4S]+ state.  
The EPR signal is rhombic and consists of two overlapping S = , species.  Substrate 
binding to MtAPR led to a marked increase in intensity and resolution of the EPR signal, 
and to minor shifts in principle g values that were not observed among a panel of 
substrate analogs, including adenosine 5$-diphosphate.  Using site-directed mutagenesis, 
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in conjunction with kinetic and EPR studies, we have also identified an essential role for 
the active site residue, Lys144 whose side chain interacts with both the iron-sulfur 
cluster and the sulfate group of APS.  The implications of these findings are discussed 
with respect to the role of the iron-sulfur cluster in the catalytic mechanism of APR. 
 
5.2 Introduction 
In bacteria and plants, activation of inorganic sulfur is required for de novo biosynthesis 
of cysteine.  To this end, the metabolic assimilation of sulfate from the environment 
proceeds via adenosine 5$-phosphosulfate (APS) or 3$-phosphoadenosine-5$-
phosphosulfate (PAPS) (1).  These intermediates are produced by the action of ATP 
sulfurylase (EC 2.7.7.4), which condenses sulfate and ATP to form APS (2, 3), and by 
APS kinase (EC 2.7.1.25), which produces PAPS from ATP and APS (6).   
 
APS and PAPS are 
reduced by enzymes in the 
reductive branch of the 
sulfate assimilation 
pathway, producing sulfite 
and adenosine 5$-
monophosphate (AMP) or 
adenosine 3$,5$-
diphosphate (PAP) (see 
Scheme 5.1).  These 
enzymes can be 
subdivided into two groups 
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according to their substrate preference, the APS reductases (APR) and the PAPS 
reductases (PAPR) (EC 1.8.99.4).  Functional and structural studies have been used to 
investigate the chemical reaction mechanism of APR and PAPR enzymes (1, 7-10).  The 
mechanism involves nucleophilic attack by the active site cysteine on the sulfur atom of 
APS or PAPS to form an enzyme S-sulfocysteine intermediate (E-Cys-S%-SO3–), which is 
cleaved by thiol-disulfide exchange with thioredoxin or glutaredoxin (Figure 5.1).  The 
sulfite product is then reduced to sulfide by sulfite reductase (EC 1.8.7.1) and utilized to 
synthesize cysteine and other essential sulfur-containing biomolecules (12).  In the 
human pathogen Mycobacterium tuberculosis, APR is a validated target against the 
latent phase of infection (13). 
 
Only a 3$-phosphate group distinguishes PAPS from APS.  Accordingly, APR and PAPR 
have nearly identical three-dimensional structures (1.6–Å rms deviation of backbone 
atoms) and share ~20% sequence identity, including the active site motif, ECG and the 
sulfonucleotide binding pocket (4, 7, 14).  However, a key difference between the two 
enzymes is that APR contains two conserved cysteine motifs, CXXC and CC.  These 
four additional cysteine residues coordinate a [4Fe-4S] cluster, which is essential for 
catalytic activity (1, 7, 15).  The only known exception is Physcomitrella patens 
sulfonucleotide reductase, PpAPR-B that lacks the cysteine pairs required to bind the 
cofactor, but can utilize both APS and PAPS as substrates (16).  However, PpAPR-B 
has to pay a significant penalty for the absence of the [4Fe-4S] cluster as evidenced by 
second-order rate constants (kcat/Km) of 3,520 and 37 M-1s-1 with APS and PAPS, 
respectively.  
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The 2.7 Å crystal structure of Pseudomonas aeruginosa APR (PaAPR) bound to 
substrate provides valuable insights into the arrangement of active site residues that are 
conserved among APRs5 (7).  The iron-sulfur cluster is coordinated by Cys228 and 
Cys231, positioned at the tip of a !-loop, along with the tandem pair, Cys139 and 
Cys140, within an "-helix (Figure 5.2A).  Coordination by sequential cysteines is highly 
unusual for [4Fe-4S] clusters and has been characterized in only one other crystal 
structure – the NuoB subunit of respiratory complex I (17).  There are four charged 
and/or polar NH(((S or OH(((S hydrogen bonds involving side-chains of absolutely 
conserved residues (Figure 5.2B and C).  In particular, the CysCys motif interacts with a 
pair of basic residues, Arg143 and Lys144.  Other interactions with the iron-sulfur cluster 
involve Thr87 and Trp246.  In the active site the phosphosulfate group of APS is 
positioned opposite the [4Fe-4S] cluster and, while no atoms intervene, the sulfate 
moiety is not in direct contact with the [4Fe-4S] cluster.  
 
Given the unusual CysCys dyad coordination and its requirement for catalytic activity, 
defining the function and properties of the iron-sulfur cluster in APR has generated 
considerable interest (1, 7, 9, 18, 19).  Most proteins containing [4Fe-4S] clusters are 
redox-active (20-23), however, the [4Fe-4S]2+ cluster in APR does not undergo redox 
changes during the catalytic cycle (1).  A purely structural role also appears unlikely, in 
light of biophysical data obtained on the apo form of APR (8, 15, 18) and the fact that 
APR and PAPR share a common protein fold (4, 7, 14).  Unfortunately, progress in this 
area has been hampered by the failure to generate a paramagnetic state of the [4Fe-4S] 
cluster that can be studied by electron paramagnetic resonance (EPR) spectroscopy and 
related methods (18, 19, 24).  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
5 Residue numbers in the text correspond to the PaAPR amino acid sequence.  The corresponding residue 
numbers in MtAPR can be identified from the sequence alignment depicted in Appendix 5.7.1. 
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Herein, we report the EPR 
spectra of MtAPR in the [4Fe-
4S]+ state.  The EPR spectrum 
of MtAPR displays a rhombic 
signal, but is complex and 
consists of at least two 
overlapping S = , species.  
Mössbauer studies of the 
native and reduced forms 
confirm the presence of a 
[4Fe-4S]2+/1+ cluster.  APS 
binding to MtAPR is 
accompanied by marked 
sharpening of the EPR signal 
and an increase in intensity, 
which is not observed among a 
panel of substrate analogs, 
including adenosine 5$-
diphosphate (ADP).  In 
addition, kinetic and EPR 
investigation of the Lys144Ala 
variant of MtAPR demonstrate 
a key function for this residue 
in catalysis and as a link 
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Figure 5.2.  The environment of the [4Fe-4S] cluster in PaAPR.  
A. The structure of PaAPR bound to substrate APS.  The [4Fe-
4S] cluster is ligated by four cysteine residues at positions 139, 
140, 228 and 231.  PDB code: 2GOY.  B. Four conserved 
residues participate in charged or polar NH-S or OH-S 
hydrogen bonds to inorganic S or cysteine S% atoms; Thr87, 
Arg143, Lys144 and Trp246 (yellow dashes).  PDB code: 
2GOY, chain A.  C. Conserved basic residues Lys144, Arg242 
and Arg245 in the active site interact with the phosphate and 
sulfate groups of APS (yellow dashes).  Residues that also 
interact with APS, but are not depicted in this Figure 6.are 
Arg171 and His259; these residues interact with the "-
phosphate group.  The shortest distance between a sulfate 
oxygen atom and a cysteine sulfur atom coordinated to the 
[4Fe-4S] cluster is 6.0 Å.  PDB code: 2GOY, chain B. 
! 108!
between APS and the iron-sulfur cluster.  These data, together with known functional 
and structural information, directly implicate the iron-sulfur cluster in the catalytic 
mechanism of APS.  
 
5.3. Results 
5.3.1 Purification and Spectroscopic Characterization of the [4Fe-4S]2+ Cluster in 
MtAPR. 
We have previously reported conditions for the purification of MtAPR (1).  However, 
yields from these preparations were low owing to the large quantity of MtAPR present in 
the insoluble protein fraction.  In order to improve the yield and stability of purified 
MtAPR, we co-expressed the MtAPR gene with the gene products of the isc operon 
required for iron-sulfur cluster biosynthesis in A. vinelandii (25).  Under these conditions 
the yield of MtAPR was typically 7 mg/L of culture, which represents an improvement 
over ~1 mg/L obtained when MtAPR is over-expressed in the absence of the isc proteins.  
The specific activity of the purified enzyme was 5 µM min-1 mg protein-1 with thioredoxin 
and DTT as reductants.  The UV-Vis absorbance spectrum of MtAPR showed a 
maximum in the visible range at 410 nm that is consistent with the presence of bound Fe 
(Appendix 5.7.2).  Analysis of Fe content by inductively coupled plasma resonance 
spectrometry for MtAPR indicated that each mole of protein contained 3.5 ± 0.4 mol of 
Fe, which is indicative of 4 Fe atoms in the cluster.  The intensity of the 410 nm peak 
was unaffected on addition of sodium dithionite (data not shown), but increased slightly 
on addition of APS (Appendix 5.7.2).  These results are analogous to those found for 
PaAPR (8).  The minor increase in absorption at 410 nm could reflect substrate-
dependent conformational changes within the C-terminal region and a concomitant 
alteration in cluster environment. 
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The 4.2-K/53-mT Mössbauer spectrum of 
MtAPR confirmed the presence of a [4Fe-
4S]2+ cluster (Figure 5.3).  The majority of the 
Fe ()90%) gives rise to a quadrupole doublet 
with parameters typical of [4Fe-4S]2+ clusters: 
isomer shift (*) of 0.45 mm/s and quadrupole 
splitting parameter (#EQ) of 1.09 mm/s.  The 
appearance of a small peak at )0.6 mm/s is 
indicative of a small amount of [2Fe-2S]2+ 
clusters (* = 0.25 mm/s, #EQ = 0.55 mm/s, 
)7% of total intensity).  The [2Fe-2S]2+ cluster 
form of MtAPR has also been observed by ESI-FT-ICR MS (15) and is most likely 
caused by aerobic degradation, analogous to other [4Fe-4S]2+ proteins.  On addition of 
APS, the Mössbauer spectrum of MtAPR was nearly identical to that in the absence of 
substrate (Appendix 5.7.3) and can be simulated as a superposition of two quadrupole 
doublets representing the [4Fe-4S]2+ clusters (* = 0.45 mm/s, 'EQ = 1.12 mm/s, 90%) 
and [2Fe-2S]2+ clusters (* = 0.25 mm/s, 'EQ = 0.55 mm/s, 10%).  
 
5.3.2 Photoreduction of the [4Fe-4S]2+ cluster in MtAPR.   
As-isolated APR from higher plants and P. aeruginosa exhibits weak isotropic signals at 
g = 2.01 attributed to a small proportion of [3Fe-4S]+ cluster and at g = 4.3 from high-
spin Fe(III) (18, 19, 24).  When MtAPR was prepared according to the previous method 
(15), similar resonances were observed (data not shown).  However, such EPR signals 
were not present in samples of MtAPR produced via the improved co-expression system.  
Earlier attempts to generate new EPR signals in assimilatory APR from higher plants 
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Figure 5.3.  4.2-K/53-mT Mössbauer spectra 
of 1 mM MtAPR.  Experimental spectra are 
shown as vertical bars.  The solid line is a 
quadrupole doublet simulation with the 
parameters quoted in the text.  The weak 
peak at )0.6 mm/s is indicative of a small 
amount of [2Fe-2S]2+ clusters (arrow).  !
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and bacteria by titrating the enzyme with 
dithionite, Ti(III)citrate or photochemical 
reduction with the deazaflavin/oxalate 
system have proven unsuccessful (18, 19, 
24).  Similarly, our earlier studies of 
MtAPR found no evidence for the 
presence of [4Fe-4S]+ after treatment with 
dithionite (15).   
 
In the present study, we first explored 
reduction of the cluster in MtAPR using 
Ti(III)citrate.  New EPR signals were 
observed, however, interpretation of the 
spectra was confounded by 
nonspecifically bound Ti(III)citrate that 
gave rise to an isotropic signal at g = 1.94 
(data not shown).  Next, we tested 
photoreduction of the [4Fe-4S]2+ center in 
MtAPR in the presence of 
deazaflavin/oxalate.  The resulting EPR 
spectrum is broad, but shows rhombic 
symmetry with apparent g-values of 2.04, 
1.94 and 1.75 (Figure. 5.4A).  The EPR 
signal also gives evidence for a second 
component with apparent g-values at 2.13 
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Figure 5.4.  Experimental EPR spectra of 
photoreduced MtAPR.  Anaerobic 250 µM MtAPR 
alone or incubated with 1 mM ligand for 10 min at 
25 °C was then photoreduced as described in 
Experimental Procedures.  Samples: A. MtAPR 
alone.  B. Cys256Ser MtAPR bound to APS.  C. 
MtAPR incubated with APS to generate the S-
sulfocysteine intermediate bound to AMP.  D. 
MtAPR bound to AMP.  E. MtAPR bound to ADP.  
F. MtAPR bound to ADP!F.  The EPR spectra 
were recorded at 10 K and the instrument 
parameters were: microwave power, 10 mW; 
receiver gain, 2 x 104; modulation amplitude, 10 
G; microwave frequency, 9.43 GHz.  
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and 1.85; however, the broad resonances 
precluded an accurate simulation of the two 
paramagnetic species.  Spin quantitation of 
the EPR signals from g = 2.5 to 1.3 indicate 
0.3 equiv of spins per mole of enzyme.  On 
the basis of observed g-values, the 
resonances can be attributed to either an S = 
, [2Fe-2Fe]+ or [4Fe-4S]+ cluster.  The 
temperature dependence of the EPR signal 
(data not shown) indicated that it was 
maximal between 8-10 K and was no longer 
visible at temperatures above 12 K, using a 
microwave power of 10 mW.  This behavior 
suggests that the paramagnetic signal arises 
from a [4Fe-4S]+ cluster.  By contrast, [2Fe-
2S]+ clusters are slow relaxing and 
observable by EPR at temperatures above 70 
K (26).   
 
5.3.3 Interaction of the Photoreduced [4Fe-
4S]+ Cluster with Substrate and Analogs.   
The [4Fe-4S] cluster at the active site of APR 
is required for catalytic activity (1); however, 
the mechanistic details are unknown and 
remain a central question for this family of 
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Figure 5.5.  Simulated EPR spectrum of 
photoreduced wild-type MtAPR after addition 
of APS.  The bottom two spectra show how 
two separate species might combine to give 
the observed signal (top spectra, solid line; 
see also Figure 5.4C).  The dashed lines 
denote the simulated EPR spectrum, which is 
the sum of two components:  Component A is 
a spectral simulation of the narrow 
component using g = 2.04, 1.94, 1.76, g 
strain (+g) = 0.017, 0.022, 0.020, and a 
Gaussian line shape.  Component B is a 
spectral simulation of the broad component 
using g = 2.10, 1.88, 1.75, g strain (+g) = 
0.038, 0.036, 0.099, and a Gaussian line 
shape.  The ratio of Component A to 
Component B is 1:1.2.  Simulated instrument 
parameters are as reported in the legend of 
Figure 5.4. 
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enzymes.  While the iron-sulfur cluster in APR does not undergo redox activity during the 
catalytic cycle (1), the 1+ state of APR can serve as a useful tool for mechanistic studies 
analogous to other enzymes that harbor redox-inactive iron-sulfur clusters such as 
aconitase (27).  Therefore, to gain insight into the functional role of the cluster we next 
investigated whether substrate binding would perturb the EPR spectrum of reduced 
MtAPR.    Two types of protein-ligand complexes were prepared: (i) wild-type MtAPR 
treated with APS to afford the S-sulfocysteine intermediate form of the enzyme bound to 
AMP, and (ii) the catalytically inactive variant, Cys256Ser MtAPR bound to APS.  
Established procedures for complex formation were performed (1, 15) and the resultant 
samples were then subjected to photoreduction.  
 
Compared to wild-type MtAPR (Figure 5.4A), the EPR spectrum of Cys256Ser MtAPR 
bound to APS is markedly sharper in appearance with apparent g-values of 2.02, 1.91 
and 1.76 (Figure 5.4B).  The EPR signal of the enzyme S-sulfocysteine intermediate 
bound to AMP also exhibits increased resolution with apparent g-values of 2.03, 1.91 
and 1.75 (Figure 5.4C).  Additionally, both spectra (Figure 5.4B and C) indicate the 
presence of a second paramagnetic species.  Spin quantitation of EPR signals from g = 
2.7 to 1.6 indicate a respective 0.45 and 0.4 equiv of spin per mole for the Cys256Ser 
and wild-type MtAPR complexes.  The heterogeneity of these samples was essentially 
unaffected by the addition of 2.5 M urea, changes in sample pH between the ranges of 
7.5 and 9.5, variation in temperature or microwave power levels (data not shown).   
 
Simulation of the signal from wild-type MtAPR treated with APS suggests that it is the 
sum of at least two S = , components (Figure 5.5).  One species has narrow lines and 
g-values at 2.04, 1.94, and 1.76 (component A), whereas the other has broad lines and 
exhibits principle g-values at 2.10 and 1.88 (component B) with an intensity ratio of 1:1.2.  
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Although simulated and experimental spectra are in overall agreement, some 
discrepancies remain, particularly with respect to signal amplitudes.  The addition of a 
third spectral component did not improve the fit quality.  However, residual differences 
between the simulated and experimental spectra may result from weak signal intensity, 
minor fluctuations in temperature around 10 K, or the large number of variables required 
to simulate a [4Fe-4S]+ cluster. 
 
Next, we tested whether the observed APS-dependent changes in the EPR spectra of 
reduced MtAPR were specific to the substrate.  To investigate this possibility, we 
analyzed the spectra of photoreduced MtAPR bound to AMP, ADP and ADP!F.  The 
EPR signal of MtAPR bound to AMP (Figure 5.4D) was similar in shape and intensity to 
enzyme alone (Figure 5.4A).  By contrast, the spectrum in the presence of ADP (Figure 
5.4E) showed a significant reduction in signal intensity.  To determine whether the 
observed changes in the EPR spectrum were due to the additional negative charge at a 
!-phosphate group (i.e., ADP) relative to a !-sulfate group (i.e., APS), we examined 
fluorine substitution of a !-nonbridging oxygen atom.  Interestingly, however, the EPR 
spectrum of MtAPR bound to ADP!F (Figure 5.4F) was essentially the same as ADP 
(Figure 5.4E).  Spin quantitation of MtAPR bound to ADP or ADP!F indicate less than 
0.1 equiv of spins per mole of enzyme in each sample.  The marked increase in signal 
resolution and intensity in the presence of APS, but not upon addition of substrate 
analogs or product reflects a unique state of the active site and cluster environment, 
which might be related to catalytic activity.  
 
5.3.4 Characterization of Lys144Ala MtAPR.   
! 114!
The preceding EPR data support the existence of mid-range electrostatic interactions 
between the cluster and APS.  Given that the side chain of Lys144 is positioned between 
coordinating Cys140 and the !-sulfate group of APS (Figure 5.2C) we reasoned that this 
residue might help mediate this interaction.  To investigate this possibility, we generated 
the Lys144Ala MtAPR variant and characterized this protein through kinetic and EPR 
studies.  An effect of 63,000-fold on kcat/KM is observed upon mutation of Lys144 to Ala 
(Table 1; see also Appendix 5.7.4).  Since the chemical step (i.e., S-sulfocysteine 
formation) is rate limiting for the reaction of APS and MtAPR (5), this value represents 
the effect of removal of the Lys residue on the overall binding and chemical 
transformation.  The mutation decreases the value of kmax by 270-fold suggesting that 
the Lys side chain stabilizes the transition state relative to the ground state complex.  To 
further explore the molecular recognition of APS, we measured the Kd value of the 
substrate for Lys144Ala MtAPR.  Relative to wild-type MtAPR, the affinity of APS for 
Lys144Ala is decreased by 400-fold.   
 
Table 5.1: Effect of Lys144Ala Mutation on APR-Catalyzed Reduction and Binding of 
APSa 
 
 kcat/Km (M
-1 s-
1)b 
fold 
reduction 
kmax (min-
1)c 
fold 
reduction 
Kd 
()M) 
fold 
reduction 
Wild-type 2.5 x 106 (1) 2.7 (1) 0.25d (1) 
Lys144Ala 40 6.3 x 104 0.01 270 #100e #400 
 
aRate constants for single-turnover reactions were determined at 30 °C in 100 mM bis-tris propane buffer, 5 
mM DTT, 10 )M Trx as described in Experimental Procedures.  In all cases, the protein was in excess over 
substrate, with at least 2.5-fold more protein than substrate.  bIn bis-tris propane at pH 7.5.  cIn bis-tris 
propane at pH 6.5.  dFrom Ref. (5).  eThe apparent Kd value was determined at 30 °C in 100 mM bis-tris 
propane pH 7.5 as described in Experimental Procedures.  
 
The UV-Vis absorbance spectrum of Lys144Ala MtAPR showed a maximum in the 
visible range at 410 nm that is consistent with the presence of bound Fe (data not 
shown).  Analysis of Fe content by inductively coupled plasma resonance spectrometry 
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for Lys144Ala MtAPR indicated that each mole of protein contained 3.3 ± 0.4 mol of Fe, 
which is consistent with 4 Fe atoms in the 
cluster.  Photoreduction of Lys144Ala 
MtAPR gave rise to a rhombic signal with 
resonances at g = 2.12, 1.99 and 1.82 
(Figure 5.6A and C).  However, the signal 
intensity was decreased relative to wild-
type MtAPR and spin quantitation 
accounted for less than 0.05 equiv of 
spins per mole of enzyme.  In the 
presence of saturating APS, the feature at 
g = 1.75 disappears and the remaining 
signal exhibits g-values at 2.12 and 1.99 
(Figure 5.6B and D).  A low-field isotropic 
Fe3+ signal accounting for less than 0.01 
equiv of spin per mole of enzyme was 
also observed in the presence of APS, 
consistent with a small degree of cluster 
degradation (data not shown).  Although 
the EPR spectra for both samples are 
relatively broad and weak, a modest 
reduction in the magnetic heterogeneity of 
MtAPR can be observed.  Together, the 
kinetic and EPR data indicate a key role 
for Lys144 in chemistry and substrate 
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Figure 5.6.  Experimental EPR spectra of 
photoreduced Lys144Ala MtAPR.  Anaerobic 250 
µM Lys144Ala MtAPR alone (A) and (C) or 
incubated with 1 mM APS (B) and (D) for 10 min 
at 25 °C was then photoreduced as described in 
Experimental Procedures.  In (A) and (B) EPR 
signal intensities have been scaled to match those 
in Figure 5.4.  In (C) and (D) the intensity of the 
EPR signals has been scaled 7.5-fold.  The EPR 
spectra were recorded at 10 K and the instrument 
parameters were: microwave power, 10 mW; 
receiver gain, 2 x 104; modulation amplitude, 10 
G; microwave frequency, 9.43 GHz.   !
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binding, and that this residue helps modulate APS-dependent changes in the iron-sulfur 
cluster environment.  
 
5.3.5 Cryoreduction of the [4Fe-4S]2+ Cluster in MtAPR.   
Although the [4Fe-4S]+ cluster serves as a useful spectroscopic tool in the study of 
MtAPR and variants, we recognize that it is not the native form of the active enzyme.  
For this reason, we attempted to probe the interaction of substrate with the [4Fe-4S]2+ 
state of MtAPR through cryoreduction-EPR studies.  In principle, %-irradiation of the 
frozen [4Fe-4S]2+ cluster affords the reduced state [4Fe-4S]+ trapped in the geometry of 
the [4Fe-4S]2+ oxidized state (28, 29).  To this end, the 2+ state of MtAPR was incubated 
in the presence or absence of APS, frozen in liquid nitrogen and then exposed to high-
energy %-irradiation at 77 K to produce the [4Fe-4S]+ cluster.   
 
The resulting spectrum in the absence of substrate (Appendix 5.7.5) is ill defined and 
relatively broad.  However, the addition of substrate APS was accompanied by a marked 
increase in signal intensity and resolution with apparent g-values at 2.08, 2.04 and 2.02 
(Appendix 5.7.5).  The observation of substrate-dependent changes in the EPR 
spectrum is in qualitative agreement with our experimental results from photoreduction.  
However, we note that the EPR spectra of cryoreduced MtAPR are distinct from those of 
the photochemically reduced enzyme.  These findings may indicate that the substrate 
interacts differently with the cluster in the +2 and +1 states.  An alternative possibility is 
that the observed EPR signals correspond to a thiyl radical formed by homolytic scission 
of the S-sulfocysteine bond.  In support of this proposal, the relatively high g-values are 
consistent with literature data for a sulfur-centered species (30, 31). 
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In addition to the aforementioned g-values, the cryoreduced samples contained an 
extremely intense signal isotropic signal at g = 2, which could arise from other non-
specifically reduced organic radicals present in the sample (Appendix 5.7.5).  4.2-K/53-
mT Mössbauer spectra of samples recorded before and after cryoreduction (Appendix 
5.7.6) indicate that ~50% of the [4Fe-4S]2+ clusters were reduced to the +1 state under 
these conditions.  Thus, Mössbauer analysis confirms the presence of the [4Fe-4S]+ 
cluster in cryoreduced samples; however, the %-irradiation also appears to have 
generated extremely intense, new paramagnetic species that are distinct from a simple 
one-electron reduction of the +2 cluster.  Lastly, no significant changes in the Mössbauer 
spectra from substrate-bound and substrate-free cryoreduced MtAPR were observed 
(Appendix 5.7.6). 
 
5.3.6 Ferricyanide Oxidation of the [4Fe-4S]2+ Cluster in MtAPR.   
The [4Fe-4S]2+ cluster in PaAPR is partially converted to the [3Fe-4S]+ form by treatment 
with the oxidant potassium ferricyanide (18).  To assess this possibility for MtAPR, a 
stoichiometric amount of potassium ferricyanide was added to the enzyme.  The 
resulting EPR signal shows a well-defined EPR resonance at g = 2.03 and a poorly 
resolved high-field component at g = 1.99 (Appendix 5.7.7).  This pattern of EPR signals 
is very similar to those of S = , [3Fe-4S]+ clusters in aconitase (27) and endonuclease 
III (32).  Spin quantitation of the EPR signals from g = 2.1 to 1.8 indicate less than 0.1 
equiv of spins per mole of enzyme.  The EPR spectrum of oxidized MtAPR also 
exhibited a signal accounting for less than 0.01 equiv of spins per mole of enzyme at g = 
4.3 that is characteristic of high-spin Fe(III).  When ferricyanide was added to MtAPR 
that had been pre-treated with APS, the intensity of the signal at g = 4.3 was increased 
by 3-fold (data not shown).  Attempts to purify the [3Fe-4S]+ cluster form of MtAPR were 
unsuccessful as the cluster rapidly decomposed upon oxidant removal.  Nonetheless, 
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these data are consistent with the existence of a labile Fe site within the [4Fe-4S]2+ 
cluster of MtAPR.  Given the constraints of tandem Cys coordination (7) and the 
proximity of Lys144, the Fe coordinated to Cys140 may correspond to the displaced 
atom. 
 
5.4 Discussion 
Iron-sulfur clusters are amazingly versatile cofactors with functions in electron transfer, 
Lewis acid-assisted enzyme catalysis, radical generation, oxidation of a wide variety of 
substrates under anaerobic conditions, and protein structure (33-38).  While numerous 
studies indicate that the iron-sulfur cluster is essential for APR activity (1, 7, 9, 15), the 
specific role of the iron-sulfur cluster has been elusive.  Progress on this front has been 
limited, in part, by the inability to generate a paramagnetic state of the [4Fe-4S] cluster 
that can be studied by EPR spectroscopy.  The present study is the first reported case in 
which the [4Fe-4S]2+ cluster of APR has been reduced to the S = , [4Fe-4S]+ form.  
 
Photoreduction in the presence of deazaflavin and oxalate turned out to be the most 
effective method to generate the paramagnetic 1+ state of MtAPR.  By contrast, 
attempts to photochemically reduce APR from plants and bacteria such as P. aeruginosa 
and B. subtilis have not been successful (15, 24).  Active site residues that interact with 
the iron-sulfur cluster and/or the substrate (e.g., Thr87, Arg143, Lys144, Arg242, Arg245, 
Trp246) are highly conserved among APRs and therefore, are unlikely to account for 
EPR behavioral differences.  On the other hand MtAPR is a monomer in solution while 
APR from other species exists as a homodimer or homotetramer (1, 19).  Along these 
lines, the structure of PaAPR shows that the face of the iron-sulfur cluster opposite the 
active site is buried at the interface between two monomeric subunits (7).  Studies on the 
effect of solvent on redox potentials of model clusters indicate that water raises the 
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reduction potential of the [4Fe-4S]2+/+ couple (39, 40).  Hence, increased solvent 
accessibility to the cluster of monomeric MtAPR may account for the ability to generate 
the 1+ state.   
 
The EPR signal of reduced MtAPR arises from a mixture of [4Fe-4S]+ clusters with S = 
,, possibly reflecting the existence of distinct conformational states.  Multiple S = , 
ground states have been observed for other [4Fe-4S] iron-sulfur enzymes such as the 
corrinoid protein from Clostridium thermoaceticum (41), human DNA primase (42), and 
the ribosomal RNA methyltransferase, RumA (43).  The apparent lack of changes in the 
EPR spectra between pH 6.5 and 9.5 suggests that the complexity does not result from 
differences in protonation state of residues near the iron-sulfur cluster.  Freezing of 
samples after photoreduction can also led to multiple signals from the same 
paramagnetic center – one from aggregated protein molecules and the other from 
dispersed molecules (44).  To investigate this possibility, we recorded the EPR spectrum 
for cryoreduced MtAPR.  In these experiments, the EPR signal that arises from the [4Fe-
4S]+ form of MtAPR is weak relative to other radical species generated during the %-
irradition process.  Nonetheless, magnetic heterogeneity is still apparent in the spectrum 
(Appendix 5.7.5).  Treatment with 1-2.5 M urea has also been reported to convert 
multiple isomeric states of an [4Fe-4S]+ cluster into a single one (41), but this was not 
the case with MtAPR.  This observation may indicate the existence of more subtle 
differences between cluster forms in MtAPR such as changes in the orientation of a Cys-
S%-Fe bond or in hydrogen bonding to a sulfur atom.   
 
Regarding possible conformational changes, PaAPR has been fortuitously crystallized 
with APS bound in two of the four monomeric subunits (7).  A comparison of bound and 
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unbound states reveals minor structural changes in residues adjacent to the iron-sulfur 
cluster (Figure 5.2B and C).  In the absence of substrate, Lys144 is present in an 
extended conformation such that the distance between the side chain and the S% atom of 
Cys140 is ~5 Å.  By contrast, the subunit with APS bound shows that the side chain of 
Lys144 adopts a bent rotamer conformation, which brings this residue within interaction 
range (i.e., 3.5 Å) of Cys140 S%.  In turn, the Cys140 side chain moves slightly upward 
(i.e., 5° rotation at the !-carbon).  It is possible then, that the heterogeneity observed in 
the EPR spectra may be related to conformational dynamics of Lys144, Cys140 and/or 
Cys256 within the C-terminus.  In support of this hypothesis, a decrease in EPR signal 
complexity was observed with Lys144Ala MtAPR (Figure 5.6).  Structural changes at 
these key residues may also account for the observation that the iron-sulfur cluster of 
APR is protected from oxidation on addition of APS (15) and that the resonance Raman 
spectra exhibit changes in Fe-S% stretching modes when substrate is bound (8).   
 
Previous models for the role of the iron-sulfur cluster in APR catalysis have postulated 
that one or two non-bridging sulfate oxygen(s) establish a direct interaction with an Fe 
atom (i.e., monodentate or bidentate coordination of the substrate) (45).  The interacting 
Fe atom could facilitate nucleophilic attack at the sulfate sulfur by acting as a Lewis acid, 
analogous to aconitase (27).  Since the cluster in APR is ligated to the protein via four 
cysteine residues the coordination number of the interacting Fe site would increase to 5 
or 6.  Based on studies of direct interaction between substrate or cofactor and [4Fe-4S]2+ 
clusters in aconitase (27), pyruvate formate-lyase activase (46), and biotin synthase (47) 
significant perturbation of the Mössbauer parameters for an interacting Fe site in MtAPR 
would be expected (46, 48, 49).  The present work, however, shows no discernable 
change in the Mössbauer spectrum upon addition of APS to MtAPR (Appendix 5.7.3), 
! 121!
suggesting that the cluster and the substrate do not establish a direct interaction.  This 
proposal is fully consistent with the crystal structure of PaAPR bound to APS, which 
shows that the sulfate oxygens are 7 Å from the closest Fe atom and 6 Å from the S% 
atom of Cys140 (Figure 5.2B) (7). 
 
On the other hand, substrate binding to MtAPR led to a marked increase in intensity and 
resolution of the EPR signal, and to minor shifts in principle g values that were not 
observed with closely related substrate analogs, ADP and ADP!F (Figure 5.4).  These 
findings correlate with observed differences in the dissociation constants (Kds) reported 
for these ligands (5) and can be rationalized on the basis of differences in anionic 
charges: !-sulfate has a net negative charge of one distributed over three oxygen atoms 
(i.e., -1/3 charge each; Kd = 0.25 !M), while !-phosphate has a net negative charge of 
two distributed over three oxygen atoms (i.e., -2/3 charge each; Kd = 5 !M) and !-
fluorophosphate has a net negative charge of one distributed over two oxygen atoms 
(i.e., -1/2 charge each; Kd = 2.5 !M).  By contrast, the similarity of EPR spectra obtained 
in the presence or absence of AMP (Figure 5.4A and D) suggests that the "-phosphate 
group is too distant from the cluster to exert any significant effect.  Taken together, these 
data are indicative of mid-range electrostatic interactions between the iron-sulfur cluster 
and the !-functional group of the ligand, which are finely attuned to the electrostatic 
properties of the sulfate in APS.  
 
In addition to differences in formal anionic charge, the sulfur atom of sulfate is larger, 
more electronegative and forms shorter bonds with oxygen relative to a phosphorous 
atom.  As a consequence, the oxygen atoms associated with a !-sulfate group are 
associated with less negative charge density, relative to oxygen atoms attached to 
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phosphate (50).  As compared to APS, the increase in negative charge density 
associated with !-non-bridging oxygen atoms of ADP and ADP!F might strengthen their 
interaction with the positively charged Lys144 side chain such that this residue moves 
away from the S% atom of coordinating Cys140.  Alternatively, or in addition, considering 
that the [4Fe-4S(Cys-S%)4] cluster has a net charge of -2 (11), repulsive electrostatic 
interactions could arise when ADP or ADP!F are bound in the active site.  Either 
scenario could account for the observed decrease in analog affinity and hamper the 
ability of the iron-sulfur cluster in MtAPR to accept an additional electron (i.e., adopt the 
reduced 1+ state).   
 
In general, spin quantitation of the EPR signals revealed less than 0.5 spin/mol MtAPR. 
These less than unitary values for the spin integration of the reduced spectra can be 
attributed to incomplete reduction of the [4Fe-4S]2+ cluster that may result from 
insufficient light intensity or illumination time.  However, changes in these parameters 
were accompanied by noticeable cluster degradation and were therefore not pursued 
further.  Despite the modest efficiency of reduction, variations in spin quantitation 
between substrate-bound (or substrate analog) and substrate-free states of MtAPR were 
observed.  These differences are likely due to ligand-dependent structural and 
electrostatic changes in cluster environment, as discussed above. 
 
The positively charged side chain of Lys144 interacts with both APS and coordinating 
Cys140, forming a link between the substrate and the iron-sulfur cluster.  Although strict 
conservation of Lys144 implies an important role, this study is the first to probe the 
precise function of this residue.  Using site-directed mutagenesis, we demonstrate that 
Lys144 is necessary for both substrate binding and transition state stabilization (Table 1).  
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Moreover, the significant decrease in EPR signal intensity for Lys144Ala MtAPR (Figure 
5.6) suggests that the proximity of the positively charged side chain of this residue may 
be an important factor in stabilizing the reduced state of the cluster.  Future 
measurements of midpoint reduction potentials could provide additional support for this 
proposal.  
 
Comparison of the EPR spectra between wild-type, Cys256Ser (Figure 5.4) and 
Lys144Ala MtAPR (Figure 5.6) shows that the Lys residue plays an important role in 
modulating substrate-dependent changes in signal resolution and intensity.  However, 
we note that the EPR spectrum of Lys144Ala still exhibits subtle differences in the 
presence or absence of APS.  In particular, the APS bound state shows small changes 
in signal intensity at g = 2.12 and 1.99, and a decrease in the spectral feature at g = 1.82.  
These differences in EPR spectra may be attributable to the intrinsic electrostatic 
interaction between the iron-sulfur cluster and the substrate.   
 
On the basis of the results reported herein, we propose a catalytic role for the iron-sulfur 
cluster in the mechanism of APS reduction, specifically in the sequence of events 
leading up to and through sulfuryl group transfer (Figure 6.7).  Prior to APS binding, the 
[4Fe-4S(Cys-S%)4]2– cluster may serve to pre-organize the positively charged side chain 
of Lys144 and possibly Arg245 (Figure 5.2B and C) within the active site, so that the 
substrate can establish interactions with these residues.  Based on the Mössbauer data 
and structural studies, APS binds to the [4Fe-4S]2+ state of APR, but does not appear to 
come into direct contact with the cluster.  Rather, EPR investigation of the [4Fe-4S]+ and 
[3Fe-4S]+ states indicate that mid-range electrostatic interactions arise between APS 
and the iron-sulfur cluster.  The charge from and polarization within the [4Fe-4S(Cys-
S%)4]2– cluster could serve to activate the sulfate group of APS, thereby facilitating S-OP 
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cleavage and S-S bond 
formation in the 
reaction.  In the 
absence of an iron-
sulfur cluster, PAPR 
may achieve something 
similar via repulsion 
between the extra 3’-
phosphate group of 
PAPS and the sulfate 
end of the 5’-
phosphosulfate.  The 
sulfate group would 
then be primed for 
nucleophilic attack by 
Cys256, leading to formation of the S-sulfocysteine enzyme intermediate.  In support of 
this proposal, experimental and theoretical studies of sulfuryl group transfer in sulfate 
esters (50, 51) indicate the need for a strong polarizing agent.  Regarding Lys144, our 
analysis demonstrates an essential role for this residue in enzyme catalysis.  Although 
only speculative at present, it is plausible that the active site Lys144 cation may orient 
the incoming Cys nucleophile with respect to the sulfate moiety and/or act as a 
“molecular guidewire” during sulfuryl transfer; either possibility could result in transition 
state stabilization.  Analogous functions for Lys and Arg residues in the active site of 
other enzymes that catalyze sulfuryl transfer have been described (52, 53). 
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Figure 5.7.  Possible reaction pathway for covalent S-sulfocysteine 
intermediate formation catalyzed by APR.  The C-terminal residues 250-
267, which carry the catalytically essential Cys256, are disordered in the 
structure of PaAPR, but can be modeled into the active site using the 
structure of S. cerevisiae PAPR (4).  In the homology-modeled structure 
(5), Cys256 is proximal to the sulfate group of APS as well as the side-
chains of Cys140 and Lys144.  Electrostatic destabilization of APS may 
arise from the juxtaposition of the electron density and partial negative 
charge that resides on the sulfide and cysteinyl sulfur atoms of the iron-
sulfur cluster (see Ref. (11) for theoretical treatment of charge 
distribution in iron-sulfur clusters).  Repulsion between APS and the iron-
sulfur cluster could be partially relieved in the transition state, thereby 
enhancing the reaction rate.  The charge build-up on the bridging sulfate 
oxygen could be stabilized by Arg171, Arg242 and His259, which are not 
indicated in this Figure 5.6.for the sake of simplicity.  
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In APR from Bacillus subtilis, on the basis of its short half-life (t1/2 ~12 min) an oxygen-
sensing function for has been proposed for the iron-sulfur cluster (24).  By comparison, 
the iron-sulfur in MtAPR is significantly more stable with a half-life of about 6 hrs (15).  
Nevertheless, it is important to note that the model we have proposed above does not 
preclude the possibility that the cluster plays a regulatory role.  Rather, the iron-sulfur 
cluster of APR may function both in a catalytic capacity and, in some organisms, as an 
oxygen-sensitive switch.  
 
5.5 Conclusion 
In summary, the data presented in this work are consistent with a catalytic function for 
the iron-sulfur cluster in APR.  On the basis of these data, we have proposed that the 
cofactor plays a role in pre-organizing active site residues and in substrate activation.  
Additional experimental and theoretical tests of these proposals are currently underway 
and will be reported in due course.  Moreover, the finding that MtAPR can be reduced to 
the [4Fe-4S]+ state opens the door for other forms of spectroscopy such as ENDOR and 
ESEEM that can provide further insight into the relationship between the substrate and 
iron-sulfur cluster. 
 
5.6 Experimental procedures 
5.6.1 Materials 
APS (#95%) was obtained from Biolog Life Sciences Institute.  ADP and AMP were 
purchased from Sigma Chemical Co.  ADP!F was synthesized as previously described 
(54).  The structure and purity (#98%) was confirmed by 1H and 31P NMR (data not 
shown).  10-Methyl-3-sulfopropyl-5-deazaisoalloxazine potassium salt (deazaflavin) was 
a generous gift from Prof. David Ballou (University of Michigan).  Titanium(III) citrate was 
prepared anaerobically from a 15% titanium(III) chloride solution in 1 M HCl with an 
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equimolar amount of citrate (trisodium salt), and neutralized to pH 7.0 with saturated 
sodium bicarbonate.  
 
5.6.2 Mutagenesis and Protein Expression 
The construction of the expression vector encoding wild-type and Cys256Ser APR from 
M. tuberculosis cloned into the vector pET24b has been previously described (55).  The 
Lys144Ala variant was generated from the wild-type MtAPR template using the Quik-
change site-directed mutagenesis kit (Stratagene) and the following primer sequence: 5$-
GCTGCCGGTTGCGCAAGGTCGTTCCCCTGGG-3$.  Plasmids encoding wild-type, 
Cys256Ser or Lys144Ala MtAPR pET24 and pACYC (containing genes encoding the isc 
operon of six accessory proteins required for Fe–S cluster biosynthesis in A. vinelandii 
under the control of an arabinose-inducible promoter) (25) were co-transformed into E. 
coli BL21(DE3) (Novagen) and plated on L-agar 50 !g/ml kanamycin and 100 !g/ml 
carbenicillin.  A single colony was picked and added to 5 ml of L-broth plus antibiotics 
and grown overnight with shaking at 37 °C.  This culture was used as a 0.5% 1 L of L-
broth plus antibiotics and grown with shaking at 37 °C until absorbance at 600 nm 
reached approximately 0.6.  Arabinose and iron citrate were added to final 
concentrations of 20 mM and 0.8 mM, respectively and the culture grown as above for 1 
hr.  At this point the flasks were removed from the incubator.  IPTG was added to a final 
concentration of 0.3 mM and the flasks were returned to the incubator and grown 
overnight at 18 °C with shaking at 200 rpm.  Cultures were harvested by centrifugation 
(4 °C, 4,300g).  After removal of the supernatant the pellets were stored at -80 °C until 
required.   
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All purification steps were carried out at 4 °C.  Cell pellets were resuspended in 30 ml 
Buffer A (20 mM sodium phosphate, 0.5 M NaCl, 10 mM imidazole; pH 7.4) 
supplemented with 0.1 mM PMSF, 10µg/ml DNase, 5 µg/ml lysozyme and lysed by 
sonication.  Lysates were centrifuged (20,000g, 15 min) and loaded onto a 5 ml HiTrap 
Chelating column (GE Healthcare, Piscataway, NJ) equilibrated in the same buffer.  
Unbound material was washed off with 50 ml of Buffer A and bound proteins then eluted 
with in Buffer B (20 mM phosphate, 0.5 M NaCl, 250 mM imidazole; pH 7.4).  Fractions 
containing wild-type or Lys144Ala were pooled, concentrated by centrifugation (Amicon 
10 kDa cutoff, Millipore, Billerica, MA) and loaded onto a 16/60 Superdex 200 size 
exclusion column previously equilibrated in Buffer C (50 mM Tris-HCl, 150 mM NaCl, 5 
mM DTT, 10% glycerol; pH 8.5 at 4 °C).  Fractions containing wild-type or Lys144Ala 
MtAPR were pooled, snap-frozen in liquid nitrogen, and stored at -80 °C.  Protein 
concentrations were determined using the extinction coefficient, &280=36,815 M-1cm-1, 
obtained from quantitative amino acid analysis (1).   
 
5.6.3 Preparation of MtAPR for EPR and Mössbauer Spectroscopy 
Samples of wild-type, Cys256Ser or Lys144Ala MtAPR suitable for Mössbauer or EPR 
spectroscopy were prepared inside of an anaerobic chamber with O2 levels % 1 ppm.  
Purified MtAPR was exchanged into anaerobic buffer containing 50 mM Tris–HCl, 150 
mM NaCl (pH 8.5 at 4 °C) and 10% glycerol.  To reduce the cluster in MtAPR, reactions 
contained 250 µM enzyme, 25 mM sodium oxalate, 250 µM deazaflavin in a total volume 
of 250 µL.  When included, substrate or other analogs were added to a final 
concentration of 1 mM and incubated with MtAPR for 10 min at 25 °C prior to 
photoreduction.  The reaction mixtures were transferred to EPR tubes, chilled in an ice-
salt bath (-6 °C) and irradiated with light from a 100 W quartz halogen lamp (Applied 
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Photophysics, Surrey, UK) for 30 min.  After illumination, samples were immediately 
frozen in liquid nitrogen and analyzed by low-temperature EPR.  Mössbauer spectra 
were recorded on proteins that contained 57Fe in place of natural-abundance iron.  57Fe 
was incorporated into MtAPR via supplementation of E. coli growth media, and samples 
contained 1 mM protein, and 2 mM APS when appropriate.  After 10 min incubation with 
substrate, samples were transferred to Mössbauer cups and frozen in liquid nitrogen. 
 
5.6.4 EPR Spectroscopy 
X-band EPR spectra of photoreduced samples were recorded on a Bruker EMX 
spectrometer (Billerica, MA) equipped with an Oxford Instruments ITC4 temperature 
controller, a Hewlett-Packard model 5340 automatic frequency counter and Bruker 
gaussmeter.  Figure legends contain relevant instrumental parameters.  The sample 
buffer was used to record baselines under conditions identical to those in which the 
sample spectra were obtained.  These baselines were subtracted from MtAPR spectra 
shown in the figures.  Spin concentrations in MtAPR samples were determined by 
double integration of the EPR signal over a range of 2 kgauss and comparison with 
double integrals of 1 mM Cu(ClO4)2 in sample buffer.  EPR spectra of cryoreduced 
samples were recorded on a Bruker ER-200DSRC spectrometer equipped with an 
Oxford Instruments ESR 910 continuous-flow cryostat.  Simulations of EPR spectra were 
performed using Spin Count (ver 2.6.7) created by Professsor M.P. Hendrich at 
Carnegie Mellon University.  Spin Count is available at 
http://www.chem.cmu.edu/groups/hendrich/.  
 
5.6.5 Mössbauer Spectroscopy 
Mössbauer spectra were recorded on a spectrometer from WEB research (Edina, MN) 
operating in the constant acceleration mode in transmission geometry.  Spectra were 
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recorded with the temperature of the sample maintained at 4.2 K in an externally applied 
magnetic field of 53 mT oriented parallel to the .-beam.  The quoted isomer shifts were 
relative to the centroid of the spectrum of a foil of &-Fe metal at room temperature.  Data 
analysis was performed using the program WMOSS from WEB research. 
 
5.6.6 Cryoreduction of MtAPR by Low-Temperature %-Radiolysis 
Samples containing 250 )M MtAPR were loaded into EPR tubes or Mössbauer cups and 
flash frozen in liquid nitrogen inside the glovebox.  When appropriate, APS was added to 
a final concentration of 1 mM and incubated with protein for 10 min at 25 °C prior to 
freezing.  Samples were %-irradiated (60Co; total dose of 4 Mrad) at the %-irradiation 
facility of the Breazeale nuclear reactor at the Pennsylvania State University.  During 
irradiation, samples were maintained at 77 K by immersion in liquid N2. 
 
5.6.7 MtAPR Activity Assay 
Reactions were carried out at 30 °C.  Unless otherwise indicated, the buffer consisted of 
100 mM bis-tris propane (pH 7.5) and 100 mM NaCl supplemented with 5 mM DTT and 
10 )M E. coli thioredoxin.  Production of 35SO32- from 35S-APS was monitored using 
charcoal-based separation and scintillation counting as previously reported (5).  The 
substrate was incubated with excess enzyme to ensure single-turnover conditions (>2.5-
fold molar excess of enzyme).  The reaction progress curve was plotted as the fraction 
of product versus time and was fit by a single exponential F = A[1–e(–kobst)], where F is 
the fraction product, A is the fraction of substrate converted to product at completion, kobs 
the observed rate constant, and t time.  Reactions were followed for #5 half-lives except 
for very slow reactions.  Under single-turnover conditions, it is expected that the 
concentration dependence of the enzyme will be hyperbolic (eq 1).   
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! 
kobs = kmax[E]K1/ 2 + [E]
 (1) 
 
To determine kcat/Km, a concentration of enzyme was chosen that was at least 5-fold 
below the Km value.  Although we refer to the K1/2 for maximal activity as Km, we note 
that the K1/2 for single turnover is not necessarily the same as the Km for the multiple 
turnover reaction since the latter can be affected by the rate of product release.  For 
conditions in which [E] << Km the second order rate constant, kcat/Km = kobs/[E].  We note 
that the reported values of kcat/Km are for single-turnover conditions, but the 
measurement is equivalent to steady state kcat/Km.  At a saturating concentration of 
enzyme, the observed single-turnover rate constant reaches a maximum, kmax.  To 
determine kmax, the concentration of enzyme was varied by at least 3-fold to establish 
that the observed rate was independent of the concentration of enzyme, indicating that 
the enzyme was in excess and at a saturating concentration (i.e., kobs = kmax).  The 
reported values of kcat/Km and kmax are the average of at least three independent 
determinations.  Unless otherwise indicated, the standard deviation was %15% of the 
value of the mean. 
 
5.6.8 Determination of Substrate Affinity  
The apparent dissociation constant (Kd) for 35S-APS from Lys144Ala MtAPR-ligand 
complexes was measured using an ultrafiltration binding assay reported by Hernick and 
Fierke (56).  Because the chemical step (i.e., S-sulfocysteine formation) is rate-limiting 
(5) the K1/2 is equal to Kd of APS for Lys144Ala MtAPR.  In brief, the concentration of 
substrate was kept low (i.e., below the Kd) and constant, and the concentration of the 
enzyme was varied (0 to 80 )M).  Lys144Ala MtAPR was incubated in 100 mM bis-tris 
propane, pH 7.5 at 30 °C for 15 min prior to the assay to allow for ligand equilibration.  
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Assay mixtures were then transferred into ultrafiltration devices (Microcon 30 kDa cutoff, 
Millipore, Billerica, MA), and the free and bound ligand separated by centrifuging the 
samples at 3,000 rpm for 2.5 min.  Equal volumes of the filtrate and retentate were 
removed and quantified using scintillation counting.  The ratio of EL/Ltotal was determined 
as a function of [E]total, and the Kd value was obtained by fitting eq 2 to these data.   
! 
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! 132!
5.7 Appendix 
Figure 5.7.1 Structure based sequence alignment of PaAPR and MtAPR.   
The ClustalW Multiple Sequence Alignment program was used.  The bar graph indicates 
the degree of conservation per position.  Strictly conserved residues are outlined in red, 
red letters indicate conserved residues and conserved regions are boxed in blue.  
Alignment pictures were rendered with the server ESPript 2.2 (http://espript.ibcp.fr). 
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Figure 5.7.2 UV-vis absorption spectra of MtAPR.   
UV-vis absorption of 10µM MtAPR in 50 mM Tris–HCl, 150 mM NaCl (pH 8.5 at 4 °C) 
and 10% glycerol, before (––) and after (••••) the addition of 2-fold stoichiometric excess 
of APS.  Inset shows the corresponding difference spectrum resulting from complex 
formation between MtAPR and APS.  The difference spectrum is the spectrum of the 
mixture minus spectrum of enzyme alone. 
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Figure 5.7.3 4.2-K/53-mT Mössbauer spectra of 1 mM MtAPR in the absence 
(vertical bars) or presence of 2 mM APS (solid line) 
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Figure 5.7.4 Rate and equilibrium constants for MtAPR 
A. Single-turnover reduction of APS by Lys144Ala MtAPR performed under 
subsaturating conditions as described in Materials and Methods.  Single-turnover 
reaction to measure kcat/Km was performed with 5 nM wild-type MtAPR or 20 !M 
Lys144Ala MtAPR and 0.25 nM APS.  B. Single-turnover reduction of APS by wild-type 
(filled circles) and Lys144Ala (filled triangles) MtAPR performed under saturating 
conditions as described in Materials and Methods.  Single-turnover reactions to measure 
kmax were performed with 150 !M enzyme and 50 !M APS.  C. APS binding to 
Lys144Ala MtAPR measured by ultrafiltration as described in Materials and Methods. 
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Figure 5.7.5 EPR spectra of radiolytically cryoreduced 250 !M MtAPR in the 
absence (red) or pre-incubated with 1 mM APS (blue) as described in Materials 
and Methods.   
Conditions: temperature, 77 K; microwave frequency, 9.45 GHz; microwave power, 10 
mW; modulation frequency, 100 kHz; modulation amplitude, 10 G; scan time, 167 s; time 
constant, 167 ms.  Asterisks indicate the position of the intense signal at g = 2 
emanating from free radicals generated during cryoreduction and the position of the 
peaks of hydrogen atoms formed during cryoreduction. 
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Figure 5.7.6 4.2-K/53-mT Mössbauer spectra of 250 "M MtAPR in the absence (top) 
or pre-incubated with 1 mM APS (bottom) after #-irradiation (vertical bars) as 
described in Materials and Methods.   
In these experiments, 50% of the starting material is unchanged (red solid line).  
Spectral changes that result from different orientations of the externally applied 53-mT 
magnetic field are highlighted by the black and blue arrows. 
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Figure 5.7.7 EPR spectra of oxidized wild-type MtAPR   
A. Spectra of 250 µM MtAPR treated with a stoichiometric amount of ferricyanide in 
buffer containing 50 mM Tris–HCl, 150 mM NaCl (pH 8.5 at 4 °C) and 10% glycerol. B. 
Expanded version of panel A around g = 2.  Prior to freezing, samples with protein were 
incubated with ferricyanide for 5 min at rt.  Unreacted potassium ferricyanide is present 
in the sample.  However, controls reactions carried out in the absence of protein indicate 
that it does not contribute to features in the spectrum.  Conditions: temperature, 10 K; 
microwave frequency, 9.38 GHz; microwave power, 10 mW. 
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Chapter 6 
Iron-sulfur cluster engineering provides insight into the evolution of substrate 
specificity among the family of sulfonucleotide reductases 
 
This work has been published as “Spectroscopic studies on the [4Fe-4S] cluster in 
adenosine 5’-phosphosulfate reductase from Mycobacterium tuberculosis.” ACS 
Chemical Biology. 2011, in press.  My contributions to this work include generation of p-
loop mutants in PaAPR, MtAPR, and EcPAPR by site-directed mutagenesis and 
performing all kinetic experiments.  
 
6.1 Abstract 
Assimilatory sulfate reduction supplies prototrophic organisms with reduced sulfur that is 
required for the biosynthesis of all sulfur-containing metabolites, including cysteine and 
methionine.  The reduction of sulfate requires its activation via an ATP-dependent 
activation to form adenosine-5'-phosphosulfate (APS).  Depending on the species, APS 
can be reduced directly to sulfite by APS reductase (APR) or undergo a second 
phosphorylation to yield 3'-phosphoadenosine-5'-phosphosulfate (PAPS), the substrate 
for PAPS reductase (PAPR).  These essential enzymes have no human homolog, 
rendering them attractive targets for the development of novel antibacterial drugs.  APR 
and PAPR share sequence and structure homology as well as a common catalytic 
mechanism, but the enzymes are distinguished by two features, namely, the amino acid 
sequence of the phosphate-binding loop (P-loop) and an iron-sulfur cofactor in APRs.  
Based on the crystal structures of APR and PAPR, two P-loop residues are proposed to 
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determine substrate specificity; however, this hypothesis has not been tested.  In 
contrast to this prevailing view, we report here that the P-loop motif has a modest effect 
on substrate discrimination.  Instead, by means of metalloprotein engineering, 
spectroscopic and kinetic analyses, we demonstrate that the iron-sulfur cluster cofactor 
enhances APS reduction by nearly 1000-fold, thereby playing a pivotal role in substrate 
specificity and catalysis.  These findings offer new insights into the evolution of this 
enzyme family, and extend the known functions of protein-bound iron-sulfur clusters. 
 
6.2 Introduction 
Assimilatory sulfate reduction supplies prototrophic organisms with reduced sulfur that is 
required for the biosynthesis of all sulfur-containing metabolites, including the amino 
acids cysteine and methionine (1, 2).  The reduction of sulfate requires its activation by 
an ATP-dependent activation to form adenosine-5'-phosphosulfate (APS).  For 
incorporation of sulfur into biomolecules, the sulfate in APS must be reduced to sulfite 
and finally into sulfide.  In 
plants, algae, and many 
bacteria, APS can be 
reduced directly to sulfite 
by APS reductase (APR); 
alternatively, in fungi, some 
cyanobacteria, and .-
proteobacteria, this 
compound requires a 
second phosphorylation 
step to yield 3'-
!
 
Scheme 6.1.  Reaction catalyzed by sulfonucleotide reductases.  
The reaction is catalyzed by APR when the substrate is APS (R = H) 
and by PAPR when the substrate is PAPS (R = PO32–).   
 
 
 
Scheme 6.2.  Mechanism of sulfonucleotide reduction. !
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phosphoadenosine-5'-phosphosulfate (PAPS), the substrate for PAPS reductase (PAPR; 
Scheme 6.1, Table 6.1 and Figure 6.1).  These essential enzymes, collectively known as 
sulfonucleotide reductases (SRs), have no human homolog, rendering them an attractive 
target for the development of novel antibacterial drugs and herbicides (3-6).   
 
The importance of SR for microbial and plant survival have motivated investigations of 
their catalytic mechanism and structure (6-14).  These studies support the mechanism 
shown in Scheme 6.2, which involves nucleophilic attack by a conserved C-terminal 
cysteine residue on the substrate leading to the formation of a covalent enzyme S-
sulfocysteine intermediate.  Sulfite is then released by thiol-disulfide exchange with free 
thioredoxin (Trx) in bacterial and fungal SRs or through the action of a C-terminal Trx-
like domain in plants.  Therefore, the general features of the thiol reaction chemistry are 
shared despite the differences in substrate.  SRs are homologous in sequence (~25% 
identity; Appendix 6.7.3), particularly within active site residues that line the active site 
(~50% identity and 75% similarity; Appendix 6.7.4) and share a common three-
dimensional structure (1.2 Å rms deviation; Figure 6.2, panel a) (8, 15). The SR 
monomer adopts a Rossman-like fold and is characterized by four conserved structural 
elements that define the active site: the LTDG motif, phosphate-binding loop (P-loop), 
Arg-loop, and C-terminal ECGLH segment with the catalytic cysteine (Appendix 6.7.3). 
 
Upon closer inspection sequence and structure alignments reveal two key differences 
between APR and PAPR, namely, the amino acid sequence of the P-loop and the 
presence of the cysteine motif, CC-CXXC, in APR.  The P-loop of APR is typically 
comprised of an SFS–GAED motif while the corresponding sequence in PAPR is 
SSSFGIQA (Figure 6.1, panels a and b).  In contrast to the typical role for the P-loop in 
binding a 5'-phosphate group, crystal structures show that the P-loop interacts with the 
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Figure 6.1.  Domain organization and phylogenetic classification within the sulfonucleotide reductase family.  
All SRs have a catalytic cysteine at the end of the C-terminus.  a) Bacterial APRs possess the cysteine motif 
-CC-X~80-CXXC- highlighted in blue that coordinates to a [4Fe-4S] cluster.  In PAPRs, conserved residues in 
yellow replace the cysteine motif.  The phosphate–binding loop in APR ends with two negatively charged 
residues (indicated in purple).  These residues preclude binding of the 3'-phosphate moiety of PAPS, which 
can be accommodated by the P-loop motif of PAPR as it bears residues (in green) with small and neutral 
side chains instead.  b) & c) Dendrograms illustrating the sequence homology between enzymes within the 
SR family.  The sequence alignment was performed using ClustalW (5) and the tree was constructed using 
the Geneious program (6).  Each of the three subclasses of SRs is clearly delineated: APRs from higher 
plants with their unique C-terminal domain (A. thaliana, P. patens-APR), bacterial APRs (P. aeruginosa, M. 
tuberculosis, B. subtilis) and PAPRs (E. coli, P. patens-APR-B and S. cerevisiae).  Differentiation in the P-
loop region (b) and iron-sulfur cluster coordinating residues (c) of the SRs is indicated by color: purple, 
reduce APS; green, reduce PAPS; blue, harbor a [4Fe-4S] cluster; yellow, lack the [4Fe-4S] cluster.  APR 
from B. subtilis and P. patens APR-B are unique and can reduce both APS and PAPS.!
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APS O3' hydroxyl or the PAPS 3'-phosphate (Figure 6.2, panels b and c).  The four 
additional cysteine residues in APR coordinate an iron-sulfur cluster, whereas the 
cofactor is replaced by the YN-DXXT motif in PAPR (Figure 6.1, panels a and c and 
Figure 6.2, panels d and e).  Functional analysis indicates that when the [4Fe-4S] 
cofactor is present, it is required for catalytic activity; however, the cluster is not involved 
in redox chemistry and does not bind directly to APS (6, 8, 16).  Two interesting 
exceptions exist in Bacillus subtilis, which harbors the cluster, but can utilize both APS 
and PAPS as substrates [Bs(P)APR] (17), and the moss Physcomitrella patens, which 
lacks the cysteine pairs and associated cofactor, yet can reduce APS (PpAPR-B) (18).  
Notably, these SR variants exhibit 100- to 1000-fold decreases in their second-order rate 
constants (kcat/Km) for substrate reduction (Table 6.1).  Based on the aforementioned 
observations, it has been proposed that the P-loop is the principle determinant of 
substrate specificity in these enzymes (7-10), and that the [4Fe-4S] cluster plays a 
structural and/or regulatory role (8, 16, 17). 
 
Table 6.1: Apparent second-order rate constants (kcat/Km) for assimilatory SRs.  
Activities were measured with purified recombinant enzymes, as production of sulfite 
from varying concentrations of [35S]-APS and [35S]-PAPS, in the presence of DTT and 
recombinant thioredoxin from E. coli as the electron donor.  
 
 Iron-sulfur 
cluster Substrate 
kcat/Km 
(M-1min-1) Preference
a  
P. aeruginosa APRb Yes APS 2.0 x 108 APS 
  PAPS 1.6 x 104  
 
M. tuberculosis APRb Yes APS 2.5 x 108 APS 
  PAPS 6.0 x 104  
 
B. subtilis APRc Yes APS 3.1 x 106 None 
  PAPS 1.6 x 106  
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A. thaliana APR2d Yes APS 3.8 x 108 APS 
  PAPSd 1.3 x 104  
 
P. patens APRd Yes APS 3.8 x 108 APS 
  PAPSd 3.8 x 104  
 
E. coli PAPRb No APS 7.2 x 102 PAPS 
  PAPS 2.3 x 108  
 
P. patens APR-Bd No APS 2.1 x 105 APS 
  PAPS 2.2 x 102  
 
aDefined as difference in substrate utilization of #102.  Values measured at bpH 8.0, cpH 8.0 (17), dpH 
9.0 (18).  eValue estimated as the higher limit from ref. (18).  
 
Much effort has been made to understand substrate specificity in enzymes and several 
attempts have been made to rationally alter the specificity of an enzyme with sequence 
and structural information as the blueprint for redesign (19).  One of the first successful 
examples was of changing the coenzyme specificity of Escherichia coli glutathione 
reductase from NADP to NAD (20).  Structurally, NADP and NAD differ by a phosphate 
group at the 3'-postition of the adenosine 5'-phosphate (AMP) moiety, reminiscent of 
APS and PAPS.  In glutathione reductase, the switch in coenzyme preference was 
accomplished by changing amino acids within the P-loop.  Similarly, protein engineering 
has been used successfully by Shokat and coworkers to alter the nucleotide specificity 
of the prototypical tyrosine kinase, Src, to accept non-native nucleotides (21).  This 
concept was subsequently extended to redesign kinase active sites to accept unique 
nucleotide inhibitors to facilitate direct identification of kinase targets (22).  Overall these 
studies demonstrate that enzyme redesign is a powerful tool in exploiting substrate 
recognition elements to elucidate the catalytic mechanism and function of an enzyme.   
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Although it has been proposed that SR substrate specificity is dictated by the P-loop, this 
hypothesis has not yet been tested and, moreover, does not address the potential role of 
the iron-sulfur cluster.  To gain insight into the forces driving specificity and catalytic 
efficiency of SRs we have employed metalloprotein engineering, spectroscopic and 
kinetic analyses.  On the basis of our findings, we propose that the iron-sulfur cluster is a 
major determinant of specificity in this family of enzymes, specifically by enhancing the 
efficacy of the chemical step of catalysis.  In this way, our findings offer new 
perspectives on the evolution of SRs, the function of protein-bound iron-sulfur clusters, 
and hold value for the development of inhibitors for SRs, a validated target for 
antibacterial therapy, including tuberculosis (5, 23, 24). 
!
 
Figure 6.2.  Comparison of putative substrate recognition elements in EcPAPR and PaAPR.  a) Superposition of the 
structures of EcPAPR in charcoal (PDB deposition 2O8V) and PaAPR in white (PDB deposition 2GOY) showing the 
positions of the [4Fe-4S] cluster, the P-loop region and APS bound in PaAPR.  The coordinates for PAPS bound to 
EcPAPR are assumed from ScPAPR (PDB deposition 2OQ2).  C and N indicate the carboxyl- and amino- termini of the 
proteins, respectively.  Comparison between the P-loop regions of b) PaAPR bound to APS (PDB deposition 2GOY) and 
c) EcPAPR bound to PAP (PDB deposition 2O8V, coordinates of PAP assumed from PDB deposition 2OQ2).  Hydrogen 
bonding interactions are indicated by yellow dashes.  In EcPAPR neutral Gln57 and Ala58 take the place of negatively 
charged Glu65 and Asp66 in PaAPR, respectively.  These substitutions allow hydrogen-bonding interactions with the 3'-
phosphate group of PAP and accommodate the bulkier moiety.  In PaAPR, Asp66 compensates for the charge, volume 
and hydrogen binding potential of the 3'-phosphate group.  Comparison between d) the iron-sulfur cluster coordinating 
region in PaAPR and e) the corresponding conserved residues in EcPAPR.  In PaAPR, the [4Fe-4S] cluster ligated by four 
cysteine residues at positions 139, 140, 228 and 231.  In EcPAPR, Tyr131, Asp214 and His216 have cross-linking 
hydrogen-bonding interactions.  !
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6.3 Results  
6.3.1 P-loop Residues Have Limited Contribution to Substrate Recognition 
The P-loop residues in APRs 
have the SFS–GAED motif while 
the corresponding motif in PAPR 
consists of SSSFGIQA.  In APR, 
the glutamate and aspartate 
residues interact with three P-
loop amide groups and are 
positioned above the dipole of 
the &3 helix, as if they were 
mimicking the interaction of a 
negatively charged phosphate (Figure 6.2, panels b and c).  Conversely, the 
replacement of these acidic residues with Gln and Ala in PAPR would facilitate 
interaction of the amide groups with a 3'-phosphate and accommodate the bulkier moiety.  
To investigate this proposal, we generated E65Q, D66A and E65Q D66A variants of 
APR from Pseudomonas aeruginosa (PaAPR) as well as Q57E, A58D, and Q57E A58D 
variants of PAPR from Escherichia coli (EcPAPR).  Of note, the enzymes from these 
particular species were chosen on the basis of available structural and functional 
information.  We first tested the activity of the variants with native and non-native 
substrates.  Interestingly, none of these substitutions increased kcat/Km for the non-native 
substrate (Appendix 6.7.1).  In addition, the D66A and E65Q single substitutions in 
PaAPR had at most a 10-fold effect on APS reduction, whereas the Q65E and A58D 
replacements in EcPAPR exhibited a 1000-fold effect on the reduction of PAPS.  All 
double mutants were significantly impaired relative to their wild-type counterparts.  To 
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Figure 6.3.  Changes in the equilibrium dissociation 
constants of the P-loop variants of APR and PAPR.  The 
ratios of Kd values relative to wild-type enzymes for the P-
loop variants are plotted.  Blue and green bars indicate 
inhibition by AMP and PAP, respectively. Details regarding 
the kinetic parameters of all variants are presented in 
Appendix 6.7.1. !
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complement this analysis, we measured the dissociation constants (Kd) for the reaction 
products AMP and 3'-phosphoadenosine-5'-phosphate (PAP) for the P-loop variants 
(Figure 6.3).  PaAPR variants showed at most a 2.5-fold enhancement in PAP binding, 
whereas no EcPAPR substitution enhanced association with AMP.  Analogous to kinetic 
studies, the binding of P-loop variants to the native ligand was diminished, relative to the 
wild-type enzyme.  Overall, this analysis shows that modification of the P-loop decreases 
binding and catalysis for the native ligand; however, the converse does not hold true as 
amino acid replacements do not correlate with enhancements for the non-cognate 
substrate or ligand.   
 
6.3.2 EcPAPR4cys Incorporates a [4Fe-4S] Cluster  
As the P-loop substitutions did not succeed in altering substrate specificity, a possible 
contribution of the iron-sulfur cluster was investigated.  Based on the similar three-
dimensional fold of APR and PAPR, we reasoned that EcPAPR residues (Y131, N132, 
D214, and T218) might be replaced by cysteine, and enable coordination of an iron-
sulfur cluster (Figure 6.2, panels d and e).  Thus, site-directed mutagenesis was 
employed and the resulting protein was co-expressed in bacteria with the pDB1282 
plasmid that harbors the isc operon for cluster assembly (25).  This approach afforded 
10 mg of protein per liter of culture.  The resulting enzyme, termed EcPAPR4cys, eluted 
as a dimer from the gel filtration column, analogous to wild-type EcPAPR, and the purity 
was estimated to be greater than 95% (Figure 6.4, panel a, inset).  The UV-Vis 
absorbance spectrum of EcPAPR4cys showed a maximum in the visible range at 410 
nm, which is similar to the [4Fe-4S] chromophore of PaAPR (Figure 6.4, panel a) (16).  
However, ICP analysis of EcPAPR4cys showed that each mole of protein contained only 
2.3 mole of iron.  The amount of iron could not be increased by reconstitution or 
anaerobic purification (data not shown).   
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To identify the types and relative amounts of the Fe/S clusters in EcPAPR4cys, we 
employed a combination of Mössbauer and EPR spectroscopies and analytical methods.  
ICP analysis of a sample of EcPAPR4cys enriched in 57Fe for Mössbauer spectroscopy 
reveals 2.0 Fe per polypeptide.  The 4.2-K/53-mT Mössbauer spectrum of this sample 
(Figure 6.4, panel b) shows that the majority (82%) of the iron associated with EcPAPR 
gives rise to a quadrupole doublet with parameters typical of [4Fe-4S]2+ clusters: isomer 
shift (*) of 0.45 mm/s and quadrupole splitting parameter (#EQ) of 1.03 mm/s.  The 
remaining iron (15%) exhibited properties reminiscent of a [2Fe-2S]2+ cluster (* = 0.27 
mm/s, #EQ = 0.57 mm/s).  The [2Fe-2S]2+ form is also observed in plant and bacterial 
APRs and most likely results from partial degradation of the [4Fe-4S] cluster (16, 17).  
An identical EPR sample does not reveal the spectroscopic signatures of paramagnetic 
Fe/S clusters with S = 1/2 ground state (data not shown). Taken together, Mössbauer 
and ICP analyses indicate that approximately half of all EcPAPR4cys monomers 
coordinate a [4Fe-4S] cluster. 
 
Although the iron-sulfur cluster in APR does not undergo redox chemistry during 
catalysis, the reduced form of the cluster can serve as a useful tool for characterization 
and mechanistic studies.  Along these lines, we have recently characterized the 1+ state 
of the [4Fe-4S] cluster in APR from Mycobacterium tuberculosis (MtAPR) using electron 
paramagnetic resonance (EPR) spectroscopy (16).  Like MtAPR, the EPR signal of the 
chemically reduced EcPAPR4cys is broad, but shows rhombic symmetry with apparent 
g-values of 2.07, 1.90 and 1.76, which are characteristic of a [4Fe-4S] cluster in the 1+ 
state (Figure 6.4, panel c).  Spin quantitation of the EPR signals from g = 2.33 to 1.58 
indicate low reduction efficiency (0.04 spins/mol compared to 0.4 spins/mol for MtAPR).  
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A likely explanation for the lower signal intensity is that the constellation of residues 
surrounding the EcPAPR4cys cluster differs between from MtAPR, resulting in distinct 
electronic environments and reduction potentials (Appendix 6.7.3).  Nonetheless, the 
overall similarity of Mössbauer and EPR parameters to those observed for MtAPR 
provides further support for the coordination of a [4Fe-4S]2+ cluster by EcPAPR4cys. 
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Figure 6.4.  Spectroscopic characterization of EcPAPR4cys.  a) UV-Vis absorption spectra of EcPAPR 
and EcPAPR4cys.  UV-Vis absorption of 10µM EcPAPR (!) or EcPAPR4cys (") in buffer containing 50 
mM Tris–HCl, 150 mM NaCl (pH 7.4 at 25 °C) and 10% (v/v) glycerol.  Inset, denaturing polyacrylamide 
gel with Coomassie staining displaying purified EcPAPR4cys at an apparent molecular mass of ~28 
kDa.  b) 4.2-K/53-mT Mössbauer spectra of 1 mM EcPAPR4cys.  Experimental spectra are shown as 
vertical bars.  The solid line is a quadrupole doublet simulation with the following parameters: () /1= 
0.45 mm/s, "EQ1= 1.03 mm/s (82%) and ( ) /2= 0.27 mm/s, "EQ2= 0.57 mm/s (15%).  The 
parameters for the majority species ( ) are consistent with a [4Fe-4S]2+ cluster and the parameters 
for the minor species () are consistent with a [2Fe-2S]2+ cluster.  The remaining area of the spectrum 
is a broad featureless absorbing species that accounts for approximately 3% of the total area of the 
spectrum.  c) EPR spectrum of photoreduced EcPAPR4cys.  Anaerobic EcPAPR4cys (250 )M) was 
photoreduced as described in Materials and Methods.  The EPR spectrum was recorded at 10 K and the 
instrument parameters were: microwave power, 10 mW; receiver gain, 2 x 104; modulation amplitude, 10 
G and microwave frequency, 9.43 GHz.  !
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We next evaluated the effect of the 
[4Fe-4S] cluster in EcPAPR4cys 
on the ability of EcPAPR to use 
PAPS or APS as substrates.  To 
this end, we first monitored 
formation of the S-sulfocysteine 
intermediate, which is stable in 
plant and bacterial (P)APRs in the 
absence of Trx (6, 26).  
EcPAPR4cys was incubated in the 
presence or absence of APS or 
PAPS and the mass of the intact 
protein was analyzed by 
electrospray ionization mass 
spectrometry (ESI-MS).  The 
deconvoluted m/z values obtained 
from these experiments are listed 
in Appendix 6.7.2.  In the absence 
of substrate, the mass spectrum of 
EcPAPR4cys is consistent with the 
molecular weight of the apoenzyme (Figure 6.5, panel a, solid circles).  Incubation of 
EcPAPR4cys with PAPS resulted in formation of a new series of ions with a molecular 
weight 80 Da higher than enzyme alone, corresponding to the S-sulfocysteine adduct 
(Figure 6.5, panel b, asterisks).  In the presence of APS two series of ions were 
observed corresponding to molecular weight of the apoenzyme (Figure 6.5c, solid 
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Figure 6.5.  Mass spectrometric analysis of intact 
EcPAPR4cys.  ESI mass spectra of EcPAPR4cys (10 )M) 
without ligand (a), with PAPS (b) and with APS (c).  Ions 
correspond to the enzyme (E, !) and the covalent enzyme 
S-sulfocysteine intermediate (E-SO3–, ,).  The calculated 
masses after deconvolution of m/z values are 28829.23 Da 
(a), 28908.55 Da (b), 28829.23 and 28909.54 Da (c).  See 
also Appendix 6.7.12. !
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circles) and to the S-sulfocysteine intermediate (Figure 6.5, panel c, asterisks).  
Quantitative adduct formation was likely limited by our finding that not all EcPAPR4cys 
monomers are associated with a [4Fe-4S] cluster.  Control experiments performed with 
wild-type enzymes and native substrates also showed the expected mass shifts 
(Appendix 6.7.2).  These data show that EcPAPR4cys can generate the adduct with 
PAPS or APS as a substrate. 
 
6.3.3 EcPAPR4cys can reduce APS as substrate   
As reported above, EcPAPR4cys forms an enzyme S-sulfocysteine intermediate with 
APS, which should be competent for reduction by Trx to generate sulfite.  To test this 
possibility, we performed gel-labeling experiments with [35S]-labeled PAPS or APS 
(Appendix 6.7.5).  Incubation of [35S]-PAPS or [35S]-APS with EcPAPR4Cys, and 
analysis of the reaction by nonreducing SDS-PAGE, showed a radioactive band at the 
molecular weight of EcPAPR indicating transfer of the [35S]-label to the enzyme.  
Addition of Trx to this enzyme intermediate resulted in the complete loss of radiolabeling, 
as expected for reduction of the thio-sulfate bond.  Analogous experiments were carried 
out using wild-type EcPAPR, which demonstrated comparable labeling with [35S]-PAPS; 
by contrast, only a faint band was seen in reactions that contained [35S]-APS.  Taken 
together, the MS and radiolabeling experiments demonstrate that EcPAPR4cys forms a 
catalytically competent S-sulfocysteine intermediate with PAPS or APS, and that the 
variant reacts with APS with an enhanced rate compared with wild-type protein. 
 
Having established that the EcPAPR4cys iron-sulfur protein exhibits activity, we 
proceeded to measure kinetic parameters for this variant.  Table 6.2 shows the resultant 
data and is presented alongside data obtained for wild-type EcPAPR and PaAPR (see 
also Appendix 6-11).  The second-order rate constant also known as the specificity 
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constant (kcat/Km; representing the reaction for free enzyme and substrate) demonstrates 
that EcPAPR4cys catalyzes APS reduction with approximately 600-fold less efficiency 
relative to PaAPR.  Importantly, however, that the rate of APS reduction by the variant 
protein is nearly 1000-fold increased compared to wild-type EcPAPR.  On the other hand, 
the kcat/Km for reaction of EcPAPR4cys with PAPS is almost the same as the native 
enzyme.   
 
Table 6.2: Single-turnover rate and equilibrium constants for PaAPR, EcPAPR and 
EcPAPR4cys.a  
Enzyme 
Iron 
content 
(mol 
Fe/mol 
protein) 
kcat/Km 
(M-1 min-1)b 
kmax 
(min-1)c 
K1/2 
("M) 
KdAMP 
("M)g 
KdPAP 
("M)g 
 
 APS PAPS APS PAPS APSd PAPSe   
PaAPR 3.5 2.2 x 107 1.2 x 103 3.1 %1 x 10-3 0.1 #100f 35 8.1 x 103 
EcPAPR %0.1 %40 3.2 x 106 %1 x 10-3 1.6 #100f 0.9 3.4 x 103 1.4 
EcPAPR
4cys 
2.3 3.9 x 104 6.8 x 106 0.1 1.8 #100f 0.1 5.6 x 103 4.3 
 
aMeasurements represent the average of three or more independent determinations and the S. D. was 
%15% of the value in all cases.  The concentration of protein was determined by quantitative amino acid 
analysis and further corrected by the amount of active enzyme present.  Unless otherwise stated, reaction 
conditions were 100 mM Bis-Tris propane, pH 6.5, 5 mM dithiothreitol, and 10 )M thioredoxin at 30 °C (see 
Materials and Methods).  bkcat/Km values were measured as described in Materials and Methods.  ckmax 
measured with saturating enzyme (see Materials and Methods).  d10 nM or e1 )M thioredoxin was used to 
measure K1/2 values for sulfite production, by varying the concentration of enzyme (see Materials and 
Methods).  fAt high concentrations of enzyme, the reactions became too fast to measure by hand.  gKd 
measured at pH 7.5 
 
The preceding data indicate that the iron-sulfur cluster in EcPAPR4cys contributes to 
catalytic efficiency by enhancing substrate affinity and/or stabilizing the catalytic 
transition state.  To gain further insight into the role of the iron-sulfur cluster in these rate 
enhancements, we evaluated the saturating single-turnover rate constant (kmax) and the 
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K1/2 for EcPAPR4cys and wild-type enzymes 
(Table 6.2).  These data reveal that 
EcPAPR4cys exhibits a 100-fold increase in 
the value of kmax for APS relative to EcPAPR, 
while the kmax for PAPS was the same within 
error.  A 9-fold enhancement in the K1/2 of 
PAPS was observed for EcPAPR4cys 
compared to wild-type, but differences in the 
K1/2 of APS could not be discerned due to the 
limitations imparted by the maximum 
achievable enzyme concentration.  As 
expected, the K1/2 values for all enzymes with 
cognate substrate were 102-103–fold greater 
relative to the non-cognate substrate.  The 
binding of AMP and PAP to the 
aforementioned enzymes was also examined.  
The resulting Kd values indicate that 
incorporation of the iron-sulfur cluster in 
EcPAPR diminishes ligand binding by 1.5 to 3-
fold (Table 6.2), suggesting that increased 
electrostatic repulsion from the negatively 
charged [Fe4S4(Cys)4]2- center may hamper 
binding of the 5'-phosphate dianion.  
Collectively, these results demonstrate that the 
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Figure 6.6.  Time-dependent inactivation of 
SRs.  Proteins (10 )M) were exposed to 
aerobic conditions at 4 °C over 2 days.  At 
the indicated times, each enzyme was 
analyzed for its ability to catalyze the 
reduction of APS or PAPS.  EcPAPR with 
PAPS (a), EcPAPR4cys with APS (b), inset 
shows the UV-vis absorption spectra of 
EcPAPR4cys at time 0 (black trace) and 48 
h (gray trace), and EcPAPR4cys with PAPS 
(c).!
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iron-sulfur cluster in EcPAPR enhances substrate binding and APS reduction. 
 
Finally, we evaluated the time-dependent inactivation of EcPAPR and EcPAPR4cys 
under prolonged exposure to aerobic conditions (Figure 6.6).  In the case of 
EcPAPR4cys, dissociation of the iron-sulfur cluster from the protein scaffold could also 
be monitored by loss of absorption at 410 nm.  Our data show that the half-life of 
EcPAPR, which lacks the cluster, was ~35 hours (Figure 6.6, panel a).  However, 
inactivation and concomitant cluster decomposition for EcPAPR4cys occurred at an 
enhanced rate, with a half-life of ~10 hours (Figure 6.6, panels b and c).  A strong 
correlation between an intact iron-sulfur cluster and catalytic activity is consistent with 
previous data obtained from plant and bacterial APRs (11, 17, 18, 27). 
 
6.4 Discussion 
Assimilatory sulfonucleotide reductases – APR and PAPR – exhibit similar sequences, 
structure, and thiol reaction chemistry (6-9).  Analysis of the phylogenetic distribution of 
SRs suggests that PAPR evolved from APR through a single horizontal gene transfer 
event (28).  The conserved reaction mechanism serves as a template for the divergent 
evolution of these two subclasses, which catalyze the reduction of substrates that differ 
by a single 3'-phosphate group.  There are over 15 such enzyme families with common 
reaction mechanisms despite differences in substrate utilization (29, 30).  In divergent 
evolution, protein folds and active site structural features are frequently reused amongst 
different family members and adapted to new catalytic purposes (31).  Indeed, a closer 
look at the active sites of PaAPR and EcPAPR reveals that several strictly conserved, 
positively charged lysine and arginine residues interact with the sulfate moiety or "-
phosphate (Figure 6.7 and Appendix 7.6.4).  Moreover, the C-terminal peptide segment 
bearing the ECGH motif, which includes the cysteine nucleophile, is also conserved.  
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However, two critical features distinguish APR and PAPR active sites: residues in the P-
loop region and the presence/absence of an iron-sulfur cluster.  These distinctions afford 
a unique opportunity to explore substrate recognition and identify underlying principles 
that govern specific features of APR that were targeted for alteration during the 
specialization of PAPR function. 
 
GTP/ATP-dependent proteins contain a glycine-rich motif with the sequence, 
GXXGXGKT/S, known as the P-loop (7, 32, 33).  This structural moiety forms a large 
anion hole that interacts with phosphates.  ATP pyrophosphatases (ATP PPases) harbor 
a modified P-loop, also known as the PP motif (34), with the fingerprint peptide 
SGGXDS/T.  A highly modified version of the PP motif was discovered in EcPAPR 
(SXG), which is also found in enzymes with homologous protein folds, including ATP 
sulfurylase and GMP synthetase (34-36).  Among ATP PPases, the P-loop interacts with 
the 5'-phosphates of ATP (36, 37).  Interestingly, however, structures of APR and PAPR 
co-crystallized with nucleotides show that the 3'-group on the ribose interacts with 
residues in the P-loop (8, 9).  In SRs, the motif is characterized by the hydrophobic !1-
strand and "3-helix that flank the N- and C-terminal sides of the SFS–GAED and 
SSSFGIQA sequences in PaAPR and EcPAPR, respectively.  Differences in the P-loop 
motif have also been observed in ATP synthases, wherein the sequence alterations 
have been suggested to imply diversity in nucleotide recognition and/or catalytic 
mechanism (38).  Since SRs share a common catalytic mechanism the change in P-loop 
sequences, particularly the acidic residues in APR, could be implicated in substrate 
discrimination.  
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In this study, site-directed mutagenesis of the P-loop entailed the replacement of 
negatively charged E65 and D66 PaAPR residues with corresponding neutral glutamine 
and alanine residues found in EcPAPR and visa versa.  Characterization of the resulting 
variants has led to two significant observations.  First, any change in P-loop residues 
had an adverse effect on catalytic efficiency, underscoring the essential nature of these 
highly conserved motifs in the two subclasses of catalysts.  Second, variants of APR 
exhibited only a modest enhancement in PAP binding.  This finding indicates that while 
neutral P-loop residues contribute somewhat to accommodating the 3'-phosphate group, 
they cannot account entirely for substrate specificity.  Moreover, P-loop variants of 
PAPR did not enhance binding to AMP, showing that the mere presence of a negatively 
charged residue in the P-loop sequence was insufficient.  Along these lines, it is possible 
that additional P-loop modifications are required to enhance the binding of PAPS.  For 
instance, EcPAPR S52 and S53 (of the SSFGIQA sequence) establish hydrogen bonds 
with the 3'-phosphate group of PAPS, whereas the corresponding residues in PaAPR (of 
the SFSGAED sequence) do not make any contact with the APS 3'-hydroxyl group.  
Future experiments will be required to delineate this and other possibilities. 
 
The second distinguishing feature among SRs is that APR contains the conserved 
cysteine sequence, CC-CXXC, which ligates an essential [4Fe-4S] cluster.  In place of 
this cofactor, PAPR possesses the semi-conserved motif, YN-DXXT that links the "7-
helix and C-terminal (-turn by hydrogen bond interactions.  In the course of our study, 
we attempted to substitute the cysteine pairs in PaAPR with the YN-DT motif; however, 
this variant failed to express in E. coli (data not shown).  As an alternative approach to 
investigate the role of this region, we engineered an iron-sulfur cluster into EcPAPR.  
Based on the high degree of sequence and structural homology between SRs an 
empirical approach was adopted to generate the new metal-binding site.  This strategy 
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has been employed to design novel metalloproteins, including the creation of a Mn(II)-
binding site in cytochrome c peroxidase based on structural homology with manganese 
peroxidase (39, 40).  Favorable protein folds such as the Trx scaffold have also been 
exploited to introduce a cofactor and alter enzyme function (41).  Assembly of a [2Fe-2S] 
cluster through directed evolution served to bridge two monomeric Trx subunits and 
enabled the resulting dimer to catalyze oxygen-dependent sulfhydryl oxidation (42, 43).  
In another instance, the second cysteine residue of the native CXXXCXXXC motif in the 
catalytic subunit of dimethyl-sulfoxide reductase (DmsA) was replaced leading to the 
assembly of a paramagnetic [3Fe-4S] cluster (44).   
 
In the case of EcPAPR, our goal was to introduce a [4Fe-4S] cluster in order to probe 
the role of the metallocenter in sulfonucleotide reduction.  Spectroscopy (UV-vis, 
Mössbauer, EPR, mass) and single turnover kinetic analysis were employed to 
characterize the resulting variant, termed EcPAPR4cys.  Though we did not identify 
conditions that permitted quantitative cluster incorporation into each protein monomer, 
our spectroscopic data provides strong support for the assignment of a [Fe4S4(Cys)4]2- 
center and compares favorably with studies of MtAPR (16). Comparison of kcat/Km 
between EcPAPR4cys with wild-type PaAPR and EcPAPR showed that the installation 
of an iron-sulfur cluster dramatically improved the ability to turnover the APS (~103-fold).  
Further studies revealed a minor role in substrate binding, with the majority of the rate 
enhancement stemming from the improvement in kmax, which reports on the rate of the 
chemical step.  Furthermore, time-dependent inactivation studies also showed that the 
cluster was required for catalytic activity.   
 
Previously, we have observed mid-range electrostatic interactions between the iron-
sulfur cluster and the ligand present within the APR active site (16).  These findings are 
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also supported by computational analysis (45).  Based on these data, we proposed that 
the cluster cofactor plays a role in pre-organizing positively charged active site residues 
and in substrate activation.  Specifically, that the charge from and polarization within the 
[Fe4S4(Cys)4]2– cluster could serve to activate the sulfate group of APS, thereby 
facilitating S-OP cleavage and S-S bond formation in the reaction.  In the absence of an 
iron-sulfur cluster, PAPR could achieve something similar via repulsion between the 
extra 3’-phosphate group of PAPS and the sulfate end of the 5’-phosphosulfate.  Our 
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Figure 6.7. Model for divergent evolution of PAPR from APR.  APR and PAPR can be considered to be 
at the margins of divergent evolution with optimum catalytic efficiency for APS (blue) and PAPS (green), 
as indicated by the color spectrum in the arrow.  A comparison of their active sites reveals two 
consistent features, namely, strictly conserved positively charged lysine and arginine residues (orange 
circles) that interact with the substrate, and the C-terminal peptide bearing the ECGH motif, which 
includes the cysteine nucleophile, is also conserved (pink circles).  The catalysts differ largely in their P-
loop sequence motifs and their ability to ligate a [4Fe-4S] cluster through four cysteine residues.  Based 
on the catalytic efficiencies for APS and PAPS, EcPAPR4cys and the P-loop variants appear to be 
intermediates in the evolutionary path of the functional divergence of PAPR from APR.  The catalytic 
efficiency of the P-loop variants of EcPAPR for PAPS is comparable to the wild-type enzyme and is 
therefore indicated by a break in the arrow.  Details regarding the kinetic parameters of all variants are 
presented in Table 2 and 7.6.1. !
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observation, that insertion of an iron-sulfur cluster in PAPR enhances the rate of APS 
reduction, is entirely consistent with this model.  In this regard, iron-sulfur clusters are 
extremely versatile cofactors with enzymatic functions in electron transfer, Lewis-acid 
assisted catalysis, radical generation, and source of sulfur during biosyntheses of 
cofactors (46-53).  This present study extends this list of functions to include substrate 
specificity.  
 
From our study and sequence analysis, it is clear that the natural evolution of PAPR 
from APR involved several iterations of mutations.  These factors are not easily 
recapitulated, and we note that none of the variants explored in this study resulted in a 
complete change of substrate specificity.  Functional studies of EcPAPR4cys and the P-
loop variants suggest that these enzymes may represent intermediates in the 
evolutionary pathway of SRs (Figure 6.7).  This proposal is based on two interesting 
observations related to the catalytic efficiency and relative stability.  First, is the striking 
similarity between (P)APR from B. subtilis and the P-loop variants of PaAPR.  These 
enzymes coordinate an iron-sulfur cluster, but also contain a neutral residue in the 
position equivalent to residue 66 of PaAPR (or position 58 of EcPAPR).  However, these 
catalysts all exhibit a significant reduction in catalytic efficiency with APS (#102), 
compared to wild-type PaAPR (Table 6.1).  Second, like APR-B from P. patens, the 
EcPAPR P-loop variants lack the iron-sulfur cluster and also display a decrease in 
enzyme activity relative to wild-type PaAPR (Table 1).  Interestingly, we note that both 
PpAPR-B and EcPAPR gain in stability by forfeiting the iron-sulfur cluster.  EcPAPR 
retains enzymatic activity over 2 days in contrast to APR, which loses activity within half 
a day.  Similarly, PpAPR-B remains active for 5 days compared to its homolog, PpAPR, 
which harbors a [4Fe-4S] cluster and is only active for 2 days under aerobic conditions 
(18).  Finally, we note that both BsAPR and PpAPR-B have markedly decreased 
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catalytic efficiency relative to other SRs (Table 6.1), indicating that these enzymes are 
not as specialized for the reductase function as the latter group of catalysts.  Taken 
together, these observations show how characteristics of our experimentally generated 
variants resemble those of SRs from naturally occurring species, corroborating our 
proposal that the variants are representative of intermediates in the path of divergent 
evolution of PAPR from APR (Figure 6.7). 
 
6.5 Conclusion 
In conclusion, the cysteine motif that coordinates the [4Fe-4S] cluster within APR can be 
accommodated by the PAPR scaffold and confers enhanced binding and catalytic 
activity for the APS substrate.  This work provides valuable insight into the contribution 
of the iron-sulfur cluster to catalysis, and a better understanding of the mechanisms 
involved in the divergent evolution of PAPR from APR. 
 
6.6 Experimental procedures 
6.6.1 Material 
APS (#95%) was obtained from Biolog Life Sciences Institute (Bremen, Germany).  
PAPS (#88%) was obtained from Calbiochem (La Jolla, CA). PAP, AMP, iron (III) 
chloride were purchased from Sigma-Aldrich (St. Louis, MO).  Fe-57 metal was 
purchased from Isoflex USA (San Francisco, CA) and micro bio-spin P30 columns were 
from Bio-Rad Laboratories (Hercules, CA).   
 
6.6.2 Cloning, Expression and Purification of SRs.  
Construction of the expression vectors encoding wild type PAPR from E.coli (EcPAPR), 
wild-type APR from M. tuberculosis (MtAPR) and wild-type APR from P. aeruginosa 
(PaAPR) cloned into the vector pET24b (Novagen) has been previously described (1, 2).  
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The EcPAPR4cys variant was generated from the EcPAPR template using the Quik-
change site-directed mutagenesis kit (Stratagene, La Jolla, CA) and the following primer 
sequences sequentially: YN131CC: 5$ 
CGTTGAAGGCATTGAAAAGTGCTGTGACATCAACAAAGTCGA ACC 3$, D214C: 5' 
GAAGGATATTTATCGGTGGGCTGCACC CATACAACCCGT AAATGG 3' and T217C: 
5' GGTGGGCTGCACCCATTGCACCCGTAAATGGG 3'.  Other PaAPR, MtAPR and 
EcPAPR variants using site-directed mutagenesis with the following primers: 5$ 
CAGCGGCGCCGAGGCTGTCGTCCTGGTAG 3$ for PaAPR D66A, 5$ 
CTTCAGCGGCGCCCAGGACGTCGTCCTG 3$ for PaAPR E65Q, 5$ 
CTTCCAACATGGCTGCGGCGGTGCTGGTGGATC 3$ for MtAPR D69A, 5$ 
GCTTTGGCATTCAGGATGCGGTGAGCCTGCATC 3$ for EcPAPR A58D, 5$ 
CTTTCTTCCAGCTTTGGCATTGAAGCGGCGGTGAGCCTGCATCTG 3$ for EcPAPR 
Q57E.  Successful cloning was confirmed by DNA sequencing analysis.  Plasmids 
encoding EcPAPR4cys, MtAPR or PaAPR pET24 and pACYC (containing genes 
encoding the isc operon of six accessory proteins required for Fe–S cluster biosynthesis 
in A. vinelandii under the control of an arabinose-inducible promoter) (27) were co-
transformed into E. coli BL21(DE3) (Novagen, San Diego, CA) and plated on L-agar 50 
)g/ml kanamycin and 100 )g/ml carbenicillin.  Plasmid encoding EcPAPR, EcPAPR 
A58D and EcPAPR Q57E pET24 was transformed into E. coli BL21(DE3) and plated on 
L-agar 50 )g/ml kanamycin.  A single colony was picked and added to 5 ml of L-broth 
plus antibiotics and grown overnight with shaking at 37 °C.  This culture was used as a 
0.5% 1 L of L-broth plus antibiotics and grown with shaking at 37 °C until absorbance at 
600 nm reached approximately 0.6.  For EcPAPR4cys, MtAPR and PaAPR arabinose 
and iron citrate were added to final concentrations of 20 mM and 0.8 mM, respectively 
and the culture grown as above for 1 hr.  At this point the flasks were removed from the 
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incubator.  IPTG was added to a final concentration of 0.3 mM and the flasks were 
returned to the incubator and grown overnight at 18 °C with shaking at 200 rpm.  For 
EcPAPR, EcPAPR A58D and EcPAPR Q57E after the culture reached an absorbance of 
0.6 at 600 nm, IPTG was added to a final concentration of 0.4 mM, the flasks returned to 
the incubator and grown for 5 hours at 30˚C.  Cultures were harvested by centrifugation 
(4 °C, 4,300 g).  After removal of the supernatant the pellets were stored at -80 °C until 
required.  All purification steps were carried out at 4 °C.  Cell pellets were resuspended 
in 30 ml Buffer A (20 mM sodium phosphate, 0.5 M NaCl, 10 mM imidazole; pH 7.4) 
supplemented with 0.1 mM PMSF, 10µg/ml DNase, 5 µg/ml lysozyme and lysed by 
sonication.  Lysates were centrifuged (20,000g, 15 min) and loaded onto a 5 ml HisTrap 
Chelating column (GE Healthcare, Piscataway, NJ) equilibrated in the same buffer.  
Unbound material was washed off with 50 ml of Buffer A and bound proteins then eluted 
with Buffer B (20 mM phosphate, 0.5 M NaCl, 250 mM imidazole; pH 7.4).  Fractions 
containing the desired protein were pooled, concentrated by centrifugation (Amicon 10 
kDa cutoff, Millipore, Billerica, MA) and loaded onto a 16/60 Superdex 200 size 
exclusion column previously equilibrated in Buffer C (50 mM Tris-HCl, 150 mM NaCl, 5 
mM DTT, 10% glycerol; pH 7.4 at 25 °C).  Fractions containing sulfonucleotide 
reductase were pooled, snap-frozen in liquid nitrogen, and stored at -80 °C.  Protein 
concentrations were determined by quantitative amino acid analysis (Molecular Structure 
Facility, UC-Davis, CA and Ref. (2) and corrected by the number of active molecules 
determined by the activity assay for sulfonucleotide reductases described below.  Iron 
content of each protein preparation was determined in duplicate by inductively coupled 
plasma (ICP) analysis.  
 
6.6.3 Chemical Reconstitution of EcPAPR4cys 
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Reconstitution experiments were performed in the glove box.  EcPAPR4cys desalted 
into 1.5 mL Buffer C using P30 columns, was successively incubated, with gentle stirring, 
with 5 mM DTT (30 min), 5 M equivalents of FeCl3 (added dropwise then incubated for 
45 min) and Na2S.9H2O (added dropwise then incubated for 2 h).  Excess ligand was 
removed from the reconstitution reaction by desalting the mixture using PD10-
Sepharose columns, GE Healthcare) into Buffer C. 
 
6.6.4 Gel-labeling of EcPAPR and EcPAPR4cys 
In this experiment, 5 )M EcPAPR (lanes 1-4) and EcPAPR4cys, (lanes 5-8) were 
incubated at room temperature in 50 mM bis-tris propane (pH 7.0), 100 mM NaCl with 
35S-PAPS only (lanes 1 and 5); with 35S-APS only (lanes 3 and 7); with 35S-PAPS for 10 
min followed by the addition of 10 )M thioredoxin (lanes 2 and 6) or with 35S-APS for 10 
min followed by the addition of 10 )M thioredoxin (lanes 4 and 8). SDS-PAGE load dye 
(without reductant) was added to terminate the reaction.  The samples were heated at 
60 ˚C for 3 min and size-fractionated by 12 % non-reducing SDS-PAGE.  The 
incorporation of radioactivity was analyzed with a Phosphorimager.  
 
6.6.5 Determination of active SR 
Reactions were carried out at 30 °C in 100 mM bis-tris propane (pH 6.5) buffer.  Non-
radioactive APS or PAPS was doped with a trace amount of [35S]-APS or [35S]-PAPS 
respectively, as previously described (6).  1 )M of sulfonucleotide reductase was 
incubated with 2 )M substrate.  The reactions were spotted on PEI-cellulose TLC plates, 
developed in 1M LiCl and analyzed using Typhoon Phosphorimager (GE Healthcare) 
analysis with Image Quant quantitation software.  Under conditions that had 
quantitatively produced the S-sulfocysteine intermediate, a new signal on the TLC plate 
was observed as a discrete spot that remained at the origin of the TLC plate.  For each 
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enzyme, the reaction endpoint was determined at the point where no further substrate 
was consumed or intermediate was formed.  The number of active molecules was 
calculated as the fraction A/(A+B), where A and B are signals quantified from the 
intermediate formed and the unused radioactive substrate, respectively. 
 
6.6.6 Preparation of EcPAPR4cys for EPR and Mössbauer Spectroscopy.   
Samples of EcPAPR4cys suitable for EPR spectroscopy were prepared inside of an 
anaerobic chamber with O2 levels % 1 ppm.  The procedure for photoreduction was 
carried out as previously described (16).  Briefly, purified EcPAPR4cys was exchanged 
into anaerobic buffer containing 50 mM Tris–HCl, 150 mM NaCl (pH 8.5 at 4 °C) and 
10% glycerol.  To reduce the cluster in EcPAPR4cys, reactions contained 250 )M 
enzyme, 25 mM sodium oxalate, and 250 )M deazaflavin in a total volume of 250 )L.  
The reaction mixtures were transferred to EPR tubes, chilled in an ice-salt bath (-6 °C) 
and irradiated with light from a 100 W quartz halogen lamp (Applied Photophysics, 
Surrey, UK) for 30 min.  After illumination, samples were immediately frozen in liquid 
nitrogen and analyzed by low-temperature EPR.  Mössbauer spectra were recorded on 
proteins that contained 57Fe in place of natural-abundance iron.  57Fe was incorporated 
into EcPAPR4cys by supplementation of E. coli growth media, and samples contained 1 
mM protein, were transferred to Mössbauer cups and frozen in liquid nitrogen. 
 
6.6.7 EPR Spectroscopy   
X-band EPR spectra of photoreduced samples were recorded on a Bruker EMX 
spectrometer (Billerica, MA) equipped with an Oxford Instruments ITC4 temperature 
controller, a Hewlett-Packard model 5340 automatic frequency counter and Bruker 
gaussmeter.  Figure 6.legend contains relevant instrumental parameters.  The sample 
buffer was used to record the baseline under conditions identical to those in which the 
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sample spectra were obtained.  The baseline was subtracted from the EcPAPR4cys 
spectrum shown in the figure.  Spin concentration in EcPAPR4cys samples was 
determined by double integration of the EPR signal over a range of 2 kgauss and 
comparison with double integrals of 1 mM Cu(ClO4)2 in sample buffer.  Figures were 
generated using Spin Count (ver 2.6.7) created by Professor M.P. Hendrich at Carnegie 
Mellon University.  Spin Count is available at http://www.chem.cmu.edu/groups/hendrich/.  
 
6.6.8 Mössbauer Spectroscopy 
Mössbauer spectra were recorded on a spectrometer from WEB research (Edina, MN) 
operating in the constant acceleration mode in transmission geometry.  Spectra were 
recorded with the temperature of the sample maintained at 4.2 K in an externally applied 
magnetic field of 53 mT oriented parallel to the .-beam.  The quoted isomer shifts were 
relative to the centroid of the spectrum of a foil of &-Fe metal at room temperature.  Data 
analysis was performed using the program WMOSS from WEB research. 
 
6.6.9 Mass Spectrometry 
For mass spectrometric analysis, samples were prepared by incubating 10 )M enzyme 
with 2 mM APS or PAPS, where appropriate, for 40 min at 30 °C to allow for formation of 
S-sulfocysteine intermediate.  Subsequently, the samples were exchanged into 0.1% 
formic acid using Micro Bio-Spin P30 columns (Bio Rad).  Intact proteins samples were 
analyzed on an electrospray linear ion trap mass spectrometer (LTQ-XL, Thermo 
Scientific) after separation on an Agilent Eclipse XDB-C8 2.1 mm x 15 mm trap with 
mobile phases A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile) 
which was used to trap, desalt and elute proteins onto a Varian 2.1 mm x 50 mm 5 )m 
PLRP-S C18 column with a gradient of 5% to 100% in 14 min at a flow rate of 200 
)L/min. 
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6.6.10 Kinetic assays 
Reactions were carried out at 30 °C.  Unless otherwise indicated, the buffer consisted of 
100 mM bis-tris propane (pH 6.5) supplemented with 5 mM DTT and 10 )M E. coli 
thioredoxin.  Production of [35]SO32- from [35S]-APS or [35S]-PAPS was monitored using 
charcoal-based separation and scintillation counting as previously reported (54).  The 
substrate was incubated with excess enzyme to ensure single-turnover conditions (>2.5-
fold molar excess of enzyme).  The reaction progress curve was plotted as the fraction 
of product versus time and was fit by a single exponential (eq. 1), where F is the fraction 
product, A is the fraction of substrate converted to product at completion, and t time.  
The observed rate constant (kobs) is the product of the enzyme concentration and the 
apparent second-order rate constant kcat/Km (eq. 2).  Under these conditions, the 
observed rate constant is linearly dependent upon enzyme concentration, and 
independent of substrate concentration, which demonstrated that substrate is not 
saturating.  The reported kcat/Km values are for single-turnover conditions, but are 
equivalent to steady-state kcat/Km (54).  Kinetic data were measured in at least two 
independent experiments and the standard error was typically less than 15%.  
F = A[1–e(–kobst)] (1) 
kobs = (kcat/Km)[E] (2) 
 
The maximal observed rate constant (kmax) was determined at a saturating concentration 
of enzyme ([E] >> Kd) and this was confirmed by the observation of the same rate 
constant at two different concentrations of enzyme (150 )M and 300 )M).  Because the 
observed rate constant is independent of the concentration of enzyme, this indicates that 
the observed rate constant is equal to the maximal single-turnover rate constant (kobs = 
kmax) and reports on the chemical steps after substrate binding (eq. 1).  
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Under single-turnover conditions, it is expected that the concentration dependence of the 
enzyme will be hyperbolic (eq. 3).  The K1/2 value indicates the protein concentration at 
which half of the substrate is bound.  For K1/2 determinations, the APR concentration 
was varied over a wide range in the presence of Trx. 
kobs = kmax[E]/(K1/2 + [E]) (3) 
 
The inhibition constant (Ki) was measured for ligands, AMP and PAP by inhibiting the 
APR reaction under kcat/Km conditions at pH 7.5 with varying concentration of inhibitor (I).  
The data were fit to a simple model for competitive inhibition (eq. 4) and, with 
subsaturating APR, the Ki is equal to the equilibrium dissociation constant (Kd) of the 
inhibitor. 
 (kcat/Km)obs = (kcat/Km)/(1+ [I]/Ki) (4) 
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6.7 Appendices 
Table 6.7.1 Appendix Table of P-loop variants kinetics  
Single-turnover rate and dissociation constants for PaAPR, MtAPR, EcPAPR and the 
respective P-loop variants.a  
 
Enzyme kcat/Km (M-1min-1)b 
Kd AMP 
("M) 
Kd PAP 
("M) 
 APS PAPS   
PaAPR 1.8 x 108 3.5 x 104 35 ± 2 8.1 x 103 
PaAPR 
Asp66Ala 
2.5 x 107 9.6 x 103 57 ± 12 3.3 x 103 
PaAPR 
Glu65Gln 
7.2 x 106 3.5 x 103 1.2 x 103 6.9 x 103 
PaAPR 
Glu65Gln, 
Asp66Ala 
5.0 x 105 2.5 x 103 2.8 x 103 9.7 x 103 
EcPAPR 840 1.2 x 108 3.4 x 103 1.4 ± 0.6 
EcPAPR 
Ala58Asp 
720 1.3 x 105 1.4 x 104 8.0 x 103 
EcPAPR 
Gln57Glu 
420 1.7 x 105 7.6 x 103 1.0 x 103 
EcPAPR 
Gln57Glu, 
Ala58Asp 
420 2.6 x 104 1.8 x 104 2.4 x 103 
 
aMeasurements represent the average of two or more independent determinations and the S.D. was %25% 
of the value in all cases.  Unless otherwise stated, reaction conditions were 100 mM Bis-Tris propane, pH 
7.5, 5 mM dithiothreitol, and 10 )M thioredoxin at 30 °C (see Materials and Methods).  bkcat/Km values were 
measured as described in Materials and Methods.  
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Table 6.7.2 Appendix Table of mass measurements 
Mass measurements of EcPAPR, EcPAPR4cys and MtAPR and associated enzyme S-
sulfocysteine complexes. 
 
Enzymea Measured mass (Da)b !mc, d  
EcPAPR 28910.41 (28909.76) N/A 
EcPAPR + APS 28990.84 (28989.76) 80.43 
EcPAPR + PAPS 28989.97 (28989.76) 79.56 
EcPAPR4cys 28829.23 (28828.84) N/A 
EcPAPR4cys + APS 28909.54 (28908.84) 80.31 
EcPAPR4cys + PAPS 28908.55 (28908.84) 79.56 
MtAPR 28356.88 (28356.87) N/A 
MtAPR + APS 28437.45 (28436.87) 80.57 
MtAPR + PAPS 28436.29 (28436.87) 79.41 
 
aIn reactions that contained APS or PAPS, the enzyme was incubated with substrate prior to mass analysis, 
as described in Materials and Methods.  bThe average experimental value of the most abundant isotopic 
mass over the charge state distribution, calculated by deconvolution.  Theoretical values are shown in 
parenthesis and were calculated based on the amino acid sequence.  cThe mass differences in this table 
have been calculated with respect to the masses of the corresponding intact protein.  dWith the exception of 
EcPAPR + PAPS, EcPAPR4cys + PAPS and MtAPR + APS, two series of ions were observed 
corresponding to the enzyme alone and the enzyme S-sulfocysteine adduct.  Relative abundance of these 
species is provided in the text.  
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Figure 6.7.3 Primary sequence alignment of sulfonucleotide reductases from P. 
aeruginosa, M. tuberculosis, B. subtilis, A. thaliana, P. patens (two isoforms, APR and 
APR-B), E. coli, S. cerevisiae and P. patens.  The ClustalW2 (v2.1) Multiple Sequence 
Alignment program (5) was used to align all the sequences.  Strictly conserved residues 
are outlined in red, red letters indicate conserved residues and conserved regions are 
boxed in blue.  Residues flanking the active site are boxed in green.  Positions of 
cysteine residues that coordinate to the [4Fe-4S] cluster are indicated below the 
sequence with (").  Alignment pictures were rendered with the server ESPript 2.2 
(http://espript.ibcp.fr).  
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Figure 6.7.4 Comparison of key active site regions in PaAPR and EcPAPR 
Interactions are based on PaAPR (PDB deposition 2GOY) and EcPAPR (PDB 
deposition 2O8V), crystal structures, prior functional studies (6, 7) and the present study.  
Contacts of EcPAPR with PAPS have been assumed from the coordinates of PAP 
(ScPAPR, PDB deposition 2OQ2) and APS (PaAPR, PDB deposition 2GOY).  Active 
site contacts of (a) PaAPR and (b) EcPAPR with APS and PAPS respectively, plotted in 
two dimensions. Protein residues in proximity of the ligand are shown, with hydrogen 
bonding interactions indicated as dotted lines with arrows denoting the direction of the 
bond.  Interactions from the substrate or the residue backbones of the enzyme are 
distinguished from interactions with residue side chains by a solid dot at the end of the 
interaction line.  Interactions highlighted in red are unique between the two active sites.  
In both structures, P-loop residues reside at the opposite end of the active site cleft with 
respect to active site lysine and arginine residues that interact with the 5'-sulfate moiety 
(>7Å away).  (c) The environment of the [4Fe-4S] cluster in PaAPR.  The [4Fe-4S] 
cluster is ligated by four cysteine residues at positions 139, 140, 228 and 231.  Four 
conserved residues participate in charged or polar NH-S or OH-S hydrogen bonds to 
inorganic S or cysteine S% atoms; Thr87, Arg143, Lys144 and Trp246 (yellow dashes).  
Conserved basic residues Lys144, Arg242 and Arg245 in the active site interact with the 
phosphate and sulfate groups of APS.  (d)  Residues surrounding the YN..DXXT motif in 
EcPAPR.  In the absence of the iron-sulfur cluster in EcPAPR, Tyr131 has cross-linking 
interactions with His216 and Asp214 (yellow dashes).  Similar to PaAPR, positively 
charged Lys136 and Arg231 are poised to interact with the sulfate moiety of PAPS.  Arg 
231 and Glu228 are missing from the structure of EcPAPR therefore their position is 
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assumed from the coordinates of Arg231 and Arg233 (ScPAPR, PDB deposition 2OQ2).   
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Figure 6.7.5 Gel labeling of wild type EcPAPR and EcPAPR4cys 
Gel labeling of wild type EcPAPR (lanes 1-4) and EcPAPR4cys (lanes 5-8) with either 
[35S]-PAPS or [35S]-APS, with or without Trx, was carried out as described in the 
Materials and Methods.  
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Figure 6.7.6 The reaction progress curve for P-loop variants of PaAPR and 
EcPAPR 
Under subsaturating concentration of substrate, the reaction is described by the 
apparent second order rate constant, kcat/Km.  The enzyme concentration was varied as 
indicated due to the linear relationship between concentration and activity.  a) Reduction 
of APS with PaAPR (2 nM, "), D66A PaAPR (10 nM, #) and E65Q PaAPR (20 nM, $).  
b) Reduction of APS with EcPAPR (10 )M, "), A58D EcPAPR (10 )M, #) and Q57E 
EcPAPR (10 )M, $).  c) Reduction of PAPS with PaAPR (5 )M, "), D66A PaAPR (10 
)M, #) and E65Q PaAPR (10)M, $).  d) Reduction of PAPS as substrate with EcPAPR 
(2.5 nM, "), A58D EcPAPR (0.5 )M, #) and Q57E EcPAPR (0.5 )M,$). 
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Figure 6.7.7 Binding of AMP and PAP to P-loop variants of PaAPR and EcPAPR.   
Nonlinear-least-squares fit of the data to a model for simple competitive inhibition (eq. 2) 
gave the dissociation constant Kd.  a) KdAMP of PaAPR ("), D66A PaAPR (#) and E65Q 
PaAPR ($); inset, E65Q PaAPR scaled.  b) KdAMP of EcPAPR ("), A58D EcPAPR (#) 
and Q57E EcPAPR ($).  c) KdPAP of PaAPR ("), D66A PaAPR (#) and E65Q PaAPR 
($).  d) KdPAP of EcPAPR ("), A58D EcPAPR (#) and Q57E EcPAPR ($); inset, A58D 
EcPAPR scaled. 
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Figure 6.7.8 Reaction progress curves for PaAPR, EcPAPR and EcPAPR4cys at pH 
6.5  Under subsaturating concentration of substrate, the reaction is described by the 
apparent second-order rate constant, kcat/Km, for PaAPR (a), EcPAPR (b) and 
EcPAPR4cys (c) with APS (") and PAPS (#). 
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Figure 6.7.9 Maximal rate constant 
kmax, measured under single turnover conditions with saturating enzyme at pH 6.5 for 
PaAPR (a), EcPAPR (b), EcPAPR4cys (c) with APS, and for PaAPR (d), EcPAPR (e), 
EcPAPR4cys (f) with PAPS. 
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Figure 6.7.10 The apparent affinity 
K1/2, under single turnover conditions at pH 6.5 for PaAPR (a), EcPAPR (b) and 
EcPAPR4cys (c) with APS, and for PaAPR (d), EcPAPR (e) and EcPAPR4cys (f) with 
PAPS. 
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Figure 6.7.11 Binding of AMP and PAP to EcPAPR4cys measured at pH 7.5.   
The average of three independent determinations is shown, and the error bars indicate 
the standard deviations.  Nonlinear-least-squares fit of the data to a model for simple 
competitive inhibition (eq. 4) gave the dissociation constants KdAMP (a) and KdPAP (b) for 
EcPAPR4cys. 
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Chapter 7 
Conclusions and future directions 
 
7.1 Abstract 
The data presented in the previous chapters illustrate our effort towards elucidating 
mechanistic details of the APR reaction and identifying small molecule inhibitors.  The 
present Chapter summarizes the key findings and significance of this work.  In addition, I 
discuss future directions to modify the structures of hit compounds and overcome 
limitations inherent to current therapeutic strategies.  I also present an alternative 
experimental approach to discover APR inhibitors by targeting the [4Fe-4S] cluster of 
APR, protein-protein interaction interface with thioredoxin, and evaluation of compounds 
through cell-based assays. 
 
7.2 Conclusions: strategies to develop small molecule inhibitors of APR 
Recently, APR has been validated as a promising drug target against the latent phase of 
the tuberculosis-causing bacteria (1-3).  The overall aim of this thesis was to investigate 
the mechanism of APR and exploit this information in the design and discovery of small 
molecule inhibitors.  In Chapter 1, I first discussed the current TB epidemic and 
limitations of the current treatments.  APR, which catalyzes the first committed step in 
bacterial sulfate reduction, has been identified as drug target against latent TB infection.  
I illustrated briefly the overall drug discovery pipeline and introduced our strategies to 
discover APR inhibitors through VLS and rational design.  Chapter 2 describes VLS of 
APR using Autodock, followed by biological evaluation of in silico hits.  VLS successfully 
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identified the first non-phosphate based inhibitors against APR, which constitutes an 
essential step toward inhibitor discovery. 
 
The active site of a protein consists of pockets, dynamic regions and conserved motifs.  
These active site-defined elements are involved in substrate binding, catalysis or both.  
In Chapter 3, the molecular determinants of the APR active site that underlie binding and 
specificity are discussed through a series of substrate and product analogs.  This study 
afforded insight into the key interactions between the substrate and APR, thereby 
providing a pharmacological roadmap for rational inhibitor design.  In Chapter 4, 
biochemical and biophysical data are presented that indicate the essential role of the 
conserved residue, His252, in substrate binding.  In Chapter 5, kinetic and spectroscopic 
studies were used to identify Lys144 as a molecular bridge between the iron"sulfur 
cluster and APS.  This interaction network stabilizes the catalytic transition state and 
indicates a role for the iron"sulfur cluster in APS reduction.  Finally, in Chapter 6, we 
focused on substrate discrimination in the SR family was explored.  Using site-directed 
mutagenesis and metalloprotein engineering, we generated P-loop mutations in SRs and 
installed a [4Fe-4S] cluster in PAPR.  Kinetic and spectroscopic characterization of the 
variants provided insight into the switch in molecular recognition between APR and 
PAPR, and permitted a better understanding of evolution in this family of enzymes.  
 
7.3 Future directions  
7.3.1 Computational drug design 
VLS is a valuable tool to identify inhibitors that target APR (4).  We used the APR 
pharmacophore model, generated in Chapter 2, as a template to select promising 
candidates from the larger and more chemically comprehensive Maybridge database, 
consisting of 56,000 compounds.  We chose this database for its drug-like properties 
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(e.g., bioavailability and stability).  Thus, we expected that optimized compounds from 
this library would retain these properties and have activity in cell-based systems.  The 
VLS was conducted using the 
same method as in the 
previous NCI screen and 51 
compounds, corresponding to 
0.1% of the Maybridge 
database, were selected for further biological evaluation.  Surprisingly, only two 
compounds were identified to have 50% inhibition against APR with dissociation 
constants of 44 !M (HTS02996) and 101 !M (SEW04209) (Figure 7.1).  The failure to 
identify any potent inhibitors from this library may be an indicator that the P. aeruginosa 
crystal structure used in these studies does not sufficiently model interactions with M. 
tuberculosis APR. 
 
7.3.1.1 Structure activity relationship of current leads  
Through a combination of VLS and experimental testing, several chemical scaffolds from 
the NCI library emerged as possible leads, including 1, 2 and 3 (Figure 7.2).  We are 
planning to investigate SARs for these compounds and possible to synthesize a focused 
sub-library.  In initial studies, we analyzed a series of 9-fluorenone analogs of compound 
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Figure 7.2.  Possible lead compounds 1,2 and 3 identified from an NCI screen. 
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1.  In these studies, 2,3-nitro and/or fluoro disubstituted 9-fluorenones were all effective 
inhibitors.  Since compound 1 has electron-withdrawing groups at the 2 and 3 positions, 
we must investigate the importance of the ketone moiety and determine whether the 
carbonyl undergoes nucleophilic attack by cysteine.  Compound 2 is composed of a 
purine and benzooxadiazole moiety joined by a thioether bond.  The oxadiazole and 6-
nitro functional groups in compound 2 were essential for inhibitor potency; however, the 
purine could be replaced by other aromatic groups with potential for hydrogen bonding.  
Compound 3 exhibited the most drug-like properties in our series of inhibitors owing to 
the absence of nitro or benzooxadiazole functionalities.  Hydrogen bonding interactions 
between the thiocarbonate and critical active site residues such as Lys234, Arg242 or 
Arg245 are predicted to be required for binding.  To investigate the potential of this 
scaffold, we analyzed a related series of commercially available compounds in which the 
thiocarbonate was replaced by an aromatic thio group or thioamide (Figure 7.3A).  In 
parallel with these experiments, we also explored variations in the polycyclic moiety of 
the parent compounds such as 1,2,4-triazino[5,6-B]indole (Figure 7.3B).  However, none 
of these compounds exhibited more than 50% inhibition against APR by biological assay, 
whereas the free energy of binding calculated from docking studies (#GAD4) remained 
the same.  Although SAR of 1, 2 and 3 with commercially available compounds was not 
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Figure 7.3.  Commercially available compounds that identified by similarity search based on 
compound 3.  (A) modification of thiocarbonate (B) modification of polycyclic ring 
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successful identifying compounds with improved potency, these preliminary data should 
inform the direction of future studies.  
 
7.3.1.2 Solve the X-ray structure of MtAPR in the ‘open’ and ‘closed’ states 
Once VLS appeared as a tool on the drug discovery market, people predicted that HTS 
would be replaced by VLS due to its fast and cost effective approach.  In addition, the 
docking program predicts the binding mode of the ligand to the receptor as opposed to a 
random screen.  However, VLS requires knowledge about the spatial and energetic 
relationships between the receptor and ligand (5).  Most importantly, VLS heavily relies 
on the crystal structure of the receptor to predict binding (6, 7).  An HIV protease 
inhibitor is a successful example of using VLS for anti-AIDS drug design.  Behind this 
success, there were more than 130 crystal structures of HIV protease available through 
internet access databases (8).  In contrast, we have only one APR structure from P. 
aeruginosa species, which is also missing the final 15 residues including the catalytic 
cysteine.  Clearly, an essential step forward in this research area will be to obtain the 
structure of M. tuberculosis APR in different conformational states. 
 
Toward this end, we note precedent in this area for protein kinases, which transfer a 
phosphoryl group from ATP to the peptide substrate.  In recent studies, a covalently 
linked bisubstrate inhibitor of the insulin receptor tyrosine kinase was synthesized by 
linking ATP%S to a peptide substrate analog.  This mechanism-based inhibitor helped to 
determine the crystal structure complex with inhibitor (PDB 1GAG) and is also a 
promising candidate for therapeutic intervention (9).  Along these lines, a mechanism-
based inhibitor of APR, which irreversibly modifies the catalytic cysteine, could be used 
to trap the C-terminal tail in the active site of APR and facilitate structural studies.  A 
mechanism-based inhibitor was designed by taking a potent binding scaffold and 
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attaching a reactive warhead (10, 11).  The substrate analog, adenosine 5’-
monophosphate (AMP) binds to APR with a moderate Kd value of 5.4 )M.  Thus, AMP 
was used as a binding element in the APR active site pocket (3).  We conceived of a 
vinylsulfonamide as an acyladenylate surrogate that contains a Michael acceptor to 
covalently modify the catalytic cysteine.  The vinylsulfonamide was chosen as it is the 
least reactive member in the series of Michael acceptor to minimize off-target reactions 
(12).  Previously, Aldrich and co-workers had evaluated !-ketosulfonamide adenylation 
inhibitors against alicyl-AMP ligase as potential antitubercular agents (13, 14).  Similarly, 
we synthesized 5’-deoxy-5’-N-{[(ethenyl)sulfonyl]amino}adenosine (appendix 7.5.1) as 
an irreversible inhibitor of APR (Figure 7.4) (13-16).  Mass spectrometry (appendix 7.5.2), 
biochemical and kinetic analyses (not shown) demonstrate covalent modification of the 
catalytic cysteine, Cys249 of MtAPR.  Currently, we are focusing on crystallization of 
MtAPR using this first generation mechanism-based inhibitor in collaboration with Dr. 
Gunter Schneider and Dr. Ömer Poyraz at the Karolinska Institute.  If we surmount the 
formidable obstacle of crystallization, it would significantly facilitate inhibitor discovery. 
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Figure 7.4.  Strategy to trap the C-terminal segment of MtAPR, which carries catalytic cysteine using 
michael addition of synthesized MBI_1 compound.  
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7.3.2 Rational design 
In Chapters 2-6, we established the various interactions between SR and the substrate.  
Ligand binding involves many factors, including changes of interactions between the 
ligand, solvent and target protein, as well as conformational changes in the ligand or 
receptor (17).  Rational design of APR inhibitors was initiated from a spatial arrangement 
of atoms or functional groups of small molecule inhibitors believed to be responsible for 
interactions with the enzyme.  The crystal structure of PaAPR (PDB 2GOY) was solved 
in an open conformation and revealed the presence of a [4Fe-4S] cluster that has been 
shown to be essential for catalytic activity (18).  Subsequently, we reported the EcPAPR-
Trx structure (PDB 2O8V) in an open conformation depicting two distinct interaction 
interfaces (19).  It is important to emphasize that the closed conformation represents the 
bioactive conformation wherein the catalytic cysteine can commence nucleophillic attack.  
Based on these studies, inhibitors that stabilized a closed conformation, interacted with 
the [4Fe-4S] cluster or these protein-protein interfaces could represent important new 
strategies in inhibitor discovery. 
 
7.3.2.1 Design of inhibitors that target specific APR conformations 
We have focused on active site interactions based on the crystal structure of PaAPR 
detailed in Chapter 3.  However, conformational changes were observed upon substrate 
binding in the active site by a dynamic motif, as described in Chapter 4.  Biochemical 
data and structural data show that the C-terminal 15 residues and an Arg-rich loop in 
SRs fold over the active  site, establishing the closed conformation (Figure 7.5).    Using 
homology modeling and the structure of yeast PAPR in the closed conformation (from 
Chapter 3 and 4), one could rationally design inhibitors that target different 
conformational states of MtAPR.  This strategy to discover specific inhibitors intended for 
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different enzyme 
conformations has proven 
fruitful with kinases (20, 21).  
I envision that an APR 
inhibitor designed to stabilize 
the closed conformation 
would establish important 
interactions with the C-
terminal tail.  As outlined 
above, this general strategy 
could also facilitate 
stabilization of the MtAPR enzyme for crystallography. 
 
7.3.2.2 Iron-sulfur cluster targeted APR inhibitors 
As discussed in Chapter 5 and 6, the [4Fe-4S] cluster plays an essential role in 
substrate recognition.  Functional and structural analyses indicate that the terminal 5’-
!
 
Figure 7.5.  ‘Closed’ and ‘open’ conformation by an arginine-rich 
loop and C-terminal tail 
 
 
Figure 7.6.  Potential APR inhibitors with Fe-chelating groups (R).  
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sulfate moiety of APS is poised to interact with the [4Fe-4S] cluster. Compounds 
containing moieties that chelate the catalytic metal ion in APR may have potential as 
inhibitors.  This strategy has proven successful in the development of HDAC inhibitors.  
In our lab, we have devised a strategy to design bifunctional inhibitors that would interact 
with the [4Fe-4S] cluster as well as make contacts with the adenosine-binding pocket in 
the active site (Figure 7.6).  We are using combinatorial chemistry to synthesize a library 
of inhibitors from a solid supported adenosine scaffold.  We will then screen for inhibitors 
from this library using our established APR assay (see Chapter 2).  
 
7.3.2.3 Evaluating SR-Trx interaction interfaces 
Recently, the crystal structure of the EcPAPR-Trx complex (PDB 2O8V) revealed two 
interaction interfaces of ~800 Å each (Figure 7.7A) (19).  The first interface is 
established in the vicinity of the mixed protein disulfide between Cys32 in Trx and Cys 
239 in EcPAPR (Figure 7.7C).  Interaction of the C-terminus of PAPR and the 70s loop 
of Trx involves electrostatic and hydrophobic interactions (Figure 7.7C).  The second 
recognition interface involves the --loop of PAPR and the 30s loop of Trx (Figure 7.7B).  
Previously, Knaff and colleagues used NMR to investigate the interface interactions on 
PaAPR and Trx and successfully mapped the important plausible contacts of Trx 
residues around Cys 32 to PaAPR (22).  Surprisingly, however, alanine scanning of this 
region revealed no hotspot Trx residues that significantly reduced binding to PaAPR.  
Therefore we will investigate interface residues within EcPAPR for their potential 
contribution to Trx binding based on our crystal structure (19).  The elucidation of the 
protein-protein interactions will provide insights into the catalytic mechanism as well as 
assist in the design of inhibitors to block this interaction.  
 
7.3.2.4 Evaluate inhibitors in a secondary cell-based assay 
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Jumping over the gap between experiments within recombinant enzymes- to live cells- is 
important for inhibitor discovery.  Unlike radioactivity-based assays with recombinant 
enzyme, cell-based assays afford additional information on biological activity, toxicity, 
and off-target interactions.  We will employ M. smegmatis for these studies because it is 
a close genetic relative of M. tuberculosis.  Briefly, M. smegmatis cultures will be 
incubated with the compounds and their growth in minimal media with sulfate as the sole 
sulfur source will be monitored by turbidity.  The specificity of compounds for APR will be 
confirmed by control experiments in which growth is restored by methionine 
supplementation (23, 24).  
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Figure .7.7.  Overall view of the EcPAPR-Trx complex in the cocrystal structure (PDB entry 2O8V).  (A) 
Protein-protein interfaces suggested that conformational changes of PAPR associated with Trx binding 
involve residues in the C-terminal tail (highlighted as pink) and the --loop (highlighted as gray).  (B) 
Specific recognition of PAPR by Trx occurs via residues in the --loop and a7-helix of PAPR (shown in 
gray) and the 30s loop and "2-helix of Trx (shown in yellow).  The electrostatic potential map shows 
residue interactions involve hydrogen bonds (indicated by dashed line; Trx residues in italics), aromatic 
stacking, and hydrophobic interactions.  (C) The flexible C-terminal peptide of PAPR (residues 235-244; 
shown in pink) shows interactions with Trx residues comprised of 70s loop (Trx residues 71-77; Trx 
residues in italics); the mixed disulfide is formed between Cys239 of PAPR and Cys32 of Trx. 
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7.4 Concluding remarks 
TB remains a prominent health threat due to the shortcomings of the current treatment 
regimes.  Since pharmaceutical companies are driven by profit, our efforts in academic 
institutions will serve as the foundation to identify novel targets and hit compounds.  
Herein, I have described strategies to discover inhibitors against a newly validated TB 
target, APR.  Thorough studies of enzyme and ligand interactions not only help to 
identify inhibitors, but also promote an understanding of enzyme mechanism and 
biological function.  The aforementioned computational docking, biochemical and 
biophysical studies have led to many important new insights into the APR reaction 
mechanism and should accelerate inhibitor discovery for this medically important 
enzyme.  
 
7.5 Appendix  
Figure 7.5.1 Synthesis of 5’-Deoxy-5’-N-{[(ethenyl)sulfonyl]amino}adenosine 
(13,14) 
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Figure 7.5.2. Mass spectrometric analysis of intact MtAPR complex with MBI 
ESI mass spectra of MtAPR (10 )M) without ligand (a), with MBI (b).  Ions correspond to 
the enzyme (E, a) or the covalent enzyme-MBI intermediate (E-MBI, b).  The calculated 
masses after deconvolution of m/z values are 28357.0 ± 0.25 Da (a), 28711.9 ± 0.63 Da 
(b)  
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